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Abstract 
Tracheal abnormalities, congenital or acquired, represent a currently unmet clinical 
need.  Tissue  engineering  has  recently  advanced  and  has  been  used  to  engineer 
hollow  organs,  including  tracheae,  for  clinical  use  on  a  compassionate  basis. 
However  the  current  clinically  used  method  for  tracheal  decellularisation  has 
received  mixed  success  and  requires  development  to  achieve  GMP  translation, 
quality manufacturing standards and ultimately routine clinical use. This thesis first 
examined  the  current  clinically  used  detergent-enzymatic  method  (DEM)  of 
decellularisation, a highly manual process that takes twenty-eight days to complete. 
Although the method achieved full decellularisation of non-cartilaginous regions of 
the tracheae, it failed to reduce the donor nuclear material sufficiently and resulted in 
the loss of key biochemical components, glycosaminoglycans (GAG) and collagen 
Type II, and the loss of biomechanical strength. A novel method for rapid, effective 
and non-detrimental tracheal decellularisation was required. Pressurised transmural 
flow  was  hypothesised  to  meet  those  requirements.  A  dual  chamber  bioreactor 
system  was  designed,  fabricated  and  optimised  to  enable  pressurised  transmural 
decellularisation (PTD) to be investigated. Optimal PTD process parameters were 
ascertained  and  shown  to  produce  tracheal  scaffolds  that  achieved  full 
decellularisation  of  the  non-cartilaginous  regions  of  the  tracheae,  a  reduction  of 
donor  nuclear  material  (95%)  which  met  the  currently  recommended  levels  of 
residual donor DNA for tissue engineered products, as well as maintaining GAG, 
collagen and biomechanical  strength  at  comparable levels  to  the native tracheae. 
Additional to this, the new PTD process achieved this effective and non-detrimental 
decellularisation  of  tracheae  in  five  working  days  with  a  ten-fold  cost  of  goods 
reduction.  With  further  development,  the  PTD  method  could  become  a  fully 
automatable  and  closed  process  which  could  progress  tissue  engineered  tracheae 
towards becoming a validated and regulated advanced therapy medicinal product 
(ATMP)  and  enable  the  advancement  of  tissue-engineered  tracheae  into  regular 
clinical use. 
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1  Introduction 
1.1  Structure and function of the human airway 
1.1.1  Structure and function of the human respiratory tract 
The pulmonary airway in humans, otherwise known as the respiratory system or 
respiratory tract, starts at the mouth and nose and ends at the alveolus (air sac) of the 
lung where gas-exchange occurs with blood pumped through the pulmonary artery to 
the pulmonary vein (Figure 1.1). The primary function of the pulmonary respiratory 
system is to supply oxygen (O2) to and remove carbon dioxide (CO2) from the cells 
and tissues of the body (Martin 1988). The main function of the respiratory tract is to 
ensure the air that arrives in the lungs is of the correct temperature, humidity and 
purity. Therefore the respiratory tract must act as a purifying biological barrier and 
so remove almost all of the particulates and noxious biological and chemical agents 
from the air (Martin 1988).  
After the nostrils and mouth the air is drawn into the pharynx (the throat) and onto 
the larynx (the voice box). At the laryngopharynx, air is prevented from entering the 
oesophagus by the hypopharyngeal sphincter and the larynx protects the trachea by 
preventing food from entering the respiratory tract. The larynx joins the trachea at 
the cricoid cartilage which is the only complete cartilaginous ring of either organ. 
Below the larynx is the trachea which completes the respiratory passage until the air 
passes into the bronchi and the lungs (Martin 1988). Page - 29 - of 223 
 
 
Figure 1.1: The respiratory system (Canadian_Lung_Association 2015). Permission 
to reproduce this figure has been granted by the Canadian Lung Association. 
1.1.2  Structure and function of the human trachea 
In  the  embryo,  the  cartilage,  connective  tissue  and  muscles  of  the  trachea 
differentiate  from  the  splanchnic  mesenchyme  that  surrounds  the  laryngotracheal 
tube (foregut) and the epithelium and glands of the trachea differentiate from the 
endodermal lining of the foregut (Legasto, Haller et al. 2004). In adults, the trachea 
is an average of 11 cm in length, with a range of 10 - 13 cm, and is on average 2.3 
cm in diameter laterally and 1.8 cm antero-posteriorly (Iivanov 2007). In children 
antero-posterior diameter is the greater of the two (Cameron 1999). In situ the actual 
tracheal dimensions of an individual fluctuate continuously as a result of postural Page - 30 - of 223 
 
movements and movements of the larynx and diaphragm (Martin 1988). The trachea 
starts at the lower margin of the cricoid cartilage and continues to the carina where it 
then divides into the two branches of the main bronchi. (Cameron 1999). The blood 
supply  of  the  trachea  is  complex  with  the  cervical  (upper  section)  being  mostly 
supplied by the inferior thyroid artery, the thoracic (mid-section) being supplied by 
the  innominate  (brachiocephalic)  and  subclavian  arteries  and  the  distal  (lower 
section)  being  supplied  by  the  bronchial  arteries  (Visosky  2004).  The  trachea  is 
comprised of 16-22 incomplete C-shaped cartilage rings (Baiguera, Birchall et al.) 
which are embedded into its fibrous and smooth muscular walls (Martin 1988) to 
create  rigidity  and  hold  open  the  tubular  structure  whilst  allowing  flexibility 
vertically between the cartilage rings. The cartilage rings are formed from hyaline 
cartilage (Caceci 2008). The cartilage is formed by chondroblasts which secrete the 
extracellular  matrix  components.  The  extracellular  matrix  is  composed  of 
tropocollagen  type  II,  the  basic  structural  unit  of  collagen  which  polymerises 
extracellularly  into  collagen  fibres,  and  ground  substance,  which  predominately 
consists of the GAGs, hyaluronan, chondroitin sulphate and keratan sulphate. In the 
developing foetus and human, the chondroblasts become isolated in lacunae, small 
cavities, as they produce and increase the amount of matrix between themselves. 
During this period the chondroblasts also differentiate into chondrocytes. In living 
cartilage the chondrocytes occupy the lacunae (Slomianka 2009) but as chondrocytes 
undergo cell death, termed chondroptosis by Roach in 2004 (Roach, Aigner et al. 
2004),  they  appear  to  shrink  and  retract  within  their  lacunae.  Also,  as  the 
chondrocytes undergo apoptosis, the cell and nucleus can appear darker as the cell 
condenses and the nucleus condenses and convolutes (Ford, Robinson et al. 2003, 
Roach,  Aigner  et  al.  2004).  There  are  two  means  by  which  growth  occurs  in 
cartilage,  either  interstitial  or  appositional  growth.  Interstitial  growth  occurs 
predominately in immature cartilage through the mitosis of chondroblasts that results 
in  isogenous  groups of  cells.  The cells  in  these isogenous  groups  produce small 
amounts of matrix so that the cells in the group become marginally separated from 
each other. Appositional growth occurs in immature and mature cartilage through the 
differentiation of mesenchymal stem cells from the inner chondrogenic layer of the 
perichondrium  into  chondroblasts  which  then  produce  extracellular  matrix 
(Slomianka 2009). The matrix near the isogeneous groups is termed territorial matrix 
and is more basophilic due to the higher levels of sulphated proteoglycans secreted Page - 31 - of 223 
 
by chondrocytes. Haematoxylin and Eosin (H&E) staining shows territorial matrix 
stains  darker  than  the  remainder  of  the  matrix,  known  as  interterritorial  matrix 
(Slomianka 2009). The posterior wall of the trachea is constructed from fibrous and 
muscular tissue (Martin 1988).  
Lining the trachea lumen is the respiratory epithelium. Its function is to provide an 
effective biological barrier from any particulates or noxious biological or chemical 
agents that may be inhaled. Particulate sizes of 30 µm or larger are trapped by the 
epithelial lining from the nose to the trachea, particulates of 10 µm to 3 µm are 
trapped by the lining in the bronchial tree and particulates of 3 µm to 1 µm can reach 
as far as the alveoli, where they are then trapped by the epithelial lining (Martin 
1988).  Tracheal  respiratory  epithelium  is  known  as  the  pseudostratified  ciliated 
columnar (PCC) epithelium (Chute 2008) (Figure 1.2 and Figure 1.3). It consists of 
ciliated columnar cells, secretory goblet (mucous) cells, brush cells, small granule 
cells  and  basal  cells  that  are  situated  above  a  basement  membrane  (Kolchanov, 
Ignatieva et al. 2002). There are approximately five ciliated cells to each goblet cell 
(Martin 1988). The epithelium is called pseudostratified because the columns of cells 
are tightly packed together with the nuclei towards one end to the extent that there 
appears to be several layers of cells, which is characteristic of stratified epithelium 
(Caprio 2005) (Figure 1.3). Below the epithelial layer there is the lamina propria 
layer, which is formed of loose connective tissue. The lamina propria contains elastic 
connective tissue fibres, collagen fibres, smooth muscle cells, cells of the immune 
system, nerves and blood vessels. The high levels of collagen and elastin in the 
lamina propria aid the elastic recoil of the trachea. Together the epithelial and lamina 
propria layers form what is termed the mucosa layer.  
Below the mucosa layer is the sub-mucosa layer which is comprised of a gland layer 
and a cartilage layer. Submucosal glands in the gland layer also produce mucous 
which is carried to the lumen by numerous interconnecting mucous ducts and tubules 
(Engelhardt, Schlossberg et al. 1995, Caprio 2005, Chute 2008). These glands, ducts 
and tubules help regulate the mucous secretions to the lumen surface (Engelhardt, 
Schlossberg et al. 1995). The mucous that is continuously produced by the goblet 
cells and the mucous glands forms an aqueous mucous secretion that is a mechanical 
barrier that lines the respiratory epithelium, and therefore the respiratory tract, to a 
thickness of 10 to 20 μm.  The aqueous mucous secretion consists of a top gel layer Page - 32 - of 223 
 
of hydrated mucous and a lower less viscous sol layer  (Martin 1988). There are 
typically 250 cilia per ciliated cell in the PCC epithelium, each approximately 6 μm 
in length and 0.2 μm in diameter. These cilia beat approximately 1,300 times per 
minute, in a coordinated way, in the sol layer so that the tips of the cilia hit the 
bottom of the gel layer (Caceci 2008). This moves the mucous, and the particulates 
that have been trapped by the mucous, away from the lungs to the epiglottis, where 
the mucous can be swallowed or expectorated (Caceci 2008, Chute 2008). It does 
this at a rate of 7 to 20 mm per minute which means a whole new layer of mucous 
can cover the trachea in a time  
period of 30 minutes to an hour (Martin 1988) and in so doing aids keeping the 
airway clear (Caceci 2008, Chute 2008). 
 
Figure 1.2: Light microscopy images of the trachea structure highlighting its various 
structures. 
This process is known as mucociliary clearance and it is a highly regulated process. 
Even  small  fluctuations  in  the  volume  of  the  sol  or  gel  layer  can  impede  or 
sometimes inhibit mucociliary clearance, such as observed in the pathophysiology of 
cystic  fibrosis.  The  mucous  layer  in  the  respiratory  tract  also  acts  a  waterproof 
barrier to prevent excessive uptake or transudation of water.  However it is water 
evaporating into the inspired air that humidifies it, therefore very dry air can cause Page - 33 - of 223 
 
mucosal dehydration, which increases the mucous’ viscosity and impedes its ability 
to be cleared by the cilia. This is of importance as bacteria and viruses trapped in the 
mucous  will  then  have  more  time  to  penetrate  the  underlying  cells  and  cause  a 
respiratory infection (Martin 1988). The brush cells in the respiratory epithelium are 
columnar cells that produce microvilli. These cells function as sensory cells as their 
basal surface is synaptically in contact with afferent neurons, which are known as 
sensory or receptor neurons. The small granule cells are called as such because their 
cytoplasm  contains  many  membrane-bound  dense  granules.  These  cells  release 
polypeptide hormones and catecholamine that are presumed to act in regulating the 
diameter of the tracheal lumen and tracheal vasculature (Kolchanov, Ignatieva et al. 
2002).  Basal  cells  are  thought  to  be  multipotent  stem  cells  which  are  able  to 
differentiate into the ciliated and goblet cells. Current evidence suggests that these 
cells reside in the protected niche of the mucosa ducts and glands. These cells are 
thought to be involved in the homeostasis of the respiratory epithelial layer and are 
able to migrate to and repopulate denuded areas (Rock, Randell et al. 2010). Outside 
of the cartilage is the adventitia layer which forms the outer surface of the trachea 
(Martin 1988). 
 
Figure  1.3:  High  magnification  micrograph  of  the  respiratory  epithelium.  The 
respiratory  epithelium  consists  of;  pseudostratified  ciliated  columnar  epithelium 
(EP); basal bodies (BB); goblet cells (GC); nuclei (N); cilia (C) and the basement 
membrane (Bm). 
1.1.3  Pathophysiology of the trachea 
The pathology of the trachea in humans can occur by several different means (Table 
1.1). Congenital tracheal anomalies can occur as agenesis, atresia, stenosis, webs and Page - 34 - of 223 
 
tracheomalacia. Tracheal agenesis describes failure of the trachea to develop and 
atresia describes cases where the trachea is present but not fully formed. These cases 
are almost always fatal (Iivanov 2007, Kay 2007), with most patients dying within 
hours of birth and long-term survival cases are rare. In one case a patient survived to 
6 years and 10 months (Soh, Kawahawa et al. 1999). Thankfully, these are both rare 
conditions  (Iivanov 2007, Kay 2007). Congenital  tracheal  webs  and stenoses  are 
another form of malfunction of the trachea. It is thought that they result from the 
unequal separating of the foregut when it develops into the oesophagus and trachea 
during foetal growth (Legasto, Haller et al. 2004). A tracheal web is when a thin 
layer  of  tissue  has  grown  across  and  narrows  the  tracheal  lumen,  but  does  not 
completely block the lumen. Importantly there is no abnormality of the cartilage 
structure with this condition, unlike tracheal stenosis. The position in the trachea and 
the  degree  of  occlusion  of  the  tracheal  lumen  is  proportional  to  the  degree  to 
symptoms presented by the patient. When over 75% of the lumen is obstructed, the 
patient suffers from dyspnoea (Kay 2007). 
Table 1.1. Pathophysiology of the trachea. 
Congenital tracheal stenosis is a fairly rare condition which refers to a narrowing of 
the trachea, caused either by an abnormality of the trachea itself or as a result of the 
trachea  being  compressed  by  an  external  force,  for  example,  a  cardiovascular 
Pathophysiology of 
tracheal disease 
Characteristics 
Congenital  Acquired 
Agenesis/ 
atresia 
Not 
applicable 
Absence  or  under  formed  trachea.  Respiration 
requires surgical intervention. 
Web  Not 
applicable 
Thin  layer  of  tissues  span  lumen  (<75% 
obstruction  is  asymptomatic).  No  damage  to 
cartilage.  
Stenosis  Funnel like narrowing of tracheal cartilage.  
Tracheobronchomalacia  Airway becomes flaccid and dilated. Lack of rigid 
support from cartilage rings. 
Not 
applicable 
Neoplasms  Progressive  obstruction  of  the  airway. 
Asymptomatic until near-total luminal obstruction. Page - 35 - of 223 
 
abnormality. In the majority of cases however it presents as a funnel-like narrowing 
caused by the presence of abnormal complete cartilaginous tracheal rings, instead of 
the normal C-shaped cartilaginous rings (Phipps, Raymond et al. 2006). There are 
various  degrees  of  severity  ranging  from  only  a  single  affected  tracheal  ring  to 
almost the entire length of the trachea being affected, (Kay 2007). Most forms of 
congenital stenosis are life-threatening with only the mild forms being an exception 
(Phipps, Raymond et al. 2006). Congenital tracheomalacia is a rare condition which 
occurs when the cartilage rings have not developed properly. In these cases, instead 
of providing rigid support to the trachea the walls of the trachea are flaccid to the 
extent  that  the  posterior  wall  can  move  towards  and  sometimes  even  touch  the 
anterior wall during heavy breathing (Kay 2007).  
In  adults,  pathology  of  the  trachea  includes  tracheal  neoplasms,  strictures  and 
tracheomalacia caused by infection and inflammation, trauma and post-intubation 
injuries  (Iivanov  2007).  Tracheal  neoplasms  (tumours)  are  a  rare  condition  and 
represent less than 1% of all malignant cancers and less than 0.1% of all cancer 
deaths each year (Visosky 2004, Daley 2009). 80% of tracheal primary tumours are 
malignant with 66% of these being either adenoid cystic carcinoma or squamous cell 
carcinoma (Daley 2009). The remaining one third of all tracheal tumours are of a 
varied type of either benign or malignant tumours. Tumours from surrounding tissue 
such as the larynx, thyroid, lung and oesophagus can also cause secondary tracheal 
tumours  (Daley  2009).  Most  tracheal  tumours  are  slow  growing  with  benign 
neoplasms presenting as smooth rounded tissue masses that are generally less than 2 
cm long. Malignant tumours generally present as tumours that proliferate outwardly 
on the exterior surface of the trachea and can cause ulcers (Daley 2009). Tracheal 
tumours cause progressive airway obstruction, but acute respiratory difficulty may 
not arise until the airway is almost entirely blocked. For this reason correct diagnosis 
is  usually  delayed  and  the  condition  commonly  fatal  (Daley  2009).  Tracheal 
strictures and stenoses caused by infection, inflammation, trauma or post-intubation 
injuries can cause chronic and progressive constrictive airway defects in the cartilage 
rings  which  can  restrict  the  passage  of  air.  As  discussed  previously  this  can 
ultimately  lead  to  respiratory  difficulties  which  can  potentially  be  fatal. 
Tracheobronchomalacia  can  also  occur  from  chronic  airway  inflammation  or 
infection such as a result of smoking, chronic bronchitis, emphysema, tuberculosis Page - 36 - of 223 
 
and cystic fibrosis, and results in large segments of the airway becoming flaccid and 
dilated (Marom, Goodman et al. 2001).  
1.1.4  Methods  for  addressing  pathology  and  the  limitations  of  current 
therapies 
For  congenital  tracheal  agenesis  and  atresia,  a  newborn  can  only  survive  if  an 
alternative route for respiration exists by way of a tracheo- or bronchoesophageal 
fistula (Kay 2007).  Suspicion of the condition prenatally gives the patient the best 
chance of survival as ventilation can begin immediately following birth (Panthagani, 
Santos et al. 2009). Corrective surgical techniques are available but the success rate 
is low, deeming these conditions to be non-correctable (Kay 2007). The inability to 
successfully engineer a de novo trachea from biological or artificial materials has 
hindered medical progress in this disease condition however the advancement of 
tissue engineering could provide a solution (Panthagani, Santos et al.  2009). For 
congenital tracheal webs, most are successfully treated by breaking up the web and 
thereby widening the lumen using either a laser or cutting instrument. Only much 
thickened webs need to be treated with open surgery where resection of the trachea is 
employed  (Kay  2007).  For  congenital  tracheal  stenoses,  surgery  is  the  most 
successful form of treatment. For short to mid length stenoses, slide tracheoplasty is 
the  preferred  method  as  the  trachea  is  shortened  less  than  the  trachea  is  with 
resection. For long segment tracheal stenosis, slide tracheoplasty has been used with 
some  success  but  in  many  cases  patch  tracheoplasty  with  autologous  material  is 
required  (Phipps,  Raymond  et  al.  2006).  For  cases  of  congenital  tracheomalacia, 
surgery is rarely needed. This is because, as the patient grows, the trachea cartilage is 
strengthened  so  that  by  the  age  of  2  years  old  the  condition  dissipates  without 
intervention (Kay 2007). Tracheal tumours are treated most successfully by surgical 
resection of the trachea (Daley 2009).  
Where  the  diseased  area  is  too  large  for  resection,  there  is  the  possibility  of 
transplantation  and  this  can  greatly  improve  the  quality  of  life.  Autografts  are 
possible  if  only  short  segment  replacement  is  required  and  these  segments  are 
adequately  vascularised  (Grillo  2002).  Fresh  allografts  would  also  be  possible, 
however a major limitation is the need for the allografts to be re-vascularised and 
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remainder  of  their  lives  to  prevent  major  histocompatibility  complex  (MHC) 
rejection (Grillo 2002). Considering these post-operative complications, one could 
argue it may not be justifiable to treat tracheal disease with transplantation as the 
surgical procedure is more life-threatening than the disease (Grillo 2002). Indeed, 
leading clinicians in this field consider tracheal transplant to be a debatable option 
given  that  current  surgical  procedures  are  limited.  However,  with  the  clinical 
emergence of tissue engineering it could become a viable treatment method although 
current  tissue  engineering  and  stem  cell  research  would  need  to  become  more 
advanced  to  produce  a  dependable  tracheal  substitute  (Birchall  and  Macchiarini 
2008, Badylak, Weiss et al. 2012).  
1.2  Tissue engineering 
1.2.1  What is tissue engineering? 
Tissue  engineering  emerged  in  the  early  1980s  as  a  discipline  that  draws  on 
biological, medical and engineering components. Although much has been learnt and 
changed over the last thirty years, the central goal remains the same: to be able to 
develop replacements for damaged, failing or lost organs and tissues (Langer and 
Vacanti  1993,  Simpson  and  Bowlin  2006).  Early  examples  of  cartilage  tissue 
engineering were demonstrated by Green in 1977, in which chondrocytes subjected 
to different treatments, e.g. sub-cultured or grafted onto a decalcified bone structure, 
were assessed for their ability to form collagen following an allograft (Green 1977). 
The low antigenicity of chondrocytes means that allogeneic chondrocytes can be 
used and can survive in the host for some time without rejection (Tan, Steiner et al. 
2006).  Although Green’s attempts were not entirely successful, the principles that 
were  developed  paved  the  way  for  further  work  (Green  1977,  Meyer-Blaser, 
Handschel et al. 2009).  
Current tissue engineering strategies commonly incorporate three elements. These 
are:-  
1)  Cells - to provide tissue specific functions. 
2)  Scaffolds – to provide tissue architecture and regulate aspects of the local 
cell population. 
3)  Growth  factors  -  to  regulate  cell  functions,  e.g.  proliferation  and 
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1.2.2  How can tissue engineering and regenerative medicine be used? 
For the commercially viable transplantation of tracheas there is a need to generate an 
“off-the-shelf” replacement tissue for clinicians. The replacement organs or tissues 
should have the correct form and shape of the original tissue, it should be able to 
fulfil the function of the original tissue, it should facilitate the regeneration of the 
tissue and should be able to be easily implanted and attached to the surrounding 
tissue once the defect has been removed (Hollister 2009). It is important, generally 
due to the pressing medical need, that these can be prepared for use by clinicians 
with  little  preparation  time  or  intervention  needed.  The  optimal  requirements  or 
critical quality attributes (CQA) for replacement tracheae include: removal of foreign 
(donor) immunogenic cellular material: removal of immunogenic nuclear material, 
predominately DNA, to less than 50 ng/mg (dry weight) of dsDNA (Badylak, Weiss 
et al. 2012, Keane, Londono et al. 2012); comparable tensile strength to the native 
trachea; no toxicity; no immunogenicity; long-term stability once implanted into the 
patient; and, if transplanted into children, growth potential. Theoretically, with tissue 
engineering  it  could  be  possible  that  scaffolds  for  tracheae  with  the  above 
characteristics can be generated in advance, in an off-the-shelf manner, without any 
intervention  required  from  the  potential  recipient.  However  other  important 
characteristics of the trachea include it being vascularised and seeded with patient’s 
cells to generate a respiratory epithelial lining in the lumen and chondrocytes to 
support cartilage growth and replacement. These latter requirements present a major 
challenge for generating off-the-shelf tracheas which can currently only be generated 
with  intervention  and  involvement  from  the  patient  prior  to  transplantation 
(Macchiarini, Jungebluth et al. 2008, Delaere, Vranckx et al. 2010).  
Recent advances in tissue engineering and regenerative medicine have facilitated the 
construction  of  replacement  tracheas  which  has  allowed  patients  with  tracheal 
pathology to be not only treated, but possibly cured through transplantation of these 
tissue engineered tracheas (Macchiarini, Jungebluth et al. 2008, Delaere, Vranckx et 
al.  2010).  In  order  to  achieve  this  there  has  been  a  drive  across  many  other 
disciplines to ensure that there is equipment and technology ready to support these 
advances in the tissue engineering and regenerative medicine fields. An example of 
this was the need to develop a double-chamber rotating bioreactor which enabled the 
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organs. (Asnaghi, Jungebluth et al. 2009). This bioreactor has been licenced to and 
commercialised  by  Harvard  Apparatus  Regenerative  Medicine  (HARegenMed 
2013),  which  also  has  other  tissue  engineering  bioreactor  systems  commercially 
available (HARegenMed 2013).  
1.2.3  Scaffold use in tracheal tissue engineering 
Tracheal  prosthesis  employing  silicone  (Neville,  Bolanowski  et  al.  1990)  and 
hydroxy  apatite  and  carbon  fibre  (Takahama,  Onishi  et  al.  1989)  have  been 
historically  tolerated  with  limited  pre-clinical  and  clinical  success.  There  has 
therefore been a shift to produce scaffolds that are more physiologically relevant and 
can incorporate and encourage native cell growth similar to the extra-cellular matrix 
(ECM). The ECM provides tissue specific structural elements to which cells can 
adhere (Simpson and Bowlin 2006). To be able to engineer tissues and organs, there 
is a need for clinically usable scaffold material that is not only the correct form or 
shape of the desired structure, but to which the cells can adhere and, if necessary, 
differentiate,  proliferate  and  re-organise  (Hollister  2009).  This  purports  that  any 
substitute scaffold will need to be more than a simple inert framework that is generic 
for all applications and will need to consider tissue-specific issues such as scaffold 
composition,  architecture  and  porosity  (Simpson  and  Bowlin  2006).  To  evaluate 
potential scaffolds, it must be possible to characterise how the cells interact with the 
scaffold material and it is preferable that the performance of the scaffold with the 
cells in situ can be evaluated in vitro as well as in vivo through the use of molecular, 
cellular  and  histological  methods  (Hollister  2009).  It  is  also  important  that  the 
mechanical properties of the resulting scaffold match the mechanical properties of 
the tissue it is to replace, although it is unclear as to what extent this is necessary 
(Funamoto, Nam et al. 2010). This is a challenge as there are many ways to define 
the mechanical properties of tissue in question in terms of models such as linear 
elasticity, non-linear elasticity, viscoelasticity and poroelasticity. This complexity is 
increased by the fact that the same tissue can be defined by different versions of 
these models and there is no consensus on which model should be used (Hollister 
2009). There is also the issue that even if the mechanical properties of the tissue can 
be matched in vitro, once implanted the mechanical properties may alter  in vivo 
which could affect the function of the engineered tissue (Hollister 2009). Beyond the 
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scaffold for nutrient supply and metabolic waste removal, which takes into account 
the scaffold’s diffusivity and permeability (Hutmacher 2000). All of these different 
properties need to be taken into account when designing the scaffold to determine 
the scaffold’s required critical quality attributes and ultimately the target product 
profile (TPP). 
Scaffolds  can  either  be  synthetic  or  biological  scaffolds,  the  latter  of  which  are 
typically  allogenically  or  xenogenically  derived  from  a  donor.  For  synthetic 
scaffolds, although different novel materials and structures have been adapted and 
used as scaffolds at research level, the clinical application of synthetic scaffolds has 
been  very  limited  (Hollister  2009,  Jungebluth,  Alici  et  al.  2011)  because  of  the 
complex issues involved in scaffold choice and design. Ultimately, for the scaffold 
generation  process  to  become  clinically  relevant,  it  must  be  possible to  scale-up 
production whilst adhering to quality manufacturing principles (Williams, Thomas et 
al. 2012) towards robustly generating potentially hundreds of scaffolds per year with 
minimal  CQA  variation  (Hollister  2009).  The  focus  of  this  engineering  doctoral 
project was on biological scaffolds. 
1.2.4  Biological scaffolds 
Biological scaffolds can be generated by obtaining the desired tissue or organ from 
either  a  human  donor  (allogenic)  or  an  animal  donor  (xenogenic).  For  these 
biological  scaffolds  to  be  functional  and  not  elicit  an  immune  response  in  the 
recipient, the donor’s cells need to be removed from the tissue or organ. This process 
is known as tissue decellularisation. The remaining ECM of structural and functional 
proteins has the advantages that it should have the desired structure and mechanical 
behaviour. However the process of decellularisation can have some unwanted side 
effects on the biochemical composition and ultrastructure of the ECM. As the cells 
contribute to holding the ECM in place, their removal can weaken the ECM scaffold. 
Also detergents and enzymes involved in the decellularisation process can damage 
the ECM by removing or modifying certain proteins e.g. GAGs (Gilbert, Sellaro et 
al. 2006) and undesirable alteration in the structure of the ECM could also hinder 
cell growth during recelluarisation (Gratzer, Harrison et al. 2006).  In addition to 
this, the chemical(s) used to remove the donor’s cells may have a toxic effect upon 
the viability of the newly seeded cells, or to the recipient upon transplantation, if it is 
not possible to adequately remove traces of it from the ECM (Gilbert, Sellaro et al. Page - 41 - of 223 
 
2006). An immune response and tissue rejection in the recipient could also be an 
issue if all traces of the donor cells are not removed (Balasundari, Gupta et al. 2007, 
Macchiarini, Jungebluth et al. 2008). 
Several methods have already been explored with regard to the decellularisation of 
biological tissues and organs for use as biological scaffolds; these include various 
chemical  treatments  (including  detergents,  acids,  hypotonic  and  hypertonic 
solutions),  enzymatic  treatments,  ultra-high  pressure  treatments,  cryopreservation 
treatments  and  immunological  treatments.  Various  methods,  which  have  been 
notably  applied  to  tracheal  decellularisation,  along  with  the  advantages  and 
disadvantages of each will be discussed below.  
One method, a perfusion method, for decellularising tracheas was outlined in a US 
Patent  application  form,  developed  by  Ott  (Ott,  Matthiesen  et  al.  2008),  for  the 
decellularisation of a rat lung and trachea. This method relied on two to twelve hours 
of perfusion  with  1% SDS  followed by  a fifteen minute perfusion with  distilled 
water and then a fifteen to thirty minute perfusion with 1% Triton-X. The authors 
stated that SEM micrographs were used to confirm the ECM structure was intact and 
the  respiratory  epithelium  had  been  removed  leaving  a  rough  luminal  basal 
membrane (Ott 2009). Whilst published results for this perfusion method have been 
used to demonstrate decellularisation of a rat heart, data is yet to be published on the 
lung or the tracheal decellularisation or in porcine models (Ott, Matthiesen et al. 
2008).  
Another, perhaps less conventional, method was explored by Delaere and colleagues 
(Delaere, Vranckx et al. 2010, Delaere, Vranckx et al. 2014). This method, which 
has treated five patients to date, involved the implantation of a donor trachea into the 
forearm of the recipient. During the three to nine months that the tracheae were in 
the recipients’ forearms, the respiratory epithelium and trachea were revascularised 
and  autografts  of  recipient  buccal  mucosa  were  introduced  prior  to  orthotopic 
transplantation  when  it  replaced  the  recipients’  defective  section  of  trachea. 
Immunosuppressive  medication  was  administered  for  seven  and  a  half  to  nine 
months  to  prevent  rejection.  Post-immunosuppression,  the  authors  stated  that  the 
tracheae were decellularised by the recipients’ own immune systems, without the 
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repopulated  with  the  patients’  buccal  mucosal  cells  and  vascular  network.  This 
manner  of  decellularising  the  trachea  is  interesting  as  it  employs  the  use  of  the 
patient’s own immune system to decellularise the trachea (Delaere, Vranckx et al. 
2010, Delaere, Vranckx et al. 2014). In one highlighted case, the authors presented 
evidence to demonstrate that after four months of implantation in the forearm, donor 
cells were present in the respiratory epithelium. This suggests that donor cells were 
surviving due to the fact that immunosuppressive medication was administered to the 
recipient. At the time of the orthotopic transplantation, data revealed there were no 
donor cells present in the respiratory epithelium which meant donor cell removal 
would have occurred when the immunosuppressive medication was withdrawn. This 
time period was based on the time it took for a donor skin graft to become necrotic 
and slough off and was therefore the necessary length of time (Delaere, Vranckx et 
al. 2010). Although this procedure overcomes the challenge of revascularisation, at 
up to a year in length, it is a very long and costly procedure with a high risk of 
infection as the patient would be on immunosuppressants and the forearm opened 
frequently to verify progress. Other potential limitations of the process include an 
anatomically incorrect squamous epithelial cell layer being formed due to the use of 
buccal  mucosa  and  the  fact  that  several  of  the  tissue  engineered  tracheae  have 
required stenting suggesting a loss of biomechanical properties. Unless the process 
can  be  radically  improved  upon,  this  could  render  the  procedure  unsuitable  for 
routine clinical use (Delaere, Vranckx et al. 2010, Delaere, Vranckx et al. 2014). 
Another method by Conconi (Conconi, De Coppi et al. 2005), adapted from Meezen 
(Meezan, Hjelle et al. 1975) as a way to decellularise trachea involved the following 
treatment: loose fascia was removed from the donor trachea; the trachea was then 
treated with eighteen to twenty-two cycles of incubation in distilled water treatment 
for seventy-two hours followed by 4% sodium deoxycholate for four hours at room 
temperature and 20kU per mL DNase I for three hours at room temperature. Each 
cycle of water, sodium deoxycholate and DNase I took four days to complete. Due to 
the number of steps involved in this method, automation or anything beyond small 
scale scale-up is likely to be a bioprocessing challenge. It would be advantageous if 
the  incubation  times  or  cycle  number  could  be  reliably  reduced,  but  ideally  the 
number of steps involved in each wash would be minimal. Immunohistochemistry 
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epithelial cells and glands had been removed by the decellularisation process. There 
were still a few chondrocytes detected within the cartilage rings, although these were 
mostly disrupted, with indistinct cell borders and most had lost their nuclei. However 
given the isolation and low immunogenicity of chondrocytes it is unlikely that their 
presence would raise an immunological response in the recipient, though this issue is 
yet to be resolved. MHC staining demonstrated that MHC class I expression had 
been completely removed after 25 cycles but there was still some localised MHC 
class II expression detected in several areas in the cartilage rings (Conconi, De Coppi 
et al. 2005, Macchiarini, Jungebluth et al. 2008). Originally the overall process of 
decellularising the trachea took between 72 and 88 days, although in further work 
performed on porcine models (Jungebluth, Go et al. 2009), the authors claimed to 
have been able to successfully reduce the distilled water treatment to 48 hours and 
the  number  of  sodium  deoxycholate  and    DNase  I  cycles  needed  to  17.  These 
reductions served to reduce the overall preparation time to approximately 35 days, 
with the limiting step then becoming the expansion of the recipient’s cells. However, 
from the immunostained sections shown in the paper it is ambiguous as to whether 
all  of  the  MHC  class  I  and  II  expression  has  been  completely  removed  and  to 
whether the number of nuclei has been significantly reduced after seventeen cycles 
as claimed in the paper (Jungebluth, Go et al. 2009).  
Whichever method is ultimately used for the generation of tracheal bioscaffolds will 
need to demonstrate that it can achieve the required CQA in terms of histology for 
cell and DNA removal (Sasaki, Funamoto et al. 2009, Hashimoto, Funamoto et al. 
2010), the presence of GAGs (Sasaki, Funamoto et al. 2009, Hashimoto, Funamoto 
et  al.  2010)  and  collagen  content,  which  are  important  as  they  contribute  to  the 
mechanical  properties  of the trachea.  Also  it will be important  to  ensure the re-
seeded  cells  can  redeposit  GAGs  and  proteoglycans  to  engineer  a  trachea  that 
possesses acceptable compressive and tensile properties  (Elder, Eleswarapu et al. 
2009, Funamoto, Nam et al. 2010). Most importantly the chosen method must be 
able to comply with good clinical practice (GCP) or good manufacturing practice 
(GMP)  and  will  need  to  be  scalable  in  order  to  produce  the  required  quantities 
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1.3  Tracheal transplantation for chronic airway indications  
1.3.1  Current situation 
Short segment tracheal defects, which are defined as less than half the length (five to 
six cm) of the trachea in adults and less than a third of the length of the trachea in 
children, can be repaired by resection of the trachea with end-to-end anastomoses or 
slide  tracheoplasty  (Macchiarini,  Jungebluth  et  al.  2008,  Delaere,  Vranckx  et  al. 
2010). Long segment tracheal defects can be treated by a variety of treatments. For 
stenosis, a stent or multiple stents can be positioned in the trachea to reinforce the 
tracheal structure and maintain an open airway. Alternatively a tracheostomy, which 
involves  the  formation  of  a  stoma  (artificial  opening)  in  the  trachea,  can  be 
performed, and followed by intubation with an endotracheal tube or cannula through 
which the patient  can breathe or speak  (Delaere 2009). Although such palliative 
treatments  permit  long-term  survival,  when  breathing  and  speaking  patients 
generally experience significant discomfort (Delaere 2009). An improved treatment 
would employ the use of a tracheal replacement for long segment and recurrent short 
segment defects (Delaere 2009). Autografts have been used to repair trachea defects, 
however due to limited donor sites and the specific structure of the trachea, this 
method is not optimal (Rinker 2009). A more physiological appropriate solution is 
the use of allograft tracheae from heart-beating and non-heart-beating donors, but 
this  poses  major  challenges  (NHSBT  2009).  As  the  trachea  is  immunologically 
active (Birchall and Macchiarini 2008), current allotransplantation relies on major 
histocompatibility complex (MHC) matching of the donor and the recipient in order 
to reduce the amount of immunosuppressive medication required to prevent graft 
versus  host  disease  and  graft  rejection.  This  requires  the  patient  to  wait  until  a 
matched donor is found for the allotransplantation to proceed. In the Delaere and 
colleagues tracheal allotransplantation the procedure was delayed by nine months 
whilst a suitable donor was found for the patient (Delaere, Vranckx et al. 2010).  In 
conventional allotransplantation, immunosuppressive medication therapy would then 
be  administered  to  the  patient  for  the  remainder  for  the  patient’s  life  to  prevent 
rejection and ensure graft survival. Due to the differences in drug metabolism from 
patient to patient, therapeutic drug monitoring is then required on an individual basis 
to achieve the desired therapeutic effect whilst minimising toxicity to the patient 
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immunosuppressive medication can be severe (Delaere 2009).  These can include 
high  blood  pressure,  diabetes,  high  cholesterol,  osteoporosis,  susceptibility  to 
infections  and  cancer.  Overall,  the  medication  can  reduce  life  expectancy  by  an 
average of 10 years (Hathaway, Winsett et al. 2003, Highfield 2008). This risk of 
cancer is especially relevant for patients whose tracheal defect was originally caused 
by neoplasms. The overall effect of this can result in an improved quality of life 
afforded by the transplant being diminished by the immunosuppressive drug side 
effects  (Hathaway,  Winsett  et  al.  2003).  In  the  Delaere  allotransplantation,  the 
immunosuppressive medication regime lasted only seven and a half months, whilst 
the trachea was adapted in the patient’s forearm to prevent rejection by the patient’s 
immune system, which is an acceptable length of time given the overall benefits 
(Delaere, Vranckx et al. 2010). However, in typical tracheal transplants, where the 
defects are not life-threatening and the primary objective is to improve the patient’s 
quality of life, allotransplantation is unlikely to be justified due to the nature of the 
side effects (Delaere 2009). This results in an unmet medical need for patients who 
suffer with high morbidity as a result chronic airway defects.    
1.3.2  Proof of concept in patient 
In  2008  Dr  Macchiarini  and  colleagues  performed  a  ground  breaking  clinical 
transplantation of a tissue-engineered airway into a thirty year old woman, Claudia 
Castillo, with end-stage bronchomalacia as a result of infection with tuberculosis.  
The procedure, as previously described (section 1.2.4 Biological scaffolds), involved 
a trachea from a deceased donor being decellularised using detergents and enzymes 
over a period of six weeks resulting in an ECM scaffold. Mesenchymal stem cells 
and bronchial epithelial cells were then taken from Castillo and expanded in the 
laboratory, during which time the mesenchymal stem cells were differentiated into 
chondrocytes.  The  bronchial  epithelial  cells  were  seeded  onto  the  lumen  of  the 
decellularised  scaffold  and  the  chondrocytes  were  applied  to  the  outside  of  the 
decellularised scaffold. After four days of incubating the scaffold and the attached 
cells  in  a  bioreactor  designed  specifically  for  that  purpose,  the  newly  tissue 
engineered trachea was cut to the appropriate size and was transplanted into Castillo 
without any need for immunosuppressive medication. At four days post-operatively, 
the graft was virtually impossible to distinguish from the adjoining tracheobronchial 
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operation  Castillo  was  able  to  leave  the  hospital  and  as  a  result  her  life  was 
transformed. Pre-operatively Castillo experienced a high level of morbidity. She was 
essentially bed-bound and unable to breathe adequately enough to perform simple 
duties. Post-operatively, she was able to work full time and look after her children 
(Bristol_University 2008, Macchiarini, Jungebluth et al. 2008). At one month post-
operatively,  the  graft  was  identical  to  the  adjacent  epithelium  and  elicited  local 
bleeding  when  a  biopsy  was  taken,  which  means  revascularisation  had  occurred 
within the graft to support cell growth and survival (Macchiarini, Jungebluth et al. 
2008).  
The major success of this clinical procedure with this outcome was achieved without 
the needed for immunosuppressive medication, so there were no undesirable side 
effects, mild or serious, which could diminish Castillo’s future quality of life. Follow 
up  reports  indicated  that  five  years  on  from  the  operation,  Castillo  was  in  good 
health,  the  trachea  remained  open  with  a  functional  respiratory  epithelium  and 
showed no sign of developing anti-donor antibodies, which could be indicative of 
potential rejection, or stem cell related teratoma. However a progressive stenosis and 
partial  loss  of  mechanical  integrity  had  developed  which  required  repeated 
treatments and stenting (Baiguera, Birchall et al. 2010, Gonfiotti, Jaus et al. 2014). A 
similar case was reported for a two year follow-up of a tissue engineered tracheal 
replacement  in  a  child.  The  results  detail  that  although  after  two  years  post 
operatively the boy had a functional airway and was living a normal  active life, 
medical  intervention  including  stenting  had  been  required  until  the  respiratory 
epithelium and biomechanical strength was restored (Elliott, De Coppi et al. 2012). 
Given  that  the  alternative  to  these  highly  experimental  procedures  was  for  the 
patients to remain with a high level of morbidity, the outcomes for these patients, 
despite the need  for post-operative medical  intervention, represents landmarks in 
transplant history.  
Despite the success with this type of tissue engineered trachea transplantation, the 
transplanted  tissue-engineered  trachea  was  avascular  and  there  was  a  risk  of 
unpredictable  healing  which  could  cause  stenosis  (Macchiarini,  Jungebluth  et  al. 
2008, Delaere, Vranckx et al. 2010). There are many groups researching methods to 
aid  revascularisation  of  an  ECM  scaffold  which  are  briefly  highlighted  below. 
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wrapping trachea in fascia, which was attached to the radial artery and two radial 
veins.  The  donor  trachea  was  then  implanted  into  the  recipient’s  arm  for  nine 
months. By doing this they used the patient’s own body as a bioreactor to ensure 
revascularisation  of  the  trachea  (Delaere,  Vranckx  et  al.  2010).  Moioli  and 
colleagues reported that the addition of haematopoietic stem cells (HSC) or bone 
marrow  aspirate onto  the ECM  scaffold  could  help  with  vascularisation  (Moioli, 
Clark  et  al.  2008).  Tan  and  colleagues  reported  that  the  addition  of  vascular 
endothelial growth factor (VEGF) to a continuous flow of medium to which the 
scaffold  was  exposed  increased  angiogenesis  on  the  scaffold  (Tan,  Steiner  et  al. 
2007). Lastly, Kapickis and colleagues explored the idea of implanting a vascular 
bundle into the avascular tissue to encourage revascularisation (Kapickis, Sassu et al. 
2009). The methods proposed here, along with others, will need to be evaluated if it 
becomes apparent that revascularisation is necessary for tissue engineered tracheal 
transplantation. 
1.3.3  Health care cost concerns 
Currently there are approximately 270 patients in the United Kingdom that would 
benefit from a tracheal transplantation (Boseley 2008). Tracheal transplantation is 
theoretically an unproblematic procedure, however the high number of surgical and 
prosthetic tracheal alternatives that have been attempted throughout the last century 
implies that there is a lack of ideal tracheal replacements (Birchall and Macchiarini 
2008).    As  a  result,  tracheal  transplantations  are  somewhat  of  a  rare  event.  The 
consequence of this being the unknown mortality and morbidity associated with the 
procedure  (Birchall  and  Macchiarini  2008).  Due  to  the  lack  of  cost  analysis  for 
tracheal transplantation, data extrapolated from National Health Service for all day 
operations on head and neck cancers were used as models of tracheal transplants and 
human  lung  transplants  for  the  corresponding  immunosuppression  requirements. 
These estimate the cost of tracheal allotransplantation in 2008 at £37,000 (Guy’s 
Hospital London tariff), inclusive of preparation, patient follow-up and associated 
drug  costs  for  the  first  six  months.  After  this,  the  continuing  yearly  cost  of 
immunosuppression  is  estimated  to  be  approximately  £5,100  (Birchall  and 
Macchiarini 2008). However if the trachea were to be tissue engineered prior to 
transplantation then the cost of preparing the transplant would rise. However, given 
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cost saving of £2,550 for the first six months of post-operative care for the patient 
and then a continuing cost saving of £5,100 per annum, over the initial five years this 
saving  amounts  to  approximately  £27,500  (Birchall  and  Macchiarini  2008). 
Comparing  this  to  the  long-term  cost  of  admitting  a  patient  as  symptomatic  as 
Castillo pre-operatively into intensive care twice a week, which Macchiarini was 
quoted as saying cost £3000 per day, then the treatment cost will be swiftly recouped 
with an overall cost saving being made by the health care provider. Factoring into 
this the human cost of improved quality of life, the treatment costs are modest given 
the likely benefit to the patients (Birchall and Macchiarini 2008) and the removal of 
their reliance on the health care system. 
1.3.4  Potential techniques to achieve scale-up 
Following  on  from  the  pioneering  clinical  work  performed  by  Macchiarini  and 
colleagues  in  2008,  whereby  a  tissue-engineered  trachea  was  transplanted  into  a 
thirty year old woman with end-stage bronchomalacia (Macchiarini, Jungebluth et al. 
2008), this research project aims to build upon that achievement. To that end, the 
aim of this project is to develop a method for the rapid, effective and non-detrimental 
decellularisation of the trachea that is amenable to automation and scale-out. This 
would  represent  progress  towards  the  generation  of  a  process  for  ‘off-the-shelf’ 
tissue-engineered  trachea  that  can  be  easily  accessed  by  clinicians  to  meet  the 
medical need of patients with serious clinical airway disorders. Challenges to be 
investigated are the process of tracheal decellularisation, with the particular need for 
developing a robust technique which gives reproducible results and ideally can be 
fully or semi-automated. Also to be investigated are the analysis techniques to ensure 
the ECM and cartilage rings of the trachea remain structurally intact whilst being 
appropriately decellularised. These include light and electron microscopy techniques 
and  immunohistochemistry  methods,  qualitative  assessment  of  remaining  ECM 
components  and  biomechanical  testing  of  the  scaffolds.  With  regards  to 
recellularisation,  although  Macchiarini,  as  a  follow-on  from  the  clinical 
transplantation of a tissue-engineered airway (Macchiarini, Jungebluth et al. 2008), 
sprayed mesenchymal stem cells (MSC) directly onto the tracheal scaffold for the 
last two patients to be treated, indicating the cells can differentiate instinctively in 
vivo possibly due to the presence of protein residues on decellularised tracheal ECM, 
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be  published.  Therefore,  methods  for  the  efficient  expansion,  differentiation  and 
seeding the recipient’s cells onto the scaffold will also need to be investigated as 
well as the use of adult stem cells and progenitor cells.  
To achieve tissue engineered trachea on a commercial level, other considerations 
will  need  to  be taken  into  account.  These  include  the  procurement  of  the  donor 
scaffolds ensuring compliance with the Human Tissue Act (HTA) regulations on 
organ donation, guidance on the appropriateness of the donated trachea, primarily 
regarding  the  age  and  health  of  the  donor  and  consideration  to  the  means  of 
transporting the donated trachea to the site where the decellularisation occurs.  The 
method of procuring the patient’s cells would also entail the same considerations as 
the tracheal procurement. As mentioned previously, the process of decellularisation 
would need to comply with GMP, would need to have clearly defined CQA, TPP 
and release criteria and would ideally involve automation. The culture system for the 
expansion of the patient’s cells would again need to adhere to GMP, would ideally 
involve automation and the use of chemically defined media and associated solutions 
or, if this is not possible, evidence would be required to prove due diligence in the 
procurement of the cell culture media and/or solutions. The assembly of the tissue 
engineered trachea would have to optimise the time for culturing the cells on the 
ECM,  it  would  also  ideally  incorporate  automation  of  the  procedure,  the  use  of 
chemically-defined media, and compliance with GMP with clearly defined release 
criteria.  Delivery  to  the  site  of  transplantation  would  then  need  to  resolve  the 
logistics of packaging criteria, especially concerning the temperature control,  the 
vibration control and a method of monitoring to ensure the ranges of neither have 
been exceeded. For the actual clinical application of the tissue engineered trachea, 
considerations  include  its  on-site  storage  and  the  maximum  shelf-life  prior  to 
transplantation (Kemp 2010). Again, as tissue engineered tracheae would be classed 
as ATMP, their use in the United Kingdom would be regulated by the Medicines and 
Healthcare  products  Regulatory  Agency  (MHRA)  and  the  European  Medicines 
Agency (EMA) (Daniels 2010). 
To  achieve  true  scale-up  rather  than  just  scale-out,  the  employment  of  synthetic 
scaffolds and non-immunogenic embryonic stem cells will most likely be necessary. 
Until suitable reproducible artificial scaffolds can be created, and are proven as such 
in pre-clinical trials, then it is unlikely that true scale-up can be achieved. Similarly Page - 50 - of 223 
 
until pre-clinical and clinical trials have proven that embryonic stems cells can be 
used  in  a  non-immunogenic  manner,  true  scale-up  will  be  difficult  to  achieve 
because of the ongoing need for individual patient involvement. 
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2  Materials and Methods 
2.1  Procurement  and  preparation  of  porcine  tracheae  for 
experimentation 
Porcine tracheae, from male pigs with an average weight of 90 kg, were obtained 
from Animal Organs for Research (based at Cheale Meats Ltd. abattoir, Brentwood, 
UK). Porcine plucks, which consist of the heart, liver, windpipe, and lungs of the 
slaughtered pig, were trimmed by Matthew Cheale onsite to obtain the trachea from 
the  larynx  to  the  carina.  They  were  packaged  into  plastic  bags,  which  were 
surrounded by wet ice, in a polystyrene box and transported by motorcycle courier to 
the  laboratory.  Upon  arrival  they  were  further  trimmed  to  remove  the  cricoid 
cartilage from the upper region and the bronchi branches from the lower region of 
the trachea. The loose visceral fascia was also trimmed from the organ. The tracheae 
were either used fresh or stored (frozen) for future use as required. 
2.2  Preparation  of  porcine  tracheal  scaffolds  by  detergent-enzymatic 
method (DEM) decellularisation 
To achieve DEM decellularisation the tracheae were treated as previously reported 
(Conconi, De Coppi et al. 2005, Macchiarini, Jungebluth et al. 2008, Jungebluth, Go 
et al. 2009) with some modifications: a tenfold reduction in the concentration of 
DNase  I  to  reduce  assay  costs;  the  omission  of  the  48/72  hour  distilled  water 
incubation  step  from  every  cycle  due  to  misinterpretation  of  the  published 
methodology; and the inclusion of an overnight (18 hour) phosphate buffered saline 
(PBS)  incubation  step  (Figure  2.1).  Process  steps  were  performed  in  50  mL 
centrifugation tubes with a solution volume of up to 50 mL. 
Fresh tracheae were washed 3 x 15 minutes in 1 x phosphate buffered saline (PBS) 
(Sigma,  Poole,  UK)  containing  100  units/mL  of  penicillin,  100  µg/mL  of 
streptomycin,  and  250  ng/mL  of  amphotericin  B  solution  (Life  Technologies, 
Paisley, UK) whilst rotating at 33 revolutions per minute (rpm) at room temperature 
(RT). The tracheae were cut into approximately 5 x 30 mm length sections. The 
tracheae were then subjected to the decellularisation protocol. Initially the tracheae 
were  incubated  statically  in  distilled  water  for  72  hours  at  4°C  followed  by:  25 
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in distilled water for 4 hours at RT on a roller mixer at 33 rpm; an enzymatic step of 
2kU/mL DNase I  (Sigma, Poole, UK) in 1M sodium chloride (NaCl) (Sigma, Poole, 
UK) for 3 hours at RT on a roller mixer at 33 rpm; and a wash step of 1 x PBS 
containing 100 units/mL of penicillin, 100 µg/mL of streptomycin, and 250 ng/mL 
of amphotericin B solution 16 hours statically at 4°C. In between steps the tissues 
were washed 3 x 5 minutes in PBS containing 100 units/mL of penicillin, 100 µg/mL 
of streptomycin, and 250 ng/mL of amphotericin B solution. Samples (a single 30 
mm  section)  were  taken  for  testing  at  cycles  10,  20  and  25  at  which  point  the 
sections were stored in PBS containing 100 units/mL of penicillin, 100 µg/mL of 
streptomycin, and 250 ng/mL of amphotericin B solution at 4°C for no more than 3 
days.  Non-decellularised  control  (NDC)  tracheae  were  stored  statically  in  PBS 
containing 100 units/mL of penicillin, 100 µg/mL of streptomycin, and 250 ng/mL 
of amphotericin B solution at 4°C for matched periods of time. 
 
Figure  2.1:  Overview  of  the  detergent  and  enzymatic  method  (DEM) 
decellularisation. 
2.3  Preparation, embedding and sectioning of tissue in paraffin 
Tracheal tissues cut to 3-4 mm in depth in the transverse and sagittal planes were 
fixed in 10% neutral buffered formalin (NBF) solution in approximately 20 times the 
tissue volume for a minimum of 48 hours. The tissues were placed in appropriately 
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cassettes  were  placed  back  into  10%  NBF  until  processed.  The  tissues  were 
automatically processed using the VIP 3000 Tissue Processor (Sakura, Thatcham, 
UK) to dehydrate the tissue to remove the fixative and water, clear the tissue to 
prepare  it  for  impregnation  and  finally  impregnate  the  tissue  with  embedding 
medium. Briefly the tissues were immersed in 10% NBF for 2 hours at RT, 70% 
industrial methylated spirits (IMS) for 1 hour at RT, 90% IMS for 1 hour at RT, 3 x 
100% IMS for 1 hour at RT, 50% IMS:50% toluene for 1 hour at RT, toluene for 30 
minutes at RT, toluene for 1 hour at RT, toluene for 30 minutes at RT, paraffin wax 
for 30 minutes at 60°C, paraffin wax for 1.5 hour at 60°C, paraffin wax for 1.5 hour 
at 60°C. When the processor was finished the processed cassette was transferred to 
the Tissue Tek III embedding centre and placed into the thermal console drawer at 
60°C, where it could be stored for up to 4 hours before embedding. When ready to 
embed, a suitable sized embedding mould was selected and the base of the mould 
covered in molten wax, the tissue was removed from the cassette and embedded into 
the  mould  and  molten wax,  ensuring  the  required  surface  was  face  down  in  the 
mould. The cassette (without the lid) was placed atop the mould and the mould was 
filled with more molten wax. The mould was moved to the cryo-console at -5°C to 
solidify the wax. After approximately 30 minutes, when the wax had hardened, the 
blocks were removed from the moulds and chilled on ice. The process of sectioning 
began by roughly trimming of the tissue block on the rotary Shandon Finesse AS325 
microtome  (Thermo  Scientific,  Loughborough,  UK)  until  a  complete  section  of 
tissue was obtained. The blocks were then cooled again on ice for a further 1 hour.  
Sections of 5 µm thick were the obtained from the block and floated, in a 40°C water 
bath  (Thermo  Scientific,  Loughborough,  UK),  onto  the  surface  of  the  water  and 
allowed to flatten out. The desired sections were separated and, using a pre-labelled 
slide, gently lifted out of the water. The slides were placed onto a 60°C hot plate 
overnight to dry the sections onto the slides before staining. 
2.4  Preparation, embedding and sectioning of tissue in optimum cutting 
temperature (OCT) compound  
To  analyse  specific  components  of  the  tissues,  the  tissues  were  prepared  for 
immunohistochemistry  (IHC)  and  immunofluorescence  labelling.  Tracheal  tissues 
were cut to 3-4 mm in depth in the transverse and sagittal planes and were then 
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to  preserve the tissue structure. The sections  were then  briefly rinsed in  PBS  to 
remove external sucrose solution. Cryomolds were half filled with optimum cutting 
temperature compound (OCT compound) (VWR, Leuven, Belgium). The tissue was 
positioned  carefully,  ensuring  the  side  of  interest  was  facing  the  bottom  of  the 
cryomold,  in  the  OCT  compound.  The  cryomold  was  then  filled  with  OCT 
compound until the tissue was fully submerged, ensuring there were no bubbles near 
the tissue as this would cause problems when sectioning. The cryomolds were then 
placed in liquid nitrogen to allow uniform freezing of the OCT compound and tissue 
to a solid white block. The frozen samples were removed from the cryomolds stored 
at -80°C until sectioned. When sectioning was required, the samples were transferred 
to Thermo Scientific Cryotome FE Cryostat (Thermo Scientific, Loughborough, UK) 
and mounted onto an appropriately sized cryocassette using OCT compound. The 
cryocassette  was  then  attached  to  the  cryocassette  clamp  and  OCT  compound 
embedded  sample  positioned  just  above  and  behind  the  blade.  The  sample  was 
trimmed to remove overlying OCT compound until all regions of the tissue were 
fully exposed. With the anti-roll bar in position, sections of 6 m thickness were 
then taken, using a new area of the blade, and picked up onto a positively charged 
adhesion microscope slide (Thermo Scientific Menzel-Gläser, Loughborough, UK). 
The sections were air-dried onto the slides at 60°C for approximately 4 hours before 
use then used immediately or stored at -20°C until required.   
2.5  Preparation and embedding of tissue in LR white resin   
To  analyse  the  tissues,  the  tissues  were  prepared  for  transmission  electron 
microscopy  (TEM)  by  embedding  the  tissue  in  London  Resin  (LR)  White.  This 
embedding  technique  also  enabled  histological  analysis  of  the  tissues  by 
haematoxylin and eosin staining. The tissues were pre-fixed in 3% glutaraldehyde 
(Agar  Scientific,  Stansted,  UK)  in  0.1M  sodium  cacodylate  (Agar  Scientific, 
Stansted, UK) (pH 7.4) at room temperature for 30 minutes or overnight. The tissue 
samples were then sliced with a sharp razor blade into approximately 1-2 mm thick 
sections.  These  sections  were  then  fixed  in  3%  glutaraldehyde  in  0.1M  sodium 
cacodylate (pH 7.4) at  4°C for 3 hours. The sections were then dehydrated in  a 
graded series of alcohols: 20% ethanol for 15 minutes; 50% ethanol for 15 minutes; 
70% ethanol for 15 minutes; and 3 x 90% ethanol for 10 minutes, all performed at 
RT.  The  sections  were  then  infiltrated  with  LR  white  resin  hard  grade  (Agar Page - 55 - of 223 
 
Scientific, Stansted, UK) as follows: 1:1 of LR white: 90% ethanol for 30 minutes at 
RT; pure LR white for 30 minutes at RT; pure LR white at 4°C overnight; pure LR 
white for 30 minutes at RT. The sections were then embedded into the LR white 
resin  by  placing  the  sections  into  foil  containers,  in  the  desired  orientation,  and 
covering with 50 mL LR white containing 75 µL of LR white accelerator (Agar 
Scientific, Stansted, UK). Pre-cut parafilm was gently placed on the surface of the 
resin  to  exclude  the  air.  The  sections  were  then  incubated  at  -20°C  for  1  hour 
followed by 24 hours at 4°C to polymerise the LR white. The parafilm was then 
removed from the resin blocks for final curing at room temperature for at least two 
days. 
2.6  Sectioning and analysis by transmission electron microscopy (TEM) 
Ultrathin sections (90–100 nm) of the LR White embedded tissue sections were cut 
for  TEM  analysis  with  an  ultramicrotome  (Reichert  UltracutE,  Cambridge 
Instruments,  Cambridge,  UK)  using  a  diamond  knife  (Diatome  AG,  Biel, 
Switzerland). The sections were mounted onto Formvar/Carbon coated 200 mesh 
gold grids (Agar Scientific) and stained with 0.1% (w/v) uranyl acetate in absolute 
alcohol for 5 minutes followed by Reynold’s lead citrate for 5 minutes. The sections 
were  then  examined  by  TEM  using  a  JEOL  100CX  II  transmission  electron 
microscope  (JEOL  UK,  UK)  operating  at  80  kV.  The  images  were  recorded  on 
Kodak EM 4638 film (TAAB, UK) then scanned to provide a digital image. The 
sectioning and imaging of the trachea and the decellularised scaffolds for TEM was 
performed by Nicola Mordan (UCL Eastman Dental Institute). 
2.7  Haematoxylin and eosin staining of tracheal tissue sections 
Tissue sections were stained with haematoxylin and eosin, the most common general 
purpose  stain,  to  differentiate  the  full  cellular  detail  of  tracheal  tissue  sections. 
Nuclei of cells stain blue, cartilage and mucin stain light blue/purple and other tissue 
components such as cytoplasm, connective tissue, red blood cells and muscle stain 
from pink to orange to red. 
The tissue sections on microscope slides from the paraffin embedding process were 
‘taken to water’ to remove the paraffin wax and rehydrate the tissue sections. This 
process involved immersing the slides in xylene for 5 minutes, xylene for 2 minutes, 
absolute industrial methylated spirits (IMS) for 2 minutes, 95% IMS for 2 minutes, Page - 56 - of 223 
 
70% IMS for 2 minutes and tap/distilled water for 2 minutes. The sections were then 
stained  with  Gill’s  III  haematoxylin  for  1.5  minutes,  washed  in  tap  water  for  5 
minutes, differentiated in acid-alcohol (1% HCl in 70% IMS) for 3 seconds, the 
differentiation stopped in tap water for 4 minutes and stained with 0.5% aqueous 
eosin for 5 minutes and rinsed in tap water for 20 seconds. The sections were then 
dehydrated in 70% IMS for 5 seconds, 95% IMS for 5 seconds, absolute IMS for 5 
seconds, cleared in xylene for 2 minutes and held in xylene for at least 2 minutes, 
remaining in the xylene until the sections were mounted with DPX and covered with 
coverslips. The slides were allowed to dry then examined under a microscope (Nikon 
Eclipse  Ti,  Kingston,  UK)  and  imaged  digitally  (Nikon  BR  Elements,  Kingston, 
UK).  
2.8  Analysis of cell clearance and survival following decellularisation  
A  representative  100x  or  60x  magnification  image  from  each  trachea  from  the 
specific tissue region being analysed was obtained. The nuclei, stained blue by the 
haematoxylin, were counted to investigate the clearance of cells from the different 
regions  of  the  tracheae  before,  during  and  after  the  decellularisation  process. 
Chondrocytes were also analysed further to distinguish cells that appeared healthy, 
whether the nuclei remained; and those that were undergoing chondrocyte apoptosis, 
which  was  characterised  by  condensed  nuclei  and  cell  shrinkage  resulting  in 
unstained regions in the lacunae. The cell counting was performed by Vivienne Vu 
(UCL Biochemical Engineering MEng student). Rules were applied to the counting 
process  to  ensure  consistency  throughout  the  analysis.  Statistical  analysis  was 
performed on the cell clearance and cell survival studies following decellularisation 
treatment. GraphPad Prism v5.03 (GraphPad Software, La Jolla, USA) using one-
way ANOVA and Dunnett’s multiple comparison test. 
2.9  Alcian blue staining for GAG analysis 
Tissue  sections  were  stained  with  alcian  blue  to  differentiate  acidic 
mucopolysaccharides or GAGs, found in the cartilage and mucosal glands of the 
trachea, which stain blue, nuclei of cells which stain red/pink and the cytoplasm of 
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The tissue sections on microscope slides from the paraffin embedding process were 
‘taken to water’ to remove the paraffin wax and rehydrate the tissue sections. This 
process involved immersing the slides in xylene for 5 minutes, xylene for 2 minutes, 
absolute industrial methylated spirits (IMS) for 2 minutes, 95% IMS for 2 minutes, 
70% IMS for 2 minutes and tap/distilled water for 2 minutes. The sections were then 
stained with 1% alcian blue in 3% acetic acid (pH 2.5) for 5 minutes, washed in tap 
water for 2 minutes and stained with 0.1% nuclear fast red in 5% aluminium sulphate 
for  1  minute  and  rinsed  in  tap  water  for  20  seconds.  The  sections  were  then 
dehydrated in 70% IMS for 5 seconds, 95% IMS for 5 seconds, absolute IMS for 5 
seconds, cleared in xylene for 2 minutes and held in xylene for at least 2 minutes, 
remaining in the xylene until the sections were mounted with DPX and covered with 
coverslips. The slides were allowed to dry then examined under a microscope (Nikon 
Eclipse  Ti,  Kingston,  UK)  and  imaged  digitally  (Nikon  BR  Elements,  Kingston, 
UK).  
2.10 Fluorescence labelling for analysis of residual DNA 
Localisation  analysis  of  residual  DNA  in  the  tissue  was  performed  using  the 
fluorescent stain 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Poole, UK). 
The analysis was performed on OCT embedded tissue sections fixed to microscope 
slides. If the slide/sections had been frozen, they were brought to room temperature, 
and fixed with a fixative (acetone) then washed three times with Tris-buffered saline 
(TBS) with 0.025% Triton X-100 for 5 min. The sections were then stained with 
DAPI for 30 minutes at room temperature in the dark. The sections were briefly 
rinsed  with  TBS  then  mounted  and  cover-slipped  using  fluorescence  mounting 
medium (Dako, Ely, UK). Imaging was performed on the Nikon Eclipse TE2000-U 
with NIS-Elements BR software (Nikon). ImageJ software (NIH) or NIS-Elements 
BR software was used to annotate the images. 
2.11 IHC  primary  antibody  optimisation  for  analysis  of  ECM 
components 
Primary  antibody  optimisation  was  performed  as  described  for  the 
immunohistochemical (IHC) analysis below, with the following exceptions.  The 
fixative was; ice cold acetone for 10 minutes at -20°C, ice cold methanol for 10 
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10 minutes at RT to establish which provided optimal fixation and permeabilisation 
for each primary antibody. The primary antibody concentration was investigated at 
1:50, 1:100, 1:200 and 1:500 dilutions to determine the lowest concentration with the 
optimal staining.  
2.12 IHC for analysis of ECM components 
Immunohistochemical (IHC) analysis was performed on the OCT embedded tissue 
sections when fixed to microscope slides. If the slide/sections had been frozen, they 
were brought to room temperature, and fixed with ice cold acetone for 10 minutes at                   
-20°C then washed three times with Tris-buffered saline (TBS) with 0.025% Triton 
X-100  for  5  minutes.  The  sections  were  then  blocked,  to  reduce  non-specific 
staining, with 10% normal serum with 1% bovine serum albumin (BSA) in TBS for 
2 hours. All blocking incubation steps were performed at RT on an orbital shaker. 
The sections were then incubated overnight at 4°C with a primary antibody reactive 
to  pig  tissue,  either:  mouse  monoclonal  anti-collagen  II  (ab3092,  Abcam, 
Cambridge,  UK);  rabbit  polyclonal  anti-collagen  II  (ab300,  Abcam,  Cambridge, 
UK); sheep polyclonal anti-fibronectin (ab23516, Abcam, Cambridge, UK); or rabbit 
polyclonal anti-laminin (ab11575, Abcam, Cambridge, UK), all at 1:100 dilution in 
1% BSA in TBS. The sections were then washed two times in TBS with 0.025% 
Triton X-100 for 5 minutes. The sections were then incubated for 1 hour at RT in the 
dark  with  the  secondary  antibodies  conjugated  with  a  specific  Alexafluor,  all  at 
1:200  dilution  in  1%  BSA  in  TBS.  The  secondary  antibodies  were  either  Alexa 
Fluor® 488 goat anti-mouse IgG (H+L) (A-11001, Invitrogen, Paisley, UK) for the 
anti-collagen II (ab3092) primary antibody, Alexa Fluor® 488 goat anti-rabbit IgG 
(H+L) (A-11008, Invitrogen, Paisley, UK) for the anti-laminin and anti-collagen II 
(ab300) primary antibody,  or  Alexa Fluor 555  donkey  anti-sheep  IgG  (A-21436, 
Invitrogen, Paisley, UK), for the anti-fibronectin primary antibody. Following the 
secondary antibody incubation, the sections were washed two times with TBS for 5 
minutes before counterstaining with DAPI for 30 minutes at room temperature in the 
dark. The sections were briefly rinsed with TBS then mounted and cover-slipped 
using fluorescence mounting medium (Dako, Ely, UK). For the negative controls, 
the primary antibody was omitted. IHC imaging was performed on the Nikon Eclipse 
TE2000-U with NIS-Elements BR software (Nikon). ImageJ software (NIH) or NIS-
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2.13 Quantitative analysis of DNA content 
For the quantitative DNA analysis, approximately 25 mg of tissue, frozen at -80°C 
since harvest, was taken and minced using razor blades. The DNA was extracted 
from  the  tissue  using  the  DNeasy  Blood  &  Tissue  Kit  (Qiagen,  Crawley,  UK) 
according to the manufacturer’s instructions. Briefly, the tissue was digested and the 
cells lysed overnight at 56°C whilst shaking in proteinase K solution. The DNA is 
then selectively bound to the DNeasy membrane of a spin column, washed and then 
eluted into a buffer. The quantity of DNA extracted from the tissue was assessed 
using the NanoDrop (ND1000; NanoDrop Products, Wilmington, USA). For each 
DNA  quantitative  test,  the  concentration  of  DNA  was  normalized  to  the  tissue 
weight and the mean ± SD was determined. Two-way ANOVA was used to find any 
statistically significant differences between native and decellularised trachea, as well 
as the corresponding control tissue.  
2.14 Quantitative analysis of GAG content 
For the quantitative total sulphated GAG (sGAG) analysis, approximately 50 mg of 
tissue, frozen at -80°C since harvest, was taken and minced using razor blades. The 
GAG was extracted from the tissue using the Blyscan sGAG Assay (Biocolor Ltd, 
Carrickfergus, UK), according to the manufacturer’s instructions. Briefly, the tissue 
was digested and the cells lysed overnight at 65°C in papain solution (Sigma, Poole, 
UK). The lysate was then diluted appropriately, typically 1:100 in deionised water. 
The sGAG were then selectively bound and formed a complex with 1,9-dimethyl-
methylene blue in the dye reagent, which precipitated out of the solution. Following 
centrifugation,  the  bound  sGAG-dye  complex  pelleted  and  the  supernatant  was 
removed. The sGAG-dye complex was then dissociated and the absorbance read at 
656nm  using  the  Tecan  Sunrise  (Tecan)  or  the  Tecan  Safire2™  (Tecan)  and 
compared to a 0 - 50 µg/mL standard curve. For each GAG quantitative test, the 
concentration of GAG was normalized to the lysate dilution and the tissue weight 
and  the  mean  ±  SD  was  determined.  Two-way  ANOVA  was  used  to  find  any 
statistically significant differences between native and decellularised trachea, as well 
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2.15 Quantitative analysis of total collagen content 
For the quantitative total collagen analysis, approximately 25 mg of tissue, frozen at  
-80°C since harvest, was taken and minced using razor blades. The total collagen 
was  extracted  from  the  tissue  using  the  Quickzyme  Total  Collagen  Assay 
(2BScientific, Upper Heyford, UK), according to the manufacturer’s instructions. 
The  method  was  based  on  the  detection  of  hydroxyproline  which  is  present  in 
mammalian  collagen  and  elastin  and  was  modified  from  a  previously  described 
method  for  quantifying  hydroxyproline.  Briefly,  the  tissue  was  completely 
hydrolysed overnight at 95°C in 6M hydrochloric acid (HCl) (Sigma, Poole, UK). 
The  lysate  was  then  diluted  appropriately,  typically  1:75  in  4M  HCl.  The 
hydroxyproline  was  oxidised to  a modified form  of hydroxyproline (likely to  be 
pyrrole in the present of toluene) and then reacted with a chemical (likely to be p-
dimethylaminobenzaldehyde)  to  form  a  chromogen.  The  absorbance  of  the 
chromogen  was  read  at  570nm  using  the  Tecan  Sunrise  (Tecan)  or  the  Tecan 
Safire2™ (Tecan) and compared to a 0 - 300 µg/mL standard curve. For each total 
collagen quantitative test, the concentration of total collagen was normalized to the 
tissue weight and the mean ± SD was determined. Two-way ANOVA was used to 
find  any  statistically  significant  differences  between  native  and  decellularized 
trachea, as well as the corresponding control tissue. 
2.16 Tensile testing of tracheae tissue and scaffolds 
Tensile testing was used to evaluate the uniaxial ultimate tensile strength (stress at 
failure), the Young’s (tensile) modulus and tensile extension (strain at failure) of the 
tracheal cartilage rings, in the transverse plane for native, decellularised (DC) and  
corresponding  PBS  control  (NDC)  tracheas  from  various  stages  in  the 
decellularisation process. The Instron 5565 (Instron, High Wycombe, UK) was used 
to  mechanically  interrogate  and  record,  using  Bluehill  2  software  (Instron,  High 
Wycombe, UK), in real time the tensile properties of each sample. For the cartilage 
ring tensile testing, a section of cartilage ring was punched out of the tracheal tissue 
using a 10 x 2 mm dumbbell shaped punch in a specimen cutting press (Model S1) 
(Wallace Instruments, Cambridge, UK). The thickness of the sample was measured 
using digital callipers and recorded. The sample was then clamped into the specimen 
grips. The uniaxial tension was increased at a constant rate of 100 mm min-1 until 
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in the cartilage and assessment of the stress–strain curves. The three parameters were 
determined from the tensile stress–strain curves. All were plotted as the mean ± SD 
for each analysis. Two-way ANOVA was used to compare decellularised scaffolds 
findings with native tracheae and corresponding control (NDC) findings over the 
decellularisation process. 
2.17 Radial compression force testing of tracheae tissue and scaffolds 
Radial compression force testing was used to evaluate the resistance to collapse of 
sections of tracheae as an indication of circumferential strength of the tracheae, the 
cartilage rings and ability of a bioengineered tracheae to maintain an open airway in 
vivo (Jones, Rueggeberg et al. 2014). For the testing, 3 cm sections were cut from the 
tracheal  length  for  native,  freeze-thawed  (by  various  methods)  tracheae,  and 
decellularised (DC) tracheae. The Instron 5565 (Instron, High Wycombe, UK) was 
used to mechanically interrogate the compressive properties of each sample. As the 
compression software was not available with the current Bluehill 2 software, the 
lowering of the upper grip was manually controlled and the readings were manually 
recorded  from  the  Bluehill  2  software  package.  Small  flat  plastic  plates,  with 
graspable handles, were placed into the upper and lower grips of the Instron 5565 
(Instron, High Wycombe, UK). The 3 cm tracheal section was placed onto the lower 
grip and the upper plate manually lowered until just touching the top to the tracheal 
section. The extension and load reading on the Bluehill 2 software were reset. Using 
the fine adjust control on the Instron 5565 control pad, the upper grip was manually 
lowered at a steady rate until the lumen of the trachea was fully occluded. Load (N) 
readings were recorded every 0.5 mm of compression. The circumferential strength 
was determined by plotting the compression (mm) versus the load (N), calculating 
the straight line equation for the linear portion and the radial compressive load (N) at 
50% occlusion. The results were plotted as the mean ± SD for each analysis. Two-
way  ANOVA  was  used  to  compare  native  tracheae  findings  with  decellularised 
scaffold  findings  at  various  stages  of  the  decellularisation  process.
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3  Detergent-enzymatic method of decellularisation 
3.1  Introduction 
Since  the  high  profile  first  tissue  engineered  tracheal  transplant  in  2008 
(Macchiarini, Jungebluth et al. 2008), the method for preparing the decellularised 
human  trachea  construct  remains  unchanged.  This  clinical  gold  standard 
decellularisation method is an adaptation of a detergent-enzymatic method (DEM), 
which  investigated  the  potential  of  decellularised  porcine  tracheal  scaffolds 
repopulated with autologous cells for transplantation purposes (Conconi, De Coppi 
et al. 2005). The DEM had itself been derived from a method which described a 
detergent  based  method  that  solubilised  the  cell  membranes  and  intracellular 
components of tissue but left the basement membranes intact. Thereby inferring that 
the  ECM,  with  this  treatment,  could  remain  intact  and  indistinguishable  by 
ultrastructure  from  native  tissue  (Meezan,  Hjelle  et  al.  1975).  Meezan  had  also 
recognised  the  issue  of  agglutination  of  the  cell  debris,  primarily  the  nuclear 
material,  around  the  tissue  when  treated  with  the  detergent  and  therefore 
demonstrated that prior washes with distilled water and treatment with the enzyme 
DNase could lessen the extent of agglutination (Meezan, Hjelle et al. 1975). 
Whereas Meezan had been treating isolated organ subfractions (Meezan, Hjelle et al. 
1975), Conconi intended to decellularise a whole pig trachea and therefore altered 
Meezan’s method by increasing the incubation times and changing the order of the 
DNase and detergent steps. The new method now comprised a distilled water wash 
step, followed by a detergent treatment step and lastly an enzymatic DNase treatment 
step (Conconi, De Coppi et al. 2005). Crucially Conconi also recognised that this 
single  treatment  would  be  insufficient  for  adequate  decellularisation  of  a  whole 
trachea and therefore multiple cycles of the treatment were performed, with each 
cycle taking 79 hours or 4 working days  to  complete. Through experimentation, 
Conconi determined that although 18 cycles (which would take 72 working days to 
complete)  didn’t  completely  decellularise  the  porcine  trachea,  it  reduced  the 
immunogenicity of the trachea sufficiently and that 22 cycles (which would take 88 
working days to complete) completely decellularised the porcine trachea but resulted 
in loss of structural integrity of the trachea (Conconi, De Coppi et al. 2005). Conconi 
used the Herberhold method, which takes  the alternative approach of chemically  
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conserving  trachea  tissue  for  transplant  purposes,  as  the  control  method.  The 
Herberhold method is a process that requires a minimum of 80 days to complete 
(Herberhold,  Franz  et  al.  1980).  Conconi  successfully  demonstrated  clearance  of 
cells, along with MHCs class I and II, from the epithelial layer and sub-mucosal 
gland regions, but conceded that after 18 cycles, chondrocytes were still visible in 
the  cartilage  ring  region.  Conconi  established  that  if  the  number  of  cycles  were 
increased  from  18  to  22  then  full  decellularisation  could  be  achieved  but  that 
structural integrity of the trachea was compromised. However, as the cartilage matrix 
is  an  immunologically  privileged  region  of  tissue,  with  limited  infiltration  of 
immune cells due to lack of vasculature, it was regarded as satisfactory to merely 
remove the immunogenic material from the non-cartilaginous regions of the trachea, 
rather  than  compromise  structural  integrity.  Conconi  also  demonstrated  that 
improved seeding of chondrocytes and tracheal epithelial cells could be achieved 
over  the  Herberhold  method  treated  control  tracheas  (Conconi,  De  Coppi  et  al. 
2005), which was deemed critical prior to in vivo transplantation. 
In translating the DEM for clinical practice (Macchiarini, Jungebluth et al. 2008), it 
was determined that 18 cycles of the treatment was not sufficient to remove all traces 
of donor MHC in human trachea and it was necessary to increase the process to 25 
treatment  cycles  (Macchiarini,  Jungebluth  et  al.  2008),  which  would  take  100 
working days  to  complete. The impact  of these additional cycles, if any, on the 
structural integrity of the human tracheal scaffold was not discussed in the paper.  
Following publication of the clinically tested DEM (Macchiarini, Jungebluth et al. 
2008), follow-up work investigating the structural and morphological effects of the 
DEM on pig tracheae (Jungebluth, Go et al. 2009) and the requirement for seeding of 
the recipient’s cells on DEM tracheal scaffolds in vivo (Go, Jungebluth et al. 2010) 
were  published.  Both  of  these  papers  contained  a  revised  DEM  of  17  treatment 
cycles where the distilled water step had been reduced from 72 hours to 48 hours 
(Jungebluth, Go et al. 2009, Go, Jungebluth et al. 2010), with the authors reporting 
the revised DEM would take 35 ± 1 days to complete for pig tracheae scaffolds 
(Jungebluth, Go et al. 2009). These latter papers confirmed the cell clearance from 
all regions of the trachea, except the cartilage rings, (Jungebluth, Go et al. 2009) and 
removal of MHCs class I and II  (Jungebluth, Go et al. 2009, Go, Jungebluth et al. 
2010) described by Conconi (Conconi, De Coppi et al. 2005). They further described  
Page - 64 - of 223 
 
the mechanical characteristics of whole tracheae by testing for longitudinal uniaxial 
tensile strain (Jungebluth, Go et al. 2009), quantifying Conconi’s observed loss in 
biomechanical strength beyond 17 cycles of DEM decellularisation (Conconi, De 
Coppi et al. 2005). Jungebluth also described heterotopic allogeneic and xenogeneic 
transplantation,  observing  that  DEM  decellularisation  greatly  reduced  the 
inflammatory response from the host and prevented rejection of the implanted tissue 
(Jungebluth, Go et al. 2009). Go further described successful seeding of the DEM 
scaffolds  with  cells  and  detailed  how  orthotropic  allogeneic  transplantation  and 
maintenance of the longitudinal mechanical strength is only possible if both MSC-
derived chondrocytes and epithelial cells are seeded onto the scaffolds to prevent 
stenosis of the scaffold or bacterial/fungal contamination of the graft (Go, Jungebluth 
et al. 2010). 
When clinically translated to focus on optimisation of the decellularisation of human 
trachea (Baiguera, Jungebluth et al. 2010), the water washes were reduced to brief 
rinse steps before and during the detergent-enzyme cycles. The protocol suggested 
that between each detergent-enzymatic cycle there was an overnight PBS hold/wash 
step. This change was implemented so that 25 cycles of DEM would typically take 
30 days, which would be expected if the lengthy water washes were replaced with 
overnight static PBS hold/wash steps. Furthermore, the authors stated it could be 
shortened to a 17 day process without altering the ultimate number of cycles of the 
DEM. This suggests the authors completed up to two cycles in one day, which would 
suggest the PBS wash between these two cycles would be considerably shorter or 
skipped altogether, with an 8 hour PBS wash step every other cycle if skipped, or 4 
hour PBS wash steps between each cycle. The latter would entail laboratory staff 
working shifts to staff the laboratory 24 hours a day. Baiguera demonstrated that the 
DEM decellularisation protocol could be translated from porcine to human trachea, 
substantiating the Macchiarini paper (Macchiarini, Jungebluth et al. 2008), to obtain 
a similar reduction in cell and DNA clearance whilst maintaining longitudinal tensile 
strength. Evidence of the DEM scaffolds’ angiogenesis potential from retained pro-
angiogenic  molecules,  such  as  bFGF,  that  were  retained  on  the  decellularised 
scaffolds was also demonstrated (Baiguera, Jungebluth et al. 2010).  
By  2012,  nine  paediatric  and  adult  patients  had  received  tracheae  that  had  been 
decellularised by the DEM method and recellularised with the patient’s own cells  
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either in a bioreactor or intraoperatively on a compassionate basis ((Badylak, Weiss 
et al. 2012)). However, although no graft-related mortality had occurred 12  - 42 
months post-implantation, partial collapse had been observed in three of the patients. 
The reasons  for the collapse of these  grafts were unknown and were  considered 
unpredictable.  These  collapses  suggest  that  the  current  DEM-based  tissue 
engineering process could be compromising the structural properties of the scaffolds 
or provoking a phenotypic predominance of M1 macrophages which could hinder 
tissue remodelling (Keane, Londono et al. 2012). As a result the authors indicated 
that  improvements  would  be  necessary  to  the  decellularisation  process  and  the 
biomechanical  stabilisation  as  well  as  the  recellularisation  and  implantation 
processes (Badylak, Weiss et al. 2012) before the processes could be employed to 
manufacture tissue engineered tracheae for routine clinical use. 
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3.2  Aims and hypotheses 
3.2.1  Aims 
  To  evaluate  the  methodology  of  the  detergent-enzymatic  method  (DEM)  of 
decellularisation. 
  To evaluate and expand product validation and potential critical quality attributes 
for decellularised tracheal scaffolds. 
  To  determine  what  effect  the  decellularisation  process  has  on  key  structural 
components  needed  for:  the  recellularisation  process,  such  as  the  basement 
membrane components laminin and fibronectin; and maintaining cartilage and 
scaffold strength to resist collapse, such as collagen and GAGs. 
3.2.2  Hypotheses 
  As cells interact with their extracellular matrix, it is hypothesised that removal of 
cells during DEM will negatively impact on ECM components crucial to tracheal 
function resulting in reduced biomechanical properties. 
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3.3  Materials and methods 
3.3.1  Sectioning of LR White embedded matrices for histology  
Taking into account the desired orientation of the final tissue sections (sagittal or 
transverse), the resin embedded tissues were excised from the resin. The embedded 
tissue blocks were placed in a microtome (Ultracut E, Reichert-Jung, Depew, USA) 
sample holder and excess resin was trimmed from the face of the block with a sharp 
razor blade until the tissue was exposed. Glass knives were made (2178 Knifemaker 
II,  LKB,  Bromma,  Sweden)  and  used  to  obtain  a  smooth  flat  surface  of  the 
embedded  samples  for  sectioning.  A  new  glass  knife  was  used  to  obtain  2  µM 
sections of the samples. Cut sections were carefully placed onto a drop of distilled 
water on a microscope slide. The sections were semi-fixed to the slide by placing the 
slide onto a heating block (Dishwarmer 2, Photax, USA) for 24 hours. The slides 
were then stored in a slide container at RT until required (Partington, Mordan et al. 
2013).  
3.3.2  Histological analysis of LR White embedded matrices by toluidine blue 
staining 
Toluidine  blue,  otherwise  known  as  tolonium  chloride,  is  an  acidophilic 
metachromatic. Filtered toluidine blue was gently dropped onto the section and then 
immediately but gently washed off with distilled water. The sections were observed 
under an optical microscope (BX50, Olympus, UK) and imaged (Coolsnap-Pro cf 
color, Media Cybernetics, Bethesda, USA). 
3.3.3  Histological analysis of LR White embedded matrices by haematoxylin 
and eosin (H&E) staining 
The slides were immersed in Mayer’s haematoxylin for 1 hour at room temperature. 
The sections were then blued by being immersed in gently running tap-warm water 
for 20 minutes. The slides were then immersed in 5% eosin for 1 hour at room 
temperature.  The  sections  were  then  rinsed  very  gently  in  static  tap  water.  The 
sections were dried on the heating block for a few minutes then mounted in DPX 
Mountant (BDH Chemicals Ltd., Poole, UK). The sections were then observed under 
an optical microscope (BX50, Olympus, UK) and imaged (Coolsnap-Pro cf color,  
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Media Cybernetics, Bethesda, USA). Five representative sections for each treatment 
stage were stained (Partington, Mordan et al. 2013). 
3.3.4  Quantitative analysis of protein content 
The quantitative protein assay used was the microplate procedure for the Pierce BCA 
Protein Assay Kit which utilises bicinchoninic acid (BCA) to detect the total amount 
of protein in a sample. The principle of the assay was based upon the ability of 
protein, in an alkaline solution, to reduce copper (II) ions or cupric ions (Cu2+) to 
copper (I) ion or cuprous ion (Cu+). The Cu+ ions form a purple coloured complex 
with BCA which could be quantitated with a spectrophotometer. Briefly, dilutions 
for a standard curve of BSA were prepared. The working reagent was prepared by 
combining  Reagent  A,  containing  the  BCA,  and  Reagent  B,  containing  cupric 
sulphate. The test samples were prepared using the tissue lysis component of the 
Qiagen DNeasy Blood and Tissue Kit. The working reagent was added to the BSA 
standards and the test samples in a 96 well plate, and then incubated at 37oC for 30 
minutes.  The  plate  was  then  cooled  to  room  temperature  and  the  absorbance 
measured at 562 nm using the Tecan Safire2™ (Tecan) and compared to a 20 - 2000 
µg/mL standard curve. For each total protein quantitative test, the concentration of 
protein was normalized to the tissue weight and the mean ± SD was determined. 
Two-way ANOVA was used to find any statistically significant differences between 
native and decellularised trachea, as well as the corresponding non-decellularised 
control (NDC) (PBS treated) tissue (Partington, Mordan et al. 2013).  
3.3.5  Quantitative analysis of soluble collagen content 
The quantitative assay used to determine soluble collagen was the Biocolor Sircol™ 
Soluble  Collagen  Assay  Kit,  (Biocolor  Ltd,  Carrickfergus,  UK)  which  was  used 
according to the manufacturer’s instructions. The kit can be used to analyse cold acid 
and  pepsin  soluble  collagen  Types  I  to  V  that  are  produced  in  soft  tissues  and 
cartilages of the body, but is not suitable for covalently cross-linked collagen. The 
assay is a colorimetric assay which utilises the binding of Sirius Red in picric acid to 
the  (Gly-X-Y)  tri-peptide  of  the  triple  helix  structure  of  collagen.  Briefly, 
approximately 50 mg of tissue, frozen at -80oC since harvest, was taken and minced 
using razor blades. The tissue was digested overnight at 4ºC in pepsin (0.1 mg/ mL) 
(Sigma, Poole, UK) in 0.5M acetic acid (Sigma, Poole, UK). The acid solution was  
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then neutralised. The sample was centrifuged to pellet any non-digested tissue and 
from the supernatant fraction the collagen was isolated and concentrated. The sample 
was  then  diluted  appropriately;  typically  1:20  in  0.5M  acetic  acid.  The  soluble 
collagen was then selectively bound and formed a complex with the Sirius Red in the 
dye reagent, which precipitated out of the solution. Following centrifugation, the 
bound soluble collagen-dye complex pelleted and the supernatant was removed. The 
soluble collagen-dye complex was then dissociated in an alkaline solution and the 
absorbance read at 555 nm using the Tecan Sunrise (Tecan) or the Tecan Safire2™ 
(Tecan) and compared to a 0 - 50 µg/mL standard curve. For each soluble collagen 
quantitative test, the concentration of soluble collagen was normalized to the lysate 
dilution, the tissue weight and the mean ± SD were determined. Two-way ANOVA 
was  used  to  find  any  statistically  significant  differences  between  native  and 
decellularised  trachea,  as  well  as  the  corresponding  non-decellularised  control 
(NDC) (PBS treated) tissue (Partington, Mordan et al. 2013). 
3.3.6  Dynamic  mechanical  analysis  (DMA)  compression  testing  of  tracheae 
tissue 
Dynamic Mechanical Analysis (DMA) compression testing was used to evaluate the 
compressive properties of the cartilage rings in the tracheal wall. The PerkinElmer 
DMA 7E (PerkinElmer, Seer Green, UK) was used to mechanically interrogate and 
record, using the DMA 7E software (PerkinElmer, Seer Green, UK), in real time the 
tensile properties of each sample. For the tracheal wall testing, 5 mm x 5 mm (W x 
L) sections were punched out of a section of trachea tissue using a specimen cutting 
press (Model S1) (Wallace Instruments, Cambridge, UK). The adventitia and lamina 
propria were removed and the height of the tracheal  wall section then measured 
before compression testing using callipers. The specimen was placed into position in 
the  instrument  and  the  measurements  inputted  into  the  software.  The  force  was 
applied at 200 mN/minute up to 6000 mN and the results recorded in real time by the 
software.  The  Young’s  (compressive)  modulus  (MPa)  was  determined  for  each 
analysis. All were plotted as the mean ± SD for each analysis. Two-way ANOVA 
was used to compare the decellularised (DC) scaffold findings with native and the 
corresponding non-decellularised control (NDC) (PBS treated) trachea findings over 
the decellularisation process (Partington, Mordan et al. 2013).    
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3.4  Results 
3.4.1  Macroscopic overview of the trachea pre and post detergent-enzymatic 
method of decellularisation 
When the tracheae were delivered from Animal Organs for Research (a subsidiary of 
Cheale  Meats)  they  had  been  roughly  trimmed  from  the  pluck,  but  still  had  the 
larynx and bronchi attached in addition to surplus tissue which could include the 
tongue,  oesophagus,  aorta  and  lung  (Figure  3.1  A).  The  tracheae  were  further 
trimmed to produce tracheae that were 10 to 15 cm in length (Figure 3.1 B), but on 
average were approximately 12 cm in length with an average inner diameter (ID) of 
1.35 cm antero-posteriorly and 1.65 cm laterally and an average external diameter of 
2.23  cm  antero-posteriorly  and  2.43  cm  laterally  (Table  3.1).  The  PBS  washes 
removed the majority of the surface blood before proceeding to the DEM (Figure 3.1 
C).  After  25  cycles  of  the  DEM,  the  tracheae  sections  appeared  decoloured,  as 
expected of decellularised tissue. Importantly, the DEM-treated tracheae: retained 
the macroscopic structure of the trachea; the cartilage rings were still visible and 
detectable by touch; the mucosa layer in the lumen was still present with the ribbed 
internal surface of the posterior wall still visible; and the lumen of the trachea was 
retained  and  held  open  by  the  cartilage  rings  and  resisted  collapse  under  light 
pressure (Figure 3.1 D) (Partington, Mordan et al. 2013).  
Page - 71 - of 223 
 
 
Figure 3.1: Macroscopic view of the trachea upon arrival from the abattoir (A), after 
preparation  (B),  after  PBS  rinses  (C)  and  after  cycle  25  of  chemical  enzymatic 
decellularisation (D) (Partington, Mordan et al. 2013). Permission to reproduce this 
figure has been granted by Elsevier. 
    Antero-posteriorly   Laterally 
Porcine Trachea  Length 
(cm) 
Internal 
Diameter 
(cm) 
External 
Diameter 
(cm) 
Internal 
Diameter 
(cm) 
External 
Diameter 
(cm) 
1  12  1.1  2.2  1.5  2.3 
2  12.2  1.5  2.3  1.9  2.5 
3  12  1.5  2.2  1.7  2.5 
4  12.5  1.3  2.2  1.5  2.4 
Average Pig  12.18  1.35  2.23  1.65  2.43 
           
Average Human   11.5     1.8     2.3 
Table 3.1: Table of average pig tracheae sizes, with comparison for human tracheae 
(Iivanov 2007).  
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3.4.2  Histological  analysis  of  DEM  of  decellularisation  by  toluidine  blue 
staining  
Native,  defined  as  untreated  tracheae  harvested  from  healthy  animals,  and  DEM 
decellularised tracheal sections were stained with toluidine blue to differentiate the 
different  components  of  the  tissue  and  determine  whether  the  cells  had  been 
eliminated  from  the  trachea  during  the  decellularisation  process  to  produce  the 
tracheal  scaffolds.  In  the  native  trachea  sections,  although  the  cartilage  was 
distinguishable as purple due to the effects of weak metachromasy (Figure 3.2 C & 
E), the remainder of the tracheal tissue was orthochromatic and was only stained 
blue. Subtle differences in the intensity of the blue staining made the nuclei, and 
therefore cells, distinguishable in the epithelial layer (Figure 3.2 A) and the mucosa 
glands (Figure 3.2 B), but it was difficult to distinguish the nuclei which could lead 
to errors when cell counting to determine clearance. It was even more difficult to 
distinguish the nuclei in the lamina propria or adventitia (Figure 3.2 D & E) with the 
surrounding collagen and elastin bundles. Therefore, although the DEM processed 
trachea had been stained with toluidine blue (Figure 3.2 F), it was decided that due to 
the  unsuitability  of  the  stain  for  tracheal  tissue,  toluidine  blue  would  not  be  an 
appropriate stain for this purpose and the stained sections were not used for cell 
clearance analysis.  
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Figure  3.2:  Toluidine  staining  of  the  epithelial  layer  (A),  mucosal  glands  (B), 
cartilage (C), and adventitia (D) of native trachea and the lamina propria of native 
trachea  (E)  and  of  trachea  that  has  undergone  25  cycle  of  the  DEM  of 
decellularisation (F). 
3.4.3  Histological analysis of DEM of decellularisation by H&E staining  
Native  and  DEM  decellularised  tracheal  sections  were  stained  with  H&E  to 
determine whether this stain improved clarity, over and above toluidine blue, for 
distinguishing  cells  in  these  sections  and  would  therefore  allow  for  easier 
determination of cell clearance throughout the DEM of decellularisation process. As 
expected, the stained native tracheal sections (Figure 3.3 A, Figure 3.4 A0, Figure 
3.4 B0, Figure 3.4 C0 and Figure 3.4 D0) demonstrated typical H&E staining. The 
nuclei  were  stained  blue  by  the  haematoxylin,  with  the  remainder  of  the  tissue 
components stained a range of pinks and reds by eosin. For example, elastin bundles  
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and  red  blood  cells  were  stained  red,  collagen  and  cell  cytoplasm  were  stained 
shades  of  pink.  This  ultimately  resulted  in  tissue  sections  where  it  was  easy  to 
identify  nuclei  and  therefore  cells  within  the  tissue.  This  method  allowed 
unambiguous  observation  of  any  clearance  of  the  cells  throughout  the 
decellularisation process (Partington, Mordan et al. 2013). Therefore H&E was used 
as  the  stain  to  analyse  cell  clearance  by  decellularisation  and  also  assess  tissue 
morphology throughout the decellularisation process. The results show the staining 
of native tracheae and decellularised scaffolds at cycle 10 (Figure 3.4 A-D,1), 20 
(Figure 3.4 A-D,2) and 25 (Figure 3.3 B; Figure 3.4 A-D,3). The analysis for cell 
clearance was focussed on the four major sub-regions of the trachea: the epithelial 
region  of  the  lamina  propria;  the  sub-mucosal  gland  of  the  lamina  propria;  the 
cartilage  ring;  and  the  adventitia.  By  focussing  on  the  cell  clearance  in  these 
particular  regions,  it  was  hoped  that  an  overall  representative  view  of  the  cell 
clearance across the trachea would be achieved. Total clearance of the cells was 
achieved by cycle 10 of the DEM for the epithelial layer, sub-mucosa gland and 
adventitia  of  the  trachea  (Figure  3.4  A,1,  B,1,  and  D,1;  Figure  3.5).  Total  cell 
clearance was not achieved in the cartilage ring, but significant cell clearance was 
observed by cycle 10 (p<0.05) (Figure 3.4 C,1; Figure 3.6) which was further cleared 
by cycle 25 (p<0.01) (Figure 3.4 C,3; Figure 3.6). Apoptosis of the chondrocytes, 
which  could  be  determined  by  the  morphology  of  the  chondrocyte  according  to 
published criteria (Roach, Aigner et al. 2004), was detected from cycle 10 onwards 
(p<0.05) and represented over 90% of all residual cells detectable in the cartilage 
rings from cycle 20 onwards (Figure 3.4 C,2 and C,3; Figure 3.6). 
With regard to the microscopic morphological analysis of the trachea as it progressed 
through  the  DEM  of  decellularisation,  the  overall  ECM  structure  was  preserved 
(Figure 3.3 A and B) after 25 cycles of the DEM, with the ECM of the lamina 
propria,  the  sub-mucosa  glands,  the  cartilage  rings  and  the  adventitia  remaining 
identifiable. At 100x magnification it was possible to observe that the majority of the 
pseudostratified columnar epithelium was removed. It was also possible to observe 
potential  damage  to  the  elastin  fibres,  stained  red,  as  they  appeared  to  become 
disrupted  as  the  DEM  progressed  (Figure  3.4  A,3).  The  sub-mucosal  glands 
generally appeared undamaged throughout the DEM (Figure 3.4 B,1 and B,3) but 
occasionally appeared to lose their internal structure (Figure 3.4 B,2). The cartilage  
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rings  appeared  undamaged  (Figure  3.4  C,3)  and  the  adventitia  retained  enough 
structure to observe decellularised blood vessels (Figure 3.4 D,1) during the initial 
part of the DEM, but became slightly more disrupted as the DEM progressed (Figure 
3.4 D,2 and D,3) (Partington, Mordan et al. 2013).  
 
Figure 3.3: Histological staining by H&E of the trachea as native tissue (A) and after 
cycle 25 (B). Scale bar = 500 mm (Partington, Mordan et al. 2013). 
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Figure  3.4:  Histological  staining  by  H&E  of  the  tracheal  epithelial  layer  (A), 
mucosal gland (B) cartilage ring (C) and  adventitia (D) as native tissue (0), after 
cycle 10 (1), after cycle 20 (2) and after cycle 25 (3). Scale bar = 10 mm (Partington, 
Mordan  et  al.  2013).  Permission  to  reproduce  this  figure  has  been  granted  by 
Elsevier.  
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Figure 3.5: Cell clearance (by histological analysis of H&E) of the mucosa, sub-
mucosa and adventitia sub-regions of the trachea as native tissue, after cycle 10, after 
cycle 20 and after cycle 25 (Partington, Mordan et al. 2013). Permission to reproduce 
this figure has been granted by Elsevier. 
 
Figure  3.6:  Chondrocyte  clearance  and  apoptosis  from  the  cartilage  ring  of  the 
trachea as native tissue, after cycle 10, after cycle 20 and after cycle 25 (Partington, 
Mordan  et  al.  2013).  Permission  to  reproduce  this  figure  has  been  granted  by 
Elsevier.  
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3.4.4  Analysis  of  DNA  removal  by  detergent-enzymatic  method  of 
decellularisation 
A  statistically  significant  reduction  in  the  concentration  of  DNA  was  observed 
throughout the DEM of decellularisation compared to native trachea. Following 10 
cycles an increased amount of DNA had been removed due to the decellularisation 
process compared to the non-decellularised controls (DC: 274.96 ± 55.04 ng/mg, 
P<0.005; NDC: 393.07 ± 118.04 ng/mg, P<0.01) versus the native trachea (742.2 ± 
236.6 ng/mg) (Figure 3.7). However, after 25 cycles of the DEM of decellularisation, 
the decellularised scaffold (264.66 ± 69.92 ng/mg, P<0.005) and non-decellularised 
control (284.05 ± 37.74 ng/mg, P<0.005) had achieved a similar reduction in DNA 
compared to the native tissue despite no DNase treatment in the non-decellularised 
control group (Figure 3.7) (Partington, Mordan et al. 2013). 
 
Figure  3.7:  DNA  quantification  in  tracheal  tissue  during  decellularisation 
demonstrated  a  similar  reduction  in  the  decellularised  (P<0.005)  and  non-
decellularised groups (P<0.005) compared to the native trachea despite no DNase 
treatment  in  the  non-decellularised  group  (Partington,  Mordan  et  al.  2013). 
Permission to reproduce this figure has been granted by Elsevier. 
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DAPI  staining  revealed  the  locality  of  the  remaining  DNA  in  the  decellularised 
group was predominantly in the lamina propria and the cartilage rings (Figure 3.8 A-
D). It was clearly visible in the cartilage rings after 25 cycles of the DEM (Figure 3.8 
D),  as  expected  from  the  H&E  staining.  It  was  also  possible  to  visualise  DNA 
smeared  over  the  ECM  fibres  in  the  lamina  propria  and  particularly  in  the  sub-
mucosa  gland  regions  after  25  cycles  of  DEM  whereas  in  the  native  tissue  the 
nuclear material is identifiably contained within the nuclei of the cells (Figure 3.8 
A).  
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Figure 3.8: Fluorescent labeling of nuclear material with DAPI in the native trachea 
(A) and in scaffolds produced by DEM after cycle 10 (B), cycle 20 (C) and cycle 25 
(D). Scale bar = 100 µm.  
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3.4.5  Analysis  of  protein  concentration  throughout  and  following  the 
detergent-enzymatic method of decellularisation  
Analysis of the protein concentration revealed that there was no significant change in 
the total protein concentration in the DEM scaffolds compared to the native trachea 
(Figure 3.9). The non-decellularised controls also retained similar total protein to the 
native trachea (Figure 3.9) (Partington, Mordan et al. 2013). 
 
Figure 3.9: Protein quantification demonstrated no change in the decellularised (DC) 
and non-decellularised (NDC) groups,  at  any time point, compared to  the native 
trachea (Partington, Mordan et al. 2013). Permission to reproduce this figure has 
been granted by Elsevier. 
3.4.6  Analysis of key ECM proteins (laminin and fibronectin) throughout and 
following the detergent-enzymatic method of decellularisation 
Although the overall total protein appeared not to be affected by the DEM, the effect 
of the DEM was investigated specifically on two key ECM proteins, laminin and 
fibronectin, due to their importance for recellularisation using immunofluorescence 
labelling. In the native trachea (Figure 3.10 A, B, and B’), laminin is shown with 
staining of the basement membrane, sub-mucosal glands and connective tissue in the 
lamina propria region. Laminin was clearly present in the same tissue sub-structures 
after 25 cycles of the DEM (Figure 3.10 C and C’). Labelling of the fibronectin 
protein in the native tissue demonstrated its presence throughout the trachea: in the 
basement membrane, sub-mucosal glands and connective tissue of the lamina propria  
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as well as the cartilage rings, the adventitia and the intra-cartilage rings connective 
tissue  (Figure  3.10  D,  E  and  E’).  It  was  possible  to  observe  similar  levels  of 
fluorescence labelling in the scaffolds that had undergone 25 cycles of the DEM 
(Partington, Mordan et al. 2013). 
 
Figure 3.10: Immunofluorescence labelling of the two key ECM components laminin 
and fibronectin demonstrated they were conserved after the DEM decellularisation 
process. Laminin staining (A-C) in the native tracheae (A, B, B’) demonstrated the 
staining to be localised to the lamina propria (lp), with the mucosal glands (mg) and 
basement membrane (bm) clearly stained, and connective tissue (ct). No laminin 
staining was observed in the cartilage (ca). In the DEM scaffold, the same structures 
were positively stained (C, C’). Fibronectin staining (D - F) in the native tracheae 
(D, E, E’) and the DEM scaffold (F, F’) demonstrated similar expression patterns 
and was present in the lamina propria (lp), connective tissue (ct), adventitia (ad) as 
well as at a low level in the cartilage (ca). Co-staining with DAPI indicated that 
genetic material remained post DEM decellularisation, mainly observed in mucosal 
glands (C’’) or bound to matrix fibrils in the lamina propria (F’’). Scale bar: (A and 
D) = 200 µm; (B, C, E, F) = 50 µm (Partington, Mordan et al. 2013). Permission to 
reproduce this figure has been granted by Elsevier.  
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3.4.7  Analysis of collagen throughout and following the detergent-enzymatic 
method of decellularisation 
Quantification of the total collagen indicated that there was no significant decrease in 
the total collagen content in the time-matched PBS stored tissue or the scaffolds that 
had undergone DEM decellularisation compared to the native tissue (Figure 3.11 A). 
There was, however, a comparable downward trend of collagen loss in both the time-
matched PBS stored tissue and the DEM decellularised scaffolds at increasing time 
points  compared  to  the  native  tissue  (Figure  3.11  A)  (Partington,  Mordan  et  al. 
2013). Quantification of the soluble collagen content indicated a loss of collagen in 
the  decellularised  scaffolds  at  cycles  10  (P<0.05),  20  (P<0.05)  and  25  (P<0.01) 
compared to the native tissue (Figure 3.11 B).  However in the time-matched PBS 
control, no significant decrease was observed compared to the native tissue, although 
similarly to  the total  collagen quantification  assay, a decreasing trend  of soluble 
collagen was noted in these controls (Figure 3.11 B). This indicated the significant 
decrease in soluble collagen in the DEM scaffolds was due to the decellularisation 
treatment (P<0.01). It should also be noted that the standard deviation of these data 
from this assay was greater than expected and therefore the value of these data must 
be considered carefully (Partington, Mordan et al. 2013).  
The collagen content was further analysed by immunofluorescence labelling of the 
cartilage rings using both a monoclonal antibody (Figure 3.12 A-C) and a polyclonal 
antibody (Figure 3.12 D - F) specific to Type II collagen. The presence of Type II 
collagen is evident in the native trachea, the non-decellularised time matched PBS 
controls and the DEM decellularised samples after 25 cycles. In both the monoclonal 
and polyclonal antibody labelling there appears to be no discernible loss of collagen 
Type II in the NDC controls but a noticeable loss in the DEM samples. However, the 
results correlate well with the total collagen assay (Figure 3.11 A) as the overall 
decrease  in  collagen  Type  II  in  the  cartilage  rings  appears  to  not  be  markedly 
different (Partington, Mordan et al. 2013).  
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Figure  3.11:  Quantitative  analysis  of  total  collagen  content  indicated  that 
decellularisation  (DC)  did  not  significantly  alter  the  total  collagen  content  (A). 
Quantitative  analysis  of  soluble  collagen  content  indicated  that  decellularisation 
(DC)  reduced  the  amount  of  soluble  collagen  compared  with  time-matched  PBS 
stored tissue (NDC) (P < 0.01) and native tissue (P < 0.01 and P < 0.05) (B). Values 
are mean ± SD; N = 5 (Partington, Mordan et al. 2013). Permission to reproduce this 
figure has been granted by Elsevier.  
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Transmission electron microscopy was performed to investigate whether the DEM 
decellularisation had affected the ultrastructure of the cartilage matrix. These results 
indicated that the ultrastructure of the interlinking collagen bundles in the cartilage 
ring matrix appeared similar in the native trachea (Figure 3.13 A) and the tracheal 
scaffolds  after  25  cycles  of  DEM  decellularisation  (Figure  3.13  B).  This  would 
suggest that no damage was caused to the collagen bundles by the decellularisation 
process (Partington, Mordan et al. 2013).  
 
Figure 3.12: Immunofluorescence labelling of type II collagen within the cartilage 
matrix using two different antibodies (A–F) suggested that, compared with native 
trachea (A and D), the DEM scaffolds (C and F), but not PBS-stored trachea (NDC) 
(B and E), experienced a decline in collagen content. Scale bar for (A–F) = 100 µm 
(Partington,  Mordan  et  al.  2013).  Permission  to  reproduce  this  figure  has  been 
granted by Elsevier. 
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Figure  3.13: TEM images  showed that the ultrastructure of the collagen bundles 
were similar in both the native trachea (A) and DEM-produced scaffolds (B), with 
parallel  bundles  of  collagen  fibres,  of  a  similar  diameter,  appearing  in  both 
examples.  Image  at  40,000x  magnification  (Partington,  Mordan  et  al.  2013). 
Permission to reproduce this figure has been granted by Elsevier. 
 
3.4.8  Analysis of glycosaminoglycans throughout and following the detergent-
enzymatic method of decellularisation 
The  level  of  sGAG  was  assessed  in  the  native  trachea,  the  time-matched  PBS 
controls and the DEM decellularised scaffolds. The results indicate a time dependent 
incremental loss of sGAG (P<0.001 at cycle 10 and P<0.005 at cycles 20 and 25) in 
both the time-matched PBS controls and the DEM decellularised scaffolds compared 
with  the  native  tracheae  that  is  only  slightly  exacerbated  by  the  DEM 
decellularisation process (Figure 3.14) (Partington, Mordan et al. 2013).    
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Figure 3.14 Quantitative sGAG analysis demonstrated a significant incremental loss 
of  sGAG  from  both  the  time-matched  PBS  controls  (NDC)  and  the  DEM 
decellularised scaffolds (DC) compared with the native tissue, which appeared to 
only be slightly accelerated by the DEM treatment (Partington, Mordan et al. 2013). 
Permission to reproduce this figure has been granted by Elsevier. 
Alcian blue staining was performed to assess whether the loss of GAG observed in 
the quantitative assay could be observed qualitatively. The results demonstrated an 
observable loss of GAG, stained blue, in both the time-matched PBS controls and in 
the DEM decellularised scaffolds compared with the native tracheae (Figure 3.15 A-
F).  However  unlike  in  the  quantitative  assay,  the  loss  of  GAG  from  the  DEM 
decellularised scaffolds  was far more pronounced, with little alcian blue staining 
visible suggesting that little GAG remained (Figure 3.15 C, F). Considering that in 
the quantitative assay approximately 60% of the sGAG remained after 25 cycles of 
DEM decellularisation, this loss, although corroborating the quantitative assay, was 
unexpected. It is possible that the sGAG Blyscan Assay is more sensitive than the 
alcian blue assay and that, below a certain threshold level, alcian blue staining does 
not  distinctly  stain  GAG,  whereas  the  assay  would  still  isolate  and  detect  GAG 
below this level (Partington, Mordan et al. 2013).  
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Figure  3.15:  Alcian  blue  staining  for  qualitative  GAG  analysis  demonstrated  a 
significant loss of sGAG from the time-matched PBS controls (B, E) and the DEM 
decellularised  scaffolds  (C,  F)  compared  with  the  native  tissue  (A,  D),  which 
appeared to be greatly accelerated by the DEM treatment (Partington, Mordan et al. 
2013). Permission to reproduce this figure has been granted by Elsevier. 
3.4.9  Tensile  testing  of  scaffolds  throughout  and  following  the  detergent-
enzymatic method of decellularisation  
Tensile testing was performed to assess the cartilage ring strength as a measure for 
retained  strength  and  rigidity  of  the  tracheae  post-decellularisation  treatment  and 
therefore potentially as a predictor of collapsibility post-transplantation in vivo. The 
tests were performed on transverse (circumferential) sections of the tracheae. The 
Young’s  modulus  was  calculated  for  the  tensile  testing,  termed  here  as  tensile 
modulus,  by  determining  the  slope  of  the  stress-strain  curve.  The  results 
demonstrated  no  significant  decrease  in  the  stiffness  in  the  time-matched  PBS 
controls (NDC) compared with the native tracheae (Figure 3.16). However in the 
DEM decellularised scaffolds (DC), there was an observed incremental decrease in 
stiffness compared to the native tissue, which results in a significant loss of stiffness 
only  after 25 cycle of DEM  treatment  (P<0.05) compared to  the native tracheae 
(Figure 3.16). Additionally, when comparing the DC with the NDC, the effect of the 
DEM decellularisation process was found to be significant (P<0.005), resulting in a 
loss of stiffness to all treated samples (Figure 3.16) (Partington, Mordan et al. 2013).  
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Figure 3.16: Young’s modulus of the tensile testing demonstrated a significant loss 
of stiffness in the DEM decellularised scaffolds (DC) only after 25 cycles (P<0.05) 
compared to the native tracheae. However the effect of the DEM treatment overall 
had a significant effect, reducing the stiffness of the DEM scaffolds, compared to the 
time-matched  PBS  controls  (NDC)  (P<0.005)  (Partington,  Mordan  et  al.  2013). 
Permission to reproduce this figure has been granted by Elsevier. 
In  addition  to  the  Young’s  modulus,  the  ultimate  tensile  stress  and  the  ultimate 
tensile strain was also calculated from the tensile testing data. The ultimate tensile 
stress  describes  the  maximum  stress  required  to  rupture  the  sample.  These  data 
correlate well with the Young’s modulus data and, similarly to the Young’s modulus 
data, demonstrate a loss of strength in the DEM scaffolds after 25 cycles of DEM 
decellularisation compared with the native tracheae (P<0.05). They also demonstrate 
a loss in strength, due to the DEM process, in cycles 10 to 25 of the DEM scaffolds 
compared to the time-matched PBS controls (p<0.005) (Figure 3.17). The ultimate 
tensile strain data, which describes the degree to which the sample is stretched before 
it  ruptures,  demonstrated  no  differences  between  the  native  tracheae,  the  time-
matched PBS controls and the DEM scaffolds (Figure 3.18) (Partington, Mordan et 
al. 2013).   
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Figure  3.17:  The  ultimate  tensile  stress  of  the  tensile  testing  demonstrated  a 
significant loss of strength in the DEM decellularised scaffolds (DC) only after 25 
cycles (P<0.05) compared to the native tracheae. However the effect of the DEM 
treatment  overall  had  a  significant  effect,  reducing  the  strength  of  the  DEM 
scaffolds, compared to the time-matched PBS controls (NDC) (P<0.005) (Partington, 
Mordan  et  al.  2013).  Permission  to  reproduce  this  figure  has  been  granted  by 
Elsevier. 
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Figure  3.18:  The  ultimate  tensile  strain  of  the  tensile  testing  demonstrated  no 
significant differences between the native tracheae, the time-matched PBS controls 
(NDC) and the DEM scaffolds (DC) (Partington, Mordan et al. 2013). Permission to 
reproduce this figure has been granted by Elsevier.  
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3.4.10  DMA  compression  testing  of  scaffolds  throughout  and  following  the 
detergent-enzymatic method of decellularisation  
DMA compression testing was performed to assess the stiffness and compressibility 
of the cartilage. The tests were performed on sections of the trachea cartilage ring. 
The Young’s modulus was calculated for the compression testing, termed here as 
compressive modulus, by determining the slope of the initial linear proportion of the 
stress-strain curve. The results demonstrated no significant decrease in the stiffness 
in the time-matched PBS controls (NDC) or the DEM decellularised scaffolds (DC) 
compared with the native tracheae (Figure 3.19). The significant increase at cycle 10 
in the time-matched PBS controls was identified to be due to a significant outlier in 
that dataset, as revealed by Grubb’s test for outliers (Partington, Mordan et al. 2013). 
 
Figure  3.19:  The  compressive  modulus  of  the  DMA  compression  testing 
demonstrated  no  significant  differences  between  the  native  tracheae,  the  time-
matched PBS controls (NDC) and the DEM scaffolds (DC) (Partington, Mordan et 
al. 2013). Permission to reproduce this figure has been granted by Elsevier. 
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3.5  Discussion  
The published methodologies of the original DEM (Conconi, De Coppi et al. 2005, 
Macchiarini, Jungebluth et al. 2008) and revised DEM (Jungebluth, Go et al. 2009, 
Go, Jungebluth et al. 2010) were ambiguous and despite personal communication 
with one of the published papers’ authors to obtain clarity on the DEM (Jungebluth 
2009), misinterpretation of the DEM occurred and resulted in an adapted DEM being 
used  in  this  thesis.  In  a  later  paper  published  in  2012, Jungebluth  described  the 
process more clearly stating that a single treatment cycle involved a 48 hour water 
incubation step followed by cycles of a 4 hour detergent step and a 3 hour enzymatic 
step (Jungebluth, Bader et al. 2012). Unless the authors were operating the process 
on a 24 hour basis, there was a 16 hour overnight incubation/holding step that was 
not described nor included in the published methods. The adapted DEM method 
described  here  (Partington,  Mordan  et  al.  2013)  however,  was  very  similar  to  a 
further  revised  DEM  method  published  by  Baiguera  and  colleagues  in  2010 
(Baiguera, Jungebluth et al. 2010), with overnight PBS hold/wash steps. 
The preparation of the airway removed the larynx, the branches to the bronchi and 
the loose overlying fascia whereas the initial PBS and water washes removed the 
superficial  blood.  This  resulted  in  reducing  the  superfluous  surface  area  which 
allowed the focus of the decellularisation to be on the trachea. 
In order to initially assess whether successful decellularisation had been achieved, 
histological  analysis  was  performed  on  the  native  tracheal  tissue  to  establish  a 
baseline, as well as on DEM decellularised scaffolds at various points to establish if 
decellularisation  had  indeed  occurred.  Initially  the  native  tracheae  and  DEM 
decellularised scaffolds were stained with toluidine blue where good staining was 
observed. However, the ability to distinguish the various regions of the trachea and 
the nuclei within those various regions of the trachea was difficult due to the overall 
similarity  in  stain  colour  and  intensity.  It  was  possible  to  crudely  establish  that 
decellularisation after 25 DEM cycles had occurred using toluidine blue, however a 
further  aim  of  the  histological  analysis  was  to  count  the  nuclei  to  quantify  cell 
clearance. For this purpose toluidine blue was considered unsuitable because of the 
high likelihood of error due to the difficulty in distinguishing the individual nuclei 
clearly.  The  decision  to  use  toluidine  blue  to  stain  trachea  was  due  to  the  
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inexperience  of  the  researchers  in  preparing  and  analysing  tracheal  tissue.  After 
some online research, it was decided that haematoxylin and eosin (H&E) would be a 
more appropriate stain, if a suitable method could be found to achieve good staining 
for hard resin embedded sections. The first tested method employed a twenty minute 
haematoxylin incubation followed by a three minute eosin incubation. However, it 
was determined that these incubations were not long enough to allow adequate stain 
penetration into the tissue and resulted in very weak staining of the tissue (data not 
shown). The second tested method (described in 3.3.3) with one hour incubations for 
both haematoxylin and eosin was tried and found to be suitable. The results from the 
histological  analysis  of  H&E  staining  on  the  native  tracheal  tissue  demonstrated 
typical H&E staining for the tracheal tissue, similar to that observed using paraffin, 
the  more  common  embedding  material.  Given  this  satisfactory  result,  the  DEM 
decellularised  scaffolds  were  also  stained  with  H&E  to  assess  whether 
decellularisation  had  been  achieved.  The  results  demonstrated  visible 
decellularisation of most regions of the tracheae, including the lamina propria, the 
epithelia layer and sub-mucosal glands as well as the adventitia layers. However, 
chondrocytes  were  observed  in  the  cartilage  rings  even  after  25  cycles  of  DEM 
decellularisation. These data agree with previously published data using the original 
and adapted DEM (Conconi, De Coppi et al. 2005, Jungebluth, Go et al. 2009) where 
chondrocytes were also still observed although the other regions of the trachea were 
cleared of cells.  
Although the absolute numbers differ (Table 3.2), comparing the clearance of cells 
from the tracheae as a whole using this revised method with the previously published 
data  (Conconi,  De  Coppi  et  al.  2005,  Jungebluth,  Go  et  al.  2009),  a  similar 
percentage reduction was observed after 20 DEM cycles compared with the native 
with approximately 5% of the cells remaining. Although, whereas all the cells were 
reportedly cleared after 22 cycles using the original DEM protocol (Conconi, De 
Coppi et al. 2005), cells still remained in the tracheal cartilage post- decellularisation 
after 25 cycles.  
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Partington, 2013  Conconi, 2005  Jungebluth, 2009 
Cycle Number  Cells/mm2 (%)  Cells/mm2 (%)  Cells/µm2 (%) 
Native  19106 (100%)  3110 (100%)  29800000* (100%) 
10  842 (4.4%)  -  15200000* (51%) 
12  -  1230 (39.5%)  - 
20  842 (4.4%)  -  1500000* (5%) 
18  -  290 (9.3%)  - 
22  -  0 (0%)  - 
25  649 (3.4%)  -  - 
Table 3.2: Cell clearance by DEM decellularisation literature comparison (Conconi, 
De Coppi et al. 2005, Jungebluth, Go et al. 2009, Partington, Mordan et al. 2013)  
*Likely to be a typographical error and actually 2980/mm2, 1520/mm2 and 150/mm2 
respectively.  
The removal of donor nuclear material, predominately DNA, is important during the 
decellularisation  process  to  ensure  all  immunogenic  material  from  the  donor  is 
adequately removed prior to recellularisation and transplantation as it can otherwise 
potentially cause an immune response in the recipient  (Zheng, Chen et al. 2005, 
Badylak and Gilbert 2008, Gilbert, Freund et al. 2009, Keane, Londono et al. 2012)}. 
DNA holds a particular challenge for decellularisation processes as it is sticky and 
has been shown to bind to the ECM upon release from the nucleus. It is because of 
this  property  that  many  decellularisation  protocols  incorporate  DNase  treatment 
steps ((Conconi, De Coppi et al. 2005); (Bolland, Korossis et al. 2007); (Keane, 
Londono et al. 2013)) or steps to mask residual DNA. The DNase treatment cleaves 
residual DNA strands independently at random sites to reduce the strand length and 
remove the DNA from the donor tissue. Analysis of the DEM scaffold quantitatively 
and qualitatively using DAPI staining indicated significantly reduced levels of DNA 
after 25 DEM cycles compared to the native tracheal tissue. However, levels were 
comparable  to  the  non-decellularised  time-matched  PBS  stored  controls,  which 
suggests that effective DNA removal was not occurring in the DEM decellularised 
scaffolds despite multiple DNase treatments. It could be possible that the original 
DEM protocol, which used ten times more DNase in the DNase step, would have 
been more effective with DNA removal. However, at the level of DNase used, an 
observable effect and a reduction over background levels would have been expected.  
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There are several reasons why the DNase treatments may not have further reduced 
the DNA content of the scaffolds. Firstly, the buffer used in the DNase step is 1M 
sodium chloride. It is widely accepted that DNase requires divalent metal cations to 
activate DNase I. Both Mg2+ and Ca2+ are required to activate DNase I effectively 
(Price 1972). A minimum concentration of Ca2+ is also required to stabilise DNase I 
against proteolytic digestion. It has also been demonstrated that ionic strength can 
affect  the  activity  of  DNase,  and  a  high  concentration  of  salts  such  as  sodium 
chloride or potassium chloride above 5mM can have a strong inhibitory effect on 
DNase activity (Price 1972). The DEM DNase reaction buffer could therefore be 
deemed as unsuitable as it contained neither Mg2+ nor Ca2+ cations and contained a 
high concentration (1M) of sodium chloride, thereby limiting, or worse, inhibiting 
the  activity  of  the  DNase.  Lastly,  the  DNase  reaction  was  performed  at  room 
temperature, assumed to be 25oC. Although the activity of the DNase is measured at 
this  temperature,  it  is  widely  acknowledged  that  the  enzymatic  activity  at  this 
temperature is limited and increasing the temperature to 37oC can improve DNA 
digestion. 
Whether complete removal of DNA is required, or feasibly achievable, is currently 
unknown.  Many  commercially  available  products  for  regenerative  medicine 
interventions have been demonstrated to have remnant DNA fragments present post-
decellularisation (Badylak and Gilbert 2008, Gilbert, Freund et al. 2009), without 
adverse reactions in  recipients. However the maximum level of DNA in the nine 
tested  products  was  in  Restore  made  from  porcine  small  intestine  (DePuy 
Orthopaedics) which had approximately 1.13 ± 0.03 ng DNA / mg of tissue (dry 
weight) and fragments sizes between 100 to 200 base pairs (bp) in size (Gilbert, 
Freund et al. 2009). The tracheal scaffolds from the DEM process had 264.66 ± 
69.92 ng DNA / mg of tissue (wet weight) which, even accounting for differences in 
tissue type and wet vs. dry weight, is a much higher level of remaining DNA. It 
would therefore be prudent to investigate ways to optimize this step to improve DNA 
removal from the scaffolds and reduce the risk of an inflammatory response from the 
recipient or potential graft rejection (Partington, Mordan et al. 2013). 
Tracheal function is dependent on its structure and the strength of that structure. The 
cells interact with the ECM via transmembrane receptors (Hynes 2009, Badylak, 
Weiss et al. 2012) and via these links play a role in the ECM homeostasis. Therefore  
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it cannot be precluded that removal of cells and therefore the loss of interaction of 
the  cells  with  the  ECM  during  a  decellularisation  process  could  in  some  way 
diminish  the  structural  integrity  of  the  ECM  (Bader  and  Macchiarini  2010, 
Partington, Mordan et al. 2013). Although decellularisation is important to remove 
immunogenic  material  from  the  donor  scaffold,  it  is  a  fine  balance  to  not  over-
decellularise the scaffold and damage it or remove components that could be useful 
in the recipient. For example, a potentially key advantage of utilising a biological 
scaffold over a synthetic scaffold is the retention of key ECM proteins laid down by 
the donor’s cells in the correct anatomical loci that will aid host recellularisation by 
directing cell adhesion, migration and differentiation. It has been shown that DEM 
decellularisation removes cells, MHC components and a significant amount of the 
DNA, however it has been reported that a core set of over 100+ polypeptides are 
retained  which  reportedly  have  roles  beyond  structural  integrity,  including 
epithelialisation and angiogenesis (Butler, Hsuan et al. 2011, Elliott, De Coppi et al. 
2012), as well as specific proteins such as bFGF (Baiguera, Jungebluth et al. 2010). 
Retention  of  protein  was  observed  in  this  investigation,  where  quantification 
revealed  total  protein  levels  were  not  diminished  after  25  cycles  of  DEM 
decellularisation nor in  the time-matched PBS-stored controls compared with the 
native  tissue.  Similarly,  when  certain  key  ECM  proteins  that  are  important  for 
recellularisation and revascularisation, laminin and fibronectin, were examined in 
more detail, good retention and expression patterns were observed. These data would 
suggest  that  upon  implantation  of  these  biologically  favourable  scaffolds, 
recellularisation and revascularisation should occur and indeed this has been shown 
in  several  of  the  reported  bioengineered  tracheal  transplants  that  utilise  DEM 
decellularised scaffolds (Macchiarini, Jungebluth et al. 2008, Elliott, De Coppi et al. 
2012).  
ECM components, such as the collagens and the GAG which are involved in the 
structural integrity of the scaffold, are also critical to retain as these will impart the 
capacity for the graft to maintain an open airway upon transplantation. It is the role 
of the cartilage rings to maintain an open airway in the presence of intrathoracic 
pressure changes that occur through normal or laboured breathing, such as hyperpnea 
or  tachypnea.  Collagen  type  II  and  GAG  are  the  main  components  of  hyaline 
cartilage and the structural integrity of the cartilage rings in the trachea are due to the  
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functional  coupling  between  the  GAG-rich  proteoglycans  which  creates  a  high 
osmotic  pressure  and  the  fibrillar  collagen  network  which  provides  the  tensile 
strength. The biomechanical properties of tracheal cartilage are non-linear (Teng, 
Ochoa et al. 2008), and so fairly complicated, however to take a holistic view, the 
circumferential strength of the cartilage rings which maintain the open airway are 
determined by their structural composition. Therefore, it is highly possible that the 
functional and structural properties of the hyaline cartilage rings would be affected if 
the ratio, quantities or arrangements of the cartilage matrix constituents were altered. 
Indeed, evidence from the literature has demonstrated that age-related loss of the 
proteoglycans content in cartilage can make the tissue stiffer. This was distinguished 
experimentally by observing an increase in the elastic modulus (Roberts, Rains et al. 
1997).  
In  this  particular  study  of  the  DEM  decellularisation  it  was  found  that  type  II 
collagen, total and soluble collagen and GAG all undergo a decline. Although no 
differences  were  observed  in  the  cartilage  or  collagen  ultrastructure  using  TEM 
between  the  native  trachea  and  the  DEM  decellularised  scaffold,  a  decrease  in 
collagen content was experimentally observed in the DEM decellularised scaffolds 
by  IHC  analysis  and  by  quantification.  These  decreases  were  observed  in  non-
decellularised  time-matched  controls  which  indicate  the  loss  could  be  occurring 
through natural degradation of the tissue over time. For specific ECM components, 
collagen  Type  II  and  soluble  collagen  content,  this  natural  loss  appears  to  be 
accelerated  by  the  DEM  decellularisation  process  and  that  the  effects  increased 
gradually over time, whereas the overall total collagen content appeared not to be 
affected further by DEM decellularisation. It could be that the natural degradation of 
the cartilage over time allows deeper penetration of the decellularisation solutions 
into the cartilage matrix, further disrupting the cartilage matrix to allow even deeper 
penetration and potentially more degradation. It could be possible that reducing the 
length of the decellularisation process could moderate collagen loss. In addition to 
collagen loss, loss was also observed in the GAG content which also appears to be 
accelerated by the DEM decellularisation. A decrease in GAG was also observed in 
other published studies using the DEM decellularisation (Haykal, Soleas et al. 2012). 
Therefore,  like  with  the  collagen,  shortening  the  length  of  the  decellularisation 
protocol may moderate GAG loss. However, despite the loss of collagen and GAG,  
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the loss of total collagen was not significant and there was still an abundance of 
collagen and GAG after the decellularisation and the gross anatomical structure was 
still preserved in the DEM scaffolds after 25 cycles (Partington, Mordan et al. 2013).  
The  Biocolor  Sircol  soluble  collagen  assay  kit  uses  an  enzymatic  process  to 
solubilise the collagen in the sample. This, as the assay kit name suggests, results in 
only  the  soluble  collagen  being  digested  and  therefore  quantified.  The  mature 
collagen in the cartilage ring is insoluble and therefore remains undigested. In this 
study, the results from the soluble collagen are approximately 60 fold less than that 
achieved from the total collagen which could be accounted for by the amount of 
collagen that remained undigested. Several researchers in the field have used this 
assay to investigate collagen loss from trachea (Gray, Turner et al. 2012); (Lange, 
Greco et al. 2014), however due to the majority of the collagen in the tracheae and 
the scaffolds remaining undigested, it is probable that this assay is not suitable for 
this tissue type and therefore should not be used for the determination of collagen 
loss  in  this  instance.  For  this  reason,  this  assay  will  not  be  used  to  analyse  the 
biochemical content trachea or tracheal scaffolds. 
The  ability  to  retain  native-like  biomechanical  strength  is  currently  a  perceived 
necessary requisite or critical quality attribute in decellularised scaffolds, especially 
for  scaffolds  that  will  perform  a  specific  structural  role.  In  tracheal  tissue 
engineering it is critical that an open airway is maintained and it is predominately the 
role of the cartilage rings to structurally support the airways and maintain an open 
airway. Failure for a tissue engineered trachea to maintain an open airway will likely 
result in the patient requiring a stent to prevent collapse. The prognosis of airway 
stenting commonly  results  in  complications  such as  infection and damage to  the 
lumen of the trachea. Therefore if a tissue engineered trachea required stenting then 
it  could  create  future  medical  complications;  rather  than  being  the  cure  to  the 
problem  it  could  ultimately  just  start  the  illness  cycle  all  over  again.  Current 
published biomechanical data of DEM has focused on uniaxial tensile testing in the 
longitudinal plane (Jungebluth, Go et al. 2009). Although this data will inform on the 
biomechanical  strength  and  strain  capacity  of  the  ECM,  it  is  limited  to  these 
parameters.  It  is  unlikely  that  longitudinal  uniaxial  testing  would  inform  on  the 
potential for a decellularised and recellularised trachea to maintain an open airway in 
vivo  post-transplantation  in  a  patient,  where  in  vivo  airway  collapse  will  be  the  
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greatest risk if biomechanical stiffness and strength are lost due to decellularisation. 
Therefore, there was  a  need to  develop  a more relevant  assay to  predict  in  vivo 
collapsibility.  A  more  relevant  test  was  determined  to  be  a  tensile  test  on  the 
cartilage rings to investigate the tensile modulus, the ultimate tensile stress and the 
ultimate tensile strain of the cartilage rings. Calculating the Young’s modulus from 
tensile testing of the cartilage rings should predict the stiffness of the cartilage rings 
and therefore the ability of the cartilage rings to maintain an open airway. 
The tracheae that were tested by the longitudinal uniaxial tensile testing maintained 
comparative  strength  to  the  native  trachea  until  cycle  17  in  porcine  trachea 
(Jungebluth 2009) and cycle 25 in the human trachea (Baiguera, Birchall et al. 2010). 
In this study, where the cartilage rings were tested, it was determined that loss of the 
Young’s modulus and the ultimate tensile stress was observed in DEM decellularised 
tracheae  after  just  10  cycles  compared  to    time-matched  PBS-stored  controls.  It 
could be possible that the loss of stiffness observed in the cartilage rings could be a 
consequence of the observed loss of GAG, soluble collagen and collagen type II. It is 
also possible that this loss of stiffness in the cartilage rings could potentially lead to 
in  vivo  tracheal  collapse  post-transplantation  and  it  would  certainly  provide  a 
plausible explanation for partial collapse in 3 out of 9 patients treated in an Italian 
cohort  ((Badylak,  Weiss  et  al.  2012)).  In  support  of  this  argument  are  cases 
previously reported in the literature where significant loss of GAG-rich proteoglycan 
and type I collagen has been identified at fracture and stenosis sites in incidences of 
in  vivo tracheal  collapse  (Mankarious, Adams  et  al.  2002) and incidences  where 
GAG-rich  proteoglycans  loss  followed  by  significant  collagen  loss  are  early 
indicators of osteoarthritis and a resulting decline in articular cartilage (Saarakkala, 
Julkunen et al. 2010). From this, one could conclude that adverse changes due to 
decellularisation  in  the  ECM  content  or  molecular  arrangement  could  result  in 
accelerated weakness and potentially an increased risk of collapse in a transplanted 
tissue engineered trachea. As the loss is observed at cycle 10 onwards, which relates 
to approximately 12 days of decellularisation processing, it could be possible that an 
optimized decellularisation process that could be completed in less cycles or time 
could negate loss of type II collagen and GAG and therefore potentially cartilage 
stiffness (Partington, Mordan et al. 2013).  
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However, it is also possible that observed failure in tissue engineered airways is not 
solely due to loss of structural rigidity of the airway due to ECM and cartilage ring 
damage during decellularisation, but could also be due to inadequate engraftment of 
seeded chondrocytes/chondrogenically-differentiated mesenchymal stromal cells or 
failure of chondrocytes or chondroblasts  from adjacent healthy tissue to migrate, 
repopulate  and  undergo  chondrogenesis  and  appropriate  maturation  in  the  tissue 
engineered  sections  of  trachea.  It  is  likely  that  re-establishment  of  the  cartilage 
homeostasis by these means will be itself necessary to prevent future failure of these 
tissue engineered airway grafts (Partington, Mordan et al. 2013). 
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3.6  Conclusions 
Although the gross macromolecular structure of the DEM decellularised trachea is 
preserved and so appears similar to native trachea, there is evidence to suggest that 
the decellularisation process results in the decline of the key structural components 
of  the  cartilage  rings,  GAG  and  collagen.  These  components  are  considered  to 
determine  the  biomechanical  strength  of  the  cartilage  rings,  and  therefore  the 
scaffold,  and  the  observed  decline  in  GAG  and  collagen  correlates  well  to  the 
observed decline in the stiffness of the cartilage rings, which could ultimately result 
in collapse of a tissue engineered tracheae made using this decellularisation method, 
when transplanted in vivo. The DEM decellularisation also failed to remove residual 
DNA which could also provoke an immune response or result in graft rejection in 
vivo when transplanted in a patient. Aspects of the DEM decellularisation require 
optimisation to produce a method that better removes immunogenic material, such as 
DNA,  within  as  short  a  time  period  as  permissible  to  also  achieve  complete 
decellularisation,  to  better  retain  GAG  and  type  II  collagen  and  therefore 
theoretically  biomechanical  stiffness  and  strength,    leading  to  increased 
biomechanical  stability  in  vivo.  The  development  of  a  rapid  and  fit-for-purpose 
method  for  decellularising  tracheae  for  tissue  engineering  purposes,  employing 
optimised  decellularisation  solutions,  solution  application  and  incubation 
temperatures would hopefully address the highlighted challenges and advance this 
field of research from cases performed on a compassionate basis to clinical studies 
and  ultimately  clinical  practice  (Partington,  Mordan  et  al.  2013).
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4  Design and engineering of a pressurised transmural bioreactor 
4.1  Introduction 
One  of  the  conclusions  drawn  from  decellularising  tracheae  with  the  detergent-
enzymatic method (DEM) (section 3.6) (Conconi, De Coppi et al. 2005, Macchiarini, 
Jungebluth et al. 2008, Jungebluth, Go et al. 2009, Go, Jungebluth et al. 2010) was 
the method of application of the decellularisation solutions to the tissue needed to be 
optimised. The concept of a pressurised transmural flow method of decellularisation 
originated during a lecture discussing the concept of tangential flow filtration, where 
fluid is recirculated past a filter under pressure so that a percentage of the fluid is 
forced  through  the  filter.  The  concept  would  involve  the  creation  of  a  pressure 
gradient  to  actively  flow  the  decellularisation  solutions  through  the  wall  of  the 
trachea, as opposed to the passive diffusion of the decellularisation solutions into the 
wall  of  the  trachea  that  immersion  generates,  as  used  in  the  DEM  of 
decellularisation.  Theoretically  application  of  the  decellularisation  solutions 
transmurally under pressure could make the decellularisation process more efficient 
and expedient.  
The initial concept envisaged that the transmural flow of fluid would be from the 
external chamber to the internal chamber as the majority of the cells in the trachea 
are located on the luminal side and therefore less cell debris would be forced through 
the  tracheal  wall  with  flow  in  this  single  direction.  It  was  also  considered  that 
turbulent flow  could  be  advantageous  over laminar flow as  better mixing of the 
decellularisation solutions would be achieved. 
In order to achieve pressurised transmural flow through the tracheae, a bioreactor 
would need to be designed and manufactured that could be used with the trachea to 
create a dual chamber system. After performing a literature search, it was realised 
that the concept of creating a pressurised transmural system had been applied to 
tissue engineering previously and that several bioreactors had been designed and 
manufactured that allowed for the creation of such dual chamber systems for hollow 
organ tissue engineering. The recellularisation of the trachea for clinical use in 2008 
(Macchiarini, Jungebluth et al. 2008) utilised a dual chamber bioreactor (Asnaghi, 
Jungebluth et al. 2009) however the use of transmural pressure was not employed in 
this instance, the dual chamber system was solely used to deliver tailored media to  
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the  different  cells  types  seeded  on  either  the  lumen  and  abluminal  sides  of  the 
trachea. Harvard Apparatus Regenerative Medicine has since purchased the rights to 
the bioreactor and have commercialised its sale as the InBreath Bioreactor for larger 
animal tissue and a smaller version, the MiniBreath Bioreactor, for small animal 
tissue (HARegenMed 2013). Harvard Apparatus Regenerative Medicine have also 
produced a bioreactor system (ORCA Bioreactor) which can be reportedly used for 
decellularisation  and  recellularisation.  The  ORCA  decellularisation  bioreactor 
chambers (HARegenMed 2013) appear to support either immersion of the tissue in a 
recirculating fluidic system or the perfusion of the decellularisation solutions through 
the  an  organ’s  blood  vessel  network  reminiscent  of  a  perfusion  decellularisation 
methodology  performed  by  other  groups  investigating  decellularisation  (Ott, 
Matthiesen et al. 2008, Price, Godin et al. 2015), but not transmural flow. Several 
examples did exist in the literature which detailed the use of pressurised transmural 
flow. One detailed where it had been used to improve the delivery of oxygen and 
nutrients into the walls of hollow tubular organs (tissue engineered arteries) to enable 
and encourage  cell migration and growth  in  these regions  (Bjork and  Tranquillo 
2009). More relevantly, a dual chamber bioreactor had also been designed to deliver 
pressurised transmural flow to decellularise blood vessels (umbilical veins) using a 
decellularisation solution of 20% acetone, 60% ethanol and 20% water (Montoya 
and  McFetridge  2009).  Another  paper  that  described  pressurised  transmural 
decellularisation for the bladder did so by achieving a pressure gradient (internal to 
external)  generated  by  distension  of  the  bladder  with  decellularisation  solutions, 
predominantly  sodium  dodecyl  sulphate  (SDS),  followed  by  treatment  with 
deoxyribonuclease  I  and  ribonuclease  A,  rather  than  through  attachment  to  a 
bioreactor (Bolland, Korossis et al. 2007). 
Where bioreactors have been used they have typically been designed by academic 
groups,  manufactured  by  local/academic  engineering  workshops  and,  apart  from 
those  commercialised  by  Harvard  Apparatus  Regenerative  Medicine,  were  not 
available  commercially.  Also,  depending  on  the  ultimate  application,  whether 
decellularisation  or  recellularisation,  and  the  specific  hollow  organs  in  question, 
which were typically blood vessels (decellularisation and recellularisation) or trachea 
(recellularisation),  the  bioreactor  would  need  to  be  tailored  for  the  organ  and 
application it was  to  be used for.  It  was  realised that an off-the-shelf  bioreactor  
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would not be available for purchase and would need to be bespoke designed for the 
specific application for decellularising trachea and that the bioreactor needed to be 
designed and manufactured in-house. 
To be able to generate transmural flow through a trachea, a bioreactor system that 
created separate internal and external chambers to allow independent access to the 
lumen and abluminal side of the trachea would be necessary. Additionally, other 
requirements  were  deemed  to  be  critical  in  the  design  of  the  bioreactor.  The 
bioreactor  would require inlet  and outlet  ports for both  the internal  and external 
chambers. The ports would need to be machined so that suitable ancillary parts could 
be affixed to enable fluid flow. It would need to be able to withstand low pressure 
concurrent with transmural flow pressures of up to 10 psi. It would need to be easily 
and  cost  effectively  sterilised  by  autoclaving  without  defection  over  multiple 
sterilisation  cycles.  In  addition  to  the  bioreactor  itself,  ancillary  parts  would  be 
required in the form of connectors, tubing, pumps and clamps/valves to enable and 
create the fluid flow path and pressure gauges/pressure transducers and temperature 
probes to monitor the fluid flow parameters.  
Ultimately  the  bioreactor  should  aid  progression  of  the  decellularisation  process, 
despite its  inherent  heterogeneity due to  the starting donor material,  towards the 
principles of precision manufacturing by providing the basis for a process that is 
controllable and repeatable with minimal user intervention and, with development, 
automatable (Williams, Thomas et al. 2012). 
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4.2  Aims and hypotheses 
Aims 
  To design a bioreactor large enough to house porcine and human trachea and 
enable transmural flow through the wall of the trachea. 
  To optimise a bioreactor system that enables and supports a controllable and 
reliable transmural decellularisation process for tracheal decellularisation. 
 
Hypotheses 
  Through the creation of a dual chamber bioreactor system, independent fluid 
flows can be created, measured and controlled. 
  By using decellularisation solutions and creating a back pressure in one of the 
chambers of the bioreactor, stable transmural flow will be achieved through 
the luminal wall of the trachea.    
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4.3  Materials, methods and results 
As this chapter focused on the development of a novel decellularisation bioreactor 
and the design of the ancillary parts of the bioreactor, the materials, methods and 
results were combined into a single section. 
4.3.1  Pressurised transmural bioreactor design v1.0  
One of the potential issues with the DEM of decellularisation (Conconi, De Coppi et 
al.  2005)  was  that  the  method  relied  on  immersion  of  the  tracheae  in  the 
decellularisation solutions which resulted in 18 to 25 cycles of the detergent and 
enzymatic treatments being required. The proposed solution to this challenge was to 
design a decellularisation process which relied upon transmural flow through the 
tracheal  wall  to  reduce  the  number  of  treatments  required.  Therefore  it  was 
anticipated that a dual chamber bioreactor with separately controllable fluid flows 
would be required to achieve a transmural flow process. The bioreactor concept and 
initial  design  was  discussed  with  UCL  Biochemical  Engineering  faculty  staff 
members; Martina Michelletti, a senior lecturer with expertise in fluid dynamics in 
reactors and Alan Craig, an engineer in the Biochemical Engineering workshop, on 
how best to achieve the transmural flow in such a bioreactor system.  
The concept of initial bioreactor design v1.0 was to enable attachment of a porcine 
trachea to create a dual chamber bioreactor with separate recirculation of an external 
fluid,  the  decellularisation  solution,  and  an  internal  fluid,  a  wash  solution.  The 
conceptual design allowed for the decellularisation solutions to be pumped into the 
external  chamber  (EC),  the  abluminal  side,  of  a  fixed  trachea  with  the  pressure 
controlled using pre and post chamber valves  and monitored using pre and post 
chamber pressure gauges. The wash solutions would be pumped through the internal 
chamber (IC), the luminal side, of the tracheal with pre and post chamber valves to 
control  pressure  and  pre  and  post  pressure  gauges  to  monitor  the  pressure.  The 
pressure of the external decellularisation solution would be greater than the internal 
wash solution causing abluminal to luminal transmural flow of the decellularised 
solution which is then removed, with cell debris, from the luminal side of the trachea 
by the wash solution. A downstream filter would, if necessary, be fitted to remove 
cell debris before the decellularisation solution is returned to the solution reservoir. 
A pulse dampener would also be considered on the internal and external circuits, if  
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necessary,  to  reduce  the  pulsatile  effect  of  the  peristaltic  pump.    From  these 
discussions, drawings were produced in PowerPoint (Figure 4.1) and presented to the 
EngD supervisors for approval to allow the bioreactor to be built. 
 
Figure  4.1  Schematic  of  the  initial  dual  chambered  pressurised  transmural 
decellularisation bioreactor design v1.0. The concept envisaged the decellularisation 
solution  to  be  pumped  under  pressure  into  the  external  chamber  of  the  tracheal 
bioreactor and whilst pumping wash solution through the internal chamber of the 
tracheal bioreactor. The pressure differential would permit transmural flow of the 
decellularisation though the tracheal wall which decellularises the trachea over the 
course of the flow. The aim was to achieve abluminal to luminal transmural flow due 
to the larger density of cells on the luminal side of the trachea in the lamina propria. 
4.3.2  Manufacture of the pressurised transmural bioreactor v1.0 
Having  gained  approval  of  the  pressurised  transmural  pressure  bioreactor  design 
v1.0, the design was presented to the UCL Biochemical Engineering workshop for 
production and, in collaboration with engineer Alan Craig, the bioreactor design was 
finalised.  Prototype  bioreactor  parts  (Figure  4.2)  produced  by  Alan  Craig  were 
tested, in particular the bioreactor length, internal diameter and the size adjustable  
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connectors (SACs) external diameter on the trachea attachment side, to ensure the 
bioreactor would be fit for purpose.  
 
Figure 4.2: Prototype parts of the SAC connectors to ensure the SACs were suitable 
for the attachment of porcine trachea. 
Once the prototype testing was complete, the pressurised transmural bioreactor was 
manufactured  and  leaked  tested  by  Alan  Craig  in  the  Biochemical  Engineering 
Workshop. The outer bioreactor tube (200 mm (L) x 36 mm (ID)) was made from 2 
mm thick polycarbonate to allow for sterilisation by autoclaving and good visibility 
of the internal components of the bioreactor as well as the trachea when in situ. The 
length of the bioreactor tube and the position of the external ports on the bioreactor 
were designed to accommodate tracheas of 85 to 120 mm in length (Figure 4.3 A and 
B). The SACs were designed to accommodate tracheas of 16 to 21 mm in internal 
diameter with grooves machined into the hollow organ attachment side of the SAC 
to facilitate securement of the organ with wire/sutures (Figure 4.3 A and Figure 4.4 
A and B). To assist with the attachment of the trachea to the SAC, a SAC was 
clamped to  a laboratory support stand with the trachea positioned onto the SAC 
(Figure 4.4 A).  The second SAC can be inserted into the top end of the trachea and 
also clamped to hold the trachea and SACs in position before securing the trachea to 
the SAC with appropriate material (Figure 4.4 A and B, Figure 4.5 A). The design of 
the lip on the SACs allows for the assembly of an O-ring (Figure 4.5 B) and an O-
ring compressor (Figure 4.5 C) to be held in place and the O-ring to be compressed 
and create a seal against the bioreactor tube as the SAC fastener is tightened (Figure 
4.5 D). As the SAC assemblies are not fixed inside the bioreactor they allow for the 
trachea to be attached and the SAC assemblies to be assembled before being passed 
through into the bioreactor tube (Figure 4.6 A). The addition of a screw allows one 
of the SAC assemblies to be easily tightened. The other SAC assembly had to be 
slightly angled to create resistance between the SAC, O-ring and O-ring compressor  
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and the bioreactor tube to allow the SAC fastener to be tightened without twisting 
the  trachea/hollow  organ  (Figure  4.6  B).  Assembly  of  the  bioreactor  with  and 
without the trachea in situ demonstrated that the bioreactor did not leak and was fit-
for-purpose. 
 
Figure  4.3:  Images  of  bioreactor  components  and  assembly.  Manufactured  from 
polycarbonate,  the  bioreactor  can  be  sterilised  by  autoclaving.  The  internal  and 
external ports were machined to produce BSP⅛ or G⅛ female threads allowing a 
range  of  adapters  to  be  fitted.  The  trachea  was  secured  to  the  size  adjustable 
connectors (SACs) using sutures outside of the bioreactor. The O-ring and the O-ring 
compressor were slotted onto the SAC and the SAC fastener was threaded onto the 
SAC but not tightened.  The internal assembly was then passed into the bioreactor 
tube. The external chamber of the bioreactor was sealed through compression of the 
O-ring  by  the  O-ring  compressor  as  the  SAC  fastener  was  tightened.  One  SAC 
assembly was prevented from rotating inside the bioreactor tube whilst tightened by 
the addition of a screw.  The other SAC assembly was prevented from rotating by 
slightly angling the SAC assembly as tightened. This allowed the bioreactor to be 
assembled and sealed without twisting the trachea in situ. 
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Figure  4.4:  Attachment  of  the  trachea  to  the  SAC  using  sutures  was  aided  by 
utilisation of a laboratory support stand (A) and clamps to hold the SAC and trachea 
in position (B). 
 
Figure  4.5: Sequential  assembly of the SACs  with the trachea in position. After 
attachment of the trachea to both SACs (A) the O-rings were positioned onto the 
SACs (B), then the O-ring compressor, with the screw in position on the left-hand 
side (C), and finally the SAC fasteners (D). 
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Figure 4.6: The assembled SACs, with the trachea in position, was passed through 
the  bioreactor  (A).  The  screw  was  slotted  into  a  slit  in  the  bioreactor  wall  and 
assisted with the tightening of the top SAC. The bottom SAC was then tightened, 
taking care not to twist the trachea (B).     
4.3.3  Visual  analysis  of  the  mixing  of  internal  and  external  flows  in  the 
pressurised transmural bioreactor v1.0 
With the manufacture of the pressurised transmural bioreactor v1.0 complete, it was 
prudent to assess the fluid flow in the internal and external chambers (IC and EC) to 
see  if  laminar  or  turbulent  flow  type  was  prevalent  and  if  the  fluid  flow  mixed 
enough to create a homogenous solution and the time-frame required to achieve a 
homogenous solution. To visualise the fluid flow in the  IC and EC, trypan blue 
(Sigma Aldrich, Poole, UK) was injected into water that was being pumped into the 
IC or EC of the bioreactor using a peristaltic pump. The bioreactor was assembled 
with 6 mm hose barb to G⅛ male thread connectors attached to each of the SAC 
connectors on the internal chamber side. Onto these hose barbs, a section of clear 
PVC tubing, sized to mimic rabbit trachea, with an ID of 6.4 mm was fixed to create 
separate internal and external chambers. Onto the two external chamber and two 
internal chamber ports, 6 mm hose barb to G⅛ male thread connectors were attached 
with 6.4 mm ID silicone tubing (FB56473, Fisher Scientific) attached to the hose 
barbs, connected to peristaltic pumps (503U and 505S, Watson Marlow, Falmouth,  
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UK)  and  placed  into  solutions  reservoirs.  The  solutions  were  pumped  using 
peristaltic pumps into either the external or internal chamber. The external chamber 
pump speeds tested were 10, 20 and 40 rpm. The internal chamber pump speeds 
tested were 2 and 3 rpm. To assess flow and mixing, the pump was operated at the 
rpm rate described with water being pumped to either one of the chambers. After 
continuous flow had been established with no air bubbles visible, trypan blue was 
injected into the water flow in the tubing and mixing in the bioreactor recorded as 
video footage (Medical Illustrations, Royal Free Hospital, London, UK). Analysis of 
the video footage allowed the type of flow and the time taken for mixing to achieve a 
homogenous solution to be determined. 
From the video footage it was possible to determine that in the internal chamber, 
with a small diameter trachea mimic, predominately laminar flow was achieved with 
both 2 and 3 rpm pump speeds (Figure 4.7 A-E; 2 rpm data not shown). The pulsatile 
effect  of  the  peristaltic  pump  potentially  aided  achievement  of  a  degree  of  non-
laminar  flow  with  complete  mixing  observed  in  the  internal  chamber  after  18 
seconds at a pump speed of 3 rpm. However, there was an observable region of 
unmixed fluid directly adjacent to the inlet port, where the tubing was wider than the 
port  inlet,  due  to  the  laminar  flow  not  enabling  backward  mixing.  This  region 
however was minimal and should not have affected the wash effect of the internal 
flow and could even be mitigated by the transmural flow from the external chamber. 
Video footage of the mixing in the external chamber, at a pump speeds of 10, 20 and 
40rpm (Figure 4.7 F – J and F’ to J’; 10 and 40 rpm data not shown), demonstrated 
turbulent  flow  with  eddies  being  created  by  the  pulsatile  flow  and  the  angle  of 
entrance of the fluid from the inlet port to the bioreactor external chamber (EC). This 
turbulent flow meant that there were no observable regions of unmixed fluid in the 
external chamber and complete mixing was observed in the external chamber after 
35 seconds at a pump speed of 40 rpm, 70 seconds at a pump speed of 20 rpm and 2 
minutes 23 seconds at a pump speed of 40 rpm 10 rpm (Figure 4.8:Figure 4.8). This 
suggested a linear relationship between mixing time and pump speed in the EC. The 
fluid flow experiments demonstrated that independent flow with complete mixing of 
the solutions could be achieved in both the internal and the external chambers.  
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Figure  4.7:  Stills  were  captured  from  mixing  experiments  on  the  internal  and 
external chamber. The internal chamber experiment demonstrated laminar flow that 
took 18.03 seconds to fully mix post injection of the dye at a pump speed of 3 rpm 
(A – E). The external chamber experiment demonstrated turbulent flow that took 70  
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seconds to fully mix post injection of the dye at a pump speed of 20 rpm (F – J and 
F’- J’). 
 
Figure 4.8: The mixing time for the specified pump speeds tested indicated there was 
a linear relationship between the two factors. N = 1. 
4.3.4  Transmural flow testing in bioreactor design v1.0 
Having established that independent flow could be achieved, the bioreactor design 
v1.0 was set up to determine if transmural flow from the EC to the IC could be 
achieved. This would to be tested by pumping a blue coloured solution through the 
EC at a higher pressure than a clear solution pumped through IC and observing if 
any  blue  dye  had  transmurally  flowed  into  the  IC.  This  involved  setting  up  the 
bioreactor  as  described  in  section  4.3.2  with  a  porcine  trachea  in  situ  securely 
attached between the internal parts of the two SACs using thin copper wire stripped 
from electrical cable. Once the trachea had been securely attached, male G⅛ to 6 
mm hose barbs connectors (795-102, RS Components, Corby, UK) were attached to 
the  SAC  ports  and  to  the  bioreactor  side  ports  with  the  addition  of 
polytetrafluoroethylene (PTFE) tape (RS components, Corby, UK) in the threaded 
joints to ensure a good seal would be maintained under pressure. Silicone tubing, 
with  an  ID of 6.4 mm, was  attached the hose barbs at  all four bioreactor ports. 
Ratchet tubing clamps (Sigma Aldrich, Poole, UK) were attached to tubing within 
close  proximity  of  the  four  ports.  Online  analogue  pressure  gauges  which  could 
measure 0-6 bar (2435919 RS components, Corby, UK) were connected upstream 
and downstream of the internal and external chambers using 3-way metal female G¼  
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T-connectors (3675922, RS components, Corby, UK) and G¼ to 6 mm hose barbs 
(795-118, RS components). Upstream of the bioreactor for the internal and external 
chambers,  the  tubing  was  placed  into  two  peristaltic  pumps  (Marlow  Watson, 
Falmouth,  UK)  to  allow  for  independent  control  of  fluid  flow  into  the  separate 
chambers. The internal chamber tubing upstream of the internal chamber pump was 
placed into a solution reservoir containing Hank’s Balanced Salt Solution (HBSS) 
(Gibco) with the corresponding return tubing, downstream of the internal chamber, 
placed into the same reservoir. The external chamber tubing upstream of the external 
chamber  pump  was  placed  into  a  solution  reservoir  containing  HBSS  and  0.4% 
trypan blue (Sigma Aldrich, Poole, UK) to give the solution a blue colour, with the 
corresponding return tubing, downstream of the external chamber, placed into the 
same reservoir. To attempt transmural flow of solution from the external chamber to 
the internal chamber, the internal and external chamber pumps were run to fill both 
chambers and remove any air bubbles then run the pumps for the IC and the EC at 
varying speeds to see if transmural flow could be achieved. Additionally, in case 
varying pump speeds did not create enough of a pressure differential between the IC 
and the EC  to  create transmural  flow then the ratchet  clamp downstream  of the 
external chamber would be semi-closed to varying levels to create a back pressure in 
the external chamber and force transmural flow. 
The  set-up  of  the  trachea  in  the  pressurised  transmural  bioreactor  v1.0  was 
accomplished  successfully  and  fluid  flow  was  achieved  through  the  internal  and 
external chamber as expected (Table 4.1 and Figure 4.9 A). However transmural 
flow was not discernibly achieved. Decreasing the speed of the internal chamber 
pump  and  increasing  the  speed  of  external  chamber  should  have  increased  the 
external  chamber  pressure  relative  to  the  internal  chamber  pressure,  however  no 
transmural flow was observed. The additional use of back pressure in the external 
chamber had no observable effect on the transmural flow either though an interesting 
effect was noted. As the external pressure increased relative to the internal pressure, 
the trachealis muscle of the trachea was pushed into the luminal area of the trachea 
(Figure 4.9 B). Reciprocally, if the internal pressure was increased relative to the 
external pressure using the downstream clamp on the internal chamber, the trachea 
swelled, again predominantly at the trachealis muscle (Figure 4.9 C). This indicated 
that the trachealis  muscle region of the trachea was,  unsurprisingly, the weakest  
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region of the trachea in terms of pressure and therefore if pressure is to be applied 
externally  then  a  steady  pressure  would  need  to  be  maintained  to  avoid  internal 
collapse of the trachea which would hinder or prevent internal fluid flow at the least 
and cause structural damage to the trachealis muscle at worst. If pressure is applied 
internally then over-pressurising could damage or even rupture the trachea in the 
trachealis  muscle  region.  The  results  from  these  transmural  flow  experiments 
indicated that achieving transmural flow from the EC (abluminal side) of the trachea 
to the IC (luminal side) of the trachea would be problematic, due to the collapsible 
nature  of  the  trachealis  muscle  and  therefore  future  transmural  decellularisation 
experiments would focus on IC to EC (luminal to abluminal) transmural flow. 
Table  4.1:  Experimental  detail  and  results  from  the  initial  attempts  to  achieve 
transmural flow. For post-EC clamp closure, the number of notches related to the 
extent of closure of the ratchet clamp. Incrementally increasing the notch the clamp 
was closed to, increased the level of closure.   
 
Internal chamber 
pump speed (rpm) 
External chamber 
pump speed (rpm) 
Post-EC 
clamp 
closure 
Time 
(min) 
Effect 
3  20  -  15  None 
1  20  -  10  None 
1  40  -  10  None 
1  40  1 notch  10  None 
1  40  2 notches  10  Tracheal collapse 
at back wall.  
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Figure 4.9: Stills from the initial transmural experiments demonstrate the trachea in 
position (A), the effect of external over-pressurisation (B) causing internal collapse 
of the trachealis muscle and the effect of internal over-pressurisation (C) causing 
external strain of the trachealis muscle. 
4.3.5  Pressurised transmural bioreactor design v1.1 
Hose barbs had been used in pressurised transmural bioreactor design v1.1 and had 
provided secure attachment of the silicone tubing with a wide range of connector 
types. However the ability to connect the ancillary parts of the bioreactor design 
together was limited due to the connectors requiring a short section of silicone tubing 
between each other. This  meant  the design required structural  support in  several 
areas of the set up. It was proposed that the hose barbs connectors would be changed 
to luer connectors. Luer connectors can be directly connected to each other without 
the need for additional tubing and although the connectors have limited load bearing, 
the luer connectors would create a rigid structure. Luer connectors are also available 
in an extremely wide variety of connectors therefore changing to luer connectors 
would allow for easy modification and future adaptation of the bioreactor’s ancillary 
parts. Luer connections are also widely used for medical and clinical applications 
and therefore provided a semi-closed system more suitable for GMP translation.  
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The hose barbs (Figure 4.10 A & B and Figure 4.12 A) were replaced by luer lock 
connectors (Figure  4.11 A  -  G and  Figure  4.12 B & C) to  create an  entire luer 
connector based system. The luer connectors produce a semi-closed system which 
allowed media changes to be performed at a lower risk of contamination in an open 
laboratory environment. For research purposes, this was advantageous as it meant 
the bioreactor system was no longer dependent on being run in or transferred into a 
class II microbiological safety cabinet when performing media changes. With regard 
to future translation to a GMP process, luer connectors can be produced to GMP 
required standards and be sterilised using a GMP validated procedure by the Royal 
Free London NHS Foundation Trust Central Sterile Services Department (CSSD). 
Luer  connectors  are  also  commonly  used  to  dock  sterile  single-use  monitoring 
devices  such as  temperature probes  and pressure transducers. Establishing a luer 
based connection system enabled an easy system for setting up and connecting the 
bioreactor with the ancillary parts and the wide variety of connection options future-
proofed the system to allow easy integration of temperature probes and pressure 
transducers.  
 
 
Figure 4.10: 6 mm hose barb to G¼ male thread (A) and T-connector with 6 mm 
hose barbs to G⅛ male thread (B).  
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Figure 4.11: 6.4 mm hose barb to male luer (A), male luer to G⅛ male thread (B), 
male luer to male luer (C), 6.4 mm hose barb to female luer (D), female luer to G⅛ 
male thread (E), female luer to female luer (F), male luer to female luer rotating 
connector (G). 
 
Figure 4.12: 0 - 6 bar pressure gauge connected to a 3 way t-connector (3 G¼ female 
threads) and G¼ male thread to 6 mm hose barbs (A). 0 -1.6 bar pressure gauge 
connected to a G⅛ female thread to male luer and a 3 way t-connector (2 female and 
1 male luer) (B). A male luer to female luer pressure transducer (C). 
 
4.3.6  Pressurised transmural bioreactor design v1.2 
Watson Marlow peristaltic pumps 503U and 505S were used in the early process 
development  stages  of  transmural  decellularisation.  Both  pumps  utilised  a  pump 
head type with two sprung rollers (Figure 4.13 A). The tubing used was Fisherbrand 
peristaltic pump grade silicone (FB56473, Fisher Scientific) which was Food and 
Drug  Administration  (FDA)  approved  and  certified  to  USP  XXII  class  6  and 
commonly used in the field of medicine (Figure 4.13 A). During the course of early 
experiments, which could last up to 10 days or 240 hours, tube creep of the silicone  
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tubing would commonly occur, mostly with devastating consequences. The tubing, 
after a certain amount of creep, would ultimately form a loose section that would be 
caught by the pump head, become entangled around the pump head, which would rip 
the tubing, causing loss of the decellularisation solution and prevent the pump head 
from spinning (Figure 4.13 B and B’). Experiments where this occurred resulted in 
the  experiments  having  to  be  discontinued  as  it  commonly  occurred  overnight. 
Consultation with various experts in the field recommended replacement of both the 
pump type and tubing type. The replacement pump that was selected was the Watson 
Marlow 323Dz which featured top tube loading head with a four cartridge roller 
(Figure 4.13 C). The replacement tube type that was selected was Bioprene tubing 
(933.0064.016,  Watson  Marlow)  which  was  certified  to  USP  Class  VI,  FDA 
compliant  and  suitable  for  biopharmaceutical  applications  (Figure  4.13  C).  This 
replacement tubing was rated to have a pump life of approximately 10,000 hours 
continuous  usage  in  a  peristaltic  pump  and  should  therefore  add  extra  process 
security by greatly reducing the likelihood of the tube splitting.  
Replacement  of  the  pump  to  the  top-loading  head  type  with  Bioprene  tubing 
instantly  increased  the  reliability  of  the  bioreactor  system  and  allowed  multiday 
decellularisation protocols to be completed without incidents and therefore allowed 
the  development  of  the  decellularisation  process.  Further  development  of  the 
pressurised  transmural  decellularisation  (PTD)  system  incorporated  a  top-loading 
pump (Figure 4.13 D) from Harvard Apparatus (Harvard Apparatus, Holliston, USA) 
which was controlled and the pump speed recorded by the Bio_1 software (Harvard 
Apparatus, Holliston, USA). The Harvard Apparatus pump developed a fault and 
therefore was only used for a few experiments. The Marlow Watson D323Z was then 
reinstalled into the system and used in subsequent experiments.  
  
Page - 123 - of 223 
 
 
Figure 4.13: The pumps used in early experiments were the Watson Marlow 503U 
(A) and 505S (not shown) peristaltic pumps which both utilized a two sprung rollers 
pump-head.  The  tubing  was  6.4  mm  ID  silicone  tubing.  Due  to  tubing  creep, 
common with the two sprung roller type of pump-head over long experiments, the 
tubing frequently became entangled in the pump head (B) and in doing so shredded 
the tubing (B’) causing leakage of the decellularisation solution. As this tended to 
occur overnight, it meant the experiment frequently had to be abandoned. Another 
style of peristaltic pump with top tube loading and a four cartridge roller (C) along 
with  6.4  mm  ID  Bioprene  tubing  was  adopted  which  mitigated  tube  creep  and 
established reliability to the pump system which allowed the development of the 
bioreactor  system  to  progress.  After  development  of  the  pressurised  transmural 
method, the system was transferred to the Harvard Apparatus OCRA controller and 
so the use of their peristaltic pump (D) was briefly used which was controlled via the 
Bio_1 software (D inset). 
4.3.7  Pressurised transmural bioreactor design v1.3 
Initially ratchet tubing clamps (Figure 4.14 A) were used to create a back pressure in 
the internal bioreactor chamber but they were not suitable as they were not sensitive 
enough for fine adjustment required to stably create the required pressure, which  
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would result in either under-pressurisation or over-pressurisation. This would either 
not  create  enough  pressure  to  achieve  transmural  flow  or  damage  the  tracheae 
respectively for the subtle tube clamping required to create a stable pressure in the 
internal chamber of the trachea for decellularisation. Due to this the ratchet tubing 
clamps where replaced by Hoffman clamps (Figure 4.14 B) which could be finely 
adjusted to clamp the tubing and create the desired back pressure in the bioreactor 
chamber, which was measured using an analogue pressure gauge. However as the 
pressure was created by clamping the tubing, attaining the required pressure was a 
tedious process which required multiple fine re-adjustments over several hours. Even 
when the pressure appeared to have stabilised, any creep or slight movement of the 
tubing  or  clamp  could  cause  a  slow  increase  or  decrease  in  the  pressure  in  the 
chamber resulting in either damage or rupture to the tracheae or a lack of transmural 
flow due to insufficient pressure. Due to the unreliability of the Hoffman clamps, the 
early  pressurised  transmural  decellularisation  experiments  where  often  prone  to 
failure and there was a need to improve the mechanism for attaining stable pressure 
within the IC of the bioreactor. 
The  proposed  solution  was  to  use  luer  one  way  check  valves  (Smart  Products, 
Morgan Hill, USA) which were purchased customised to open or crack at a specified 
pressure (Figure 4.14 C). The check valve after the internal chamber was set to 4.82 
psi. This check valve set the pressure in the internal chamber so that only once this 
pressure had been achieved in the internal chamber did the check valve open and 
allow flow of the decellularisation solution. The concept was to have a check valve 
before and after the internal chamber. This would isolate the internal chamber of the 
bioreactor  because  the  check  valves  also  had  a  high  back  pressure  capacity  of 
approximately 60 psi, so the back pressure would not affect the pump or solution 
reservoir.   
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Figure 4.14: The use of ratchet tubing clamps (A) did not allow for fine enough 
control when creating a back pressure to achieve transmural flow. Replacement with 
the  Hoffman  clamps  (B)  allowed  for  fine  control  to  transmural  flow  via  back 
pressure but did not provide long-term stable pressure over multiple days of use. 
Replacement by one-way check valves (C) set at manufacture to the desired cracking 
pressure allowed for long term stable transmural flow over multiple days without the 
need for user intervention. 
After testing samples of one-way check valves at various set pressures (0.09, 4.82, 
7.5, 13.24, 16.56 psi), two one-way check valves were incorporated into the system 
with both check valves set at 4.82 psi (0.33 bar). The first check valve was placed 
upstream  of  the  internal  chamber  of  the  transmural  bioreactor  and  monitoring 
instrumentation. The second check valve was placed downstream of the transmural 
bioreactor and monitoring instrumentation. The incorporation of the one-way check 
valves was a major process development breakthrough in maintenance of a stable 
pressure within the IC (Figure 4.15) to create transmural flow without appearing to 
damage or rupture the tracheae. Along with the simultaneous replacement of the 
pump and tubing, the check valves created a reliable decellularisation system which  
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could run without issues over multiple days, which allowed pressurised transmural 
decellularisation methodologies to be evaluated. 
 
Figure  4.15:  Readings  from  the  ORCA  controller  from  the  pressure  transducers 
positioned pre and post the internal chamber (IC), or tracheal lumen, demonstrated 
the average pre-IC pressure was 4.79 ± 0.17 psi and the average post-IC pressure 
was 4.00 ± 0.16 psi with an average difference of 0.79 psi between the two pressure 
transducers. 
4.3.8  Pressurised transmural bioreactor design v1.4 
One  of  the  conclusions  from  chapter  3.6  stated  that  performing  certain 
decellularisation steps at 37°C could be beneficial and therefore methods to warm 
the decellularisation solutions and bioreactor were explored. The early attempts at 
decellularisations  were  initially  carried  out  in  a  37°C,  5%  CO2,  humidified  cell 
culture  incubators  to  warm  the  decellularisation  solutions  and  the  internal  and 
external chambers to 37°C (Figure 4.16 A). Any leaks from the bioreactor system 
required  the  cleaning  and  decontamination  of  the  entire  incubator,  rendering  it 
unuseable for several days. Peristaltic pumps are also not best suited to the heated 
and humidified environment and can fail as a result. Additionally, if the pump started  
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to  overheat  then  this  had  a  subsequent  effect  of  preventing  the  incubator  from 
maintaining its set temperature. An ideal solution would be to have access to a non-
humidified incubator/oven capable of maintaining 37oC to prevent corrosion of the 
internal components of the pump. Also to prevent the pump from  overheating it 
would be preferable to position the pump outside of the 37°C incubator whilst fitting 
the  media  reservoir  and  bioreactor  inside  the  incubator  and  running  the  tubing 
through an access port. However exclusive access to a non-humidified 37°C was not 
feasible and the tubing and access requirements to house the pump outside of the 
current  incubator  made  doing  so  prohibitive.  The  alternative  solution  to  achieve 
running the process at 37°C was to set up a water bath (Grant Instruments, Shepreth, 
UK) adjacent to the peristaltic pump for the solution reservoir to be heated to 37°C 
before  the  solutions  were  pumped  through  the  bioreactor  (Figure  4.16  B).  The 
bioreactor,  and  the  ancillary  parts  of  the  bioreactor,  were  also  set  up  in  a  sink 
drainage area so any leaks could be easily contained and cleaned up (Figure 4.16 B). 
Because the decellularisation process was to be performed on the laboratory bench, it 
became  essential  to  monitor  the  temperature  of  the  internal  chamber.  Online 
temperature monitoring using temperature probes, (TC-02 Biorep, Miami, USA or 
PIT-6 Physitemp Instruments Inc, Clifton, USA) with tuohy borst adapters (Biorep, 
Miamo,  USA  (80409  Qosina,  Edgewood,  USA))  to  allow  connection  to  the 
bioreactor, were set up to monitor the temperature of the solutions pre-entry to and 
post-exit from the internal chamber to determine any temperature difference across 
the chamber (Figure 4.16 C and D). The temperature was displayed using either the 
Mon-a-therm 6510 (Mallinckrodt Medical, St. Louis, USA) (Figure 4.16 B), which 
was only capable of measuring the current temperature at the two sites, or the ORCA 
Bioreactor  system  (Harvard  Apparatus,  Holliston),  which  could  measure  and 
digitally record the temperatures.    
Page - 128 - of 223 
 
 
Figure  4.16:  Early  experiments  were  performed  in  a  37oC  CO2  to  maintain  the 
experiment at 37oC (A). This potentially caused instrument failure of the incubator. 
Therefore the experiment was moved to a laboratory bench where a water bath was 
used to the heat the decellularisation solution (B). Temperature probes from Harvard 
Apparatus (C) and Biorep (D) were used to monitor the solution temperature in the 
internal chamber.  
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As expected, the addition of a water bath to warm the decellularisation solutions 
allowed the bioreactor system to be positioned on a laboratory bench (Figure 4.16 B)  
and nullified the dependency on a 37°C incubator (Figure 4.16 A). Additionally, by 
setting the system up on a laboratory bench, it should reduce the incidence of pump 
or  incubator  failure.  Integration  of  temperature  probes  positioned  immediately 
upstream and immediately downstream of the internal bioreactor chamber allowed 
for monitoring of the solution temperature across the chamber. However, relying 
solely on a water bath to provide a heated environment did have its limitations. Most 
predominately there was a temperature drop of 9.31°C of the solution temperature 
from the solution reservoir in the water bath to the temperature probe positioned 
upstream  of  the  internal  chamber,  due  to  the  exposure  of  the  tubing  to  a  room 
temperature  environment.  In  addition  there  was  a  temperature  loss  of  0.84°C 
detected between the upstream and downstream temperature probes. To compensate 
for this, the water bath was set to 42.9°C, however due to the extent of temperature 
loss  and  the  desire  to  not  overheat  or  potentially  denature  the  enzymes  in  the 
decellularisation solutions, this resulted in an average internal chamber temperature 
of  33.35°C  over  the  course  of  decellularisation  process  instead  of  the  required 
temperature of 37°C (Figure 4.17). Employment of a pump that was suited to use in 
a 37°C incubator and performing the decellularisation in a 37°C incubator could 
have  resolved  this  issue. Alternatively, sourcing a heat  jacket with  an integrated 
solution heating or cooling device with an online feedback mechanism to achieve the 
desired temperature of 37°C in the luminal and abluminal chambers, as commonly 
utilised in stirred tank bioreactor systems, would provide an ideal resolution to this 
issue. After use in several PTD experiments, the Biorep temperature probe (Figure 
4.16  D)  was  deemed  unsuitable  for  the  pressurised  transmural  decellularisation 
process as the application of pressure caused the passage of the decellularisation 
solution inside the temperature probe casing, which would then leak out at T-type 
connector on the temperature probe. As this was a safety concern, this temperature 
probe was replaced by a solid metal temperature probe (Figure 4.16 C) which had no 
such issues.   
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Figure  4.17:  Readings  from  the  ORCA  controller  from  the  temperature  probes 
positioned pre and post the internal chamber (IC), or tracheal lumen, demonstrated 
the  average  pre-IC  temperature  was  33.59  ±  0.66°C  and  the  average  post-IC 
temperature was 33.10 ± 1.31°C with an average difference of 0.84°C between the 
two temperatures probes. 
4.3.9  Pressurised transmural bioreactor design v1.5 
The  bioreactor  was  initially  set  up  horizontally  on  a  stand  (Figure  4.18  A) 
manufactured by Alan  Craig  (Biochemical  Engineering Workshop, UCL).  It  was 
realised that in this orientation it was difficult to completely fill the lumen of the 
trachea (the internal chamber) as an air pocket would form inside the trachea above 
the level of the inlet and outlet ports. Removal of this air pocket required raising the 
outlet port until it was vertically above the inlet port until no more air bubbles could 
be seen in the outlet tubing. However, air would commonly build back up over the 
long periods of the decellularisation process. The proposed solution to prevent this 
air pocket during initial set up and from forming during the decellularisation process 
was to change the orientation of the bioreactor so that the inlet port was vertically 
below the outlet port (Figure 4.18 B).   
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Modifying  the  bioreactor  orientation  from  horizontal  to  vertical  (Figure  4.18  B) 
eliminated any build-up of air within the internal chamber. 
 
Figure  4.18:  Horizontal  orientation  (A)  of  the  pressurised  transmural  bioreactor 
resulted  in  a  build-up  of  air  above  the  port  inlet  and  outlets.  Rotation  of  the 
pressurised transmural bioreactor to a vertical orientation (B) prevented any such 
build-up and allowed total transmural flow through all areas the tracheae. 
4.3.10  Pressurised transmural bioreactor design v1.6 
When the trachea was attached to the SAC and placed under internal pressure, the 
trachea would deform due to the pressure and leave the trachea twisted.  To prevent 
this deformation, a GMP-grade wire mesh (Figure 4.19 A) (Biorep, Miami, USA) 
was rolled and crafted into a stent (Figure 4.19 B) to internally support the trachea in  
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vitro in the bioreactor whilst still allowing unimpeded flow of the decellularisation 
solutions (Figure 4.19 C).  
 
Figure 4.19: GMP grade wire mesh (A) was rolled and trimmed, as appropriate, to 
produce stents (B) which were then inserted into the lumen of the trachea during 
tracheal attachment to the SACs (C) as part of the bioreactor assembly.  
The  addition  of  the  internal  stent  (Figure  4.19  B)  into  the  lumen  of  the  trachea 
enabled pressurised transmural decellularisation to be achieved without deformation 
the trachea (Figure 4.20 A & B). This prevented undue strain being placed onto the 
tracheae  throughout  the  decellularisation  process  and  could  result  in  an  overall 
stronger scaffold.  
 
Figure 4.20: Pressurised transmural decellularisation without a stent would cause the 
trachea  to  twist  and  kink  (A)  which  could  weaken  the  tracheal  scaffold  at  that 
pressure point. The addition of a stent prevented such contortion (B).  
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4.4  Discussion  
Although the initial design, development and manufacture of the actual transmural 
bioreactor was successfully accomplished and was fit-for purpose without the need 
to alter the design after the prototype development, the bioreactor is only a small part 
of  a  system  required  to  successfully  achieve  pressurised  transmural  flow.  The 
ancillary  parts  of  the  system  required  to  generate  flow  and  pressure  as  well  as 
maintain  the  desired  temperature  are  equally  critical  to  the  development  of  the 
system. If any one part of the overall bioreactor system did not function correctly 
then the system failed as a whole, as happened on numerous occasions during the 
bioreactor development. Initial early experiments that investigated the possibility of 
creating transmural flow in the system highlighted the issue of luminal obstruction 
by trachealis muscle collapse when trying to obtain abluminal to luminal transmural 
flow, therefore the original concept of abluminal to luminal transmural flow was 
changed to luminal to abluminal flow. Even though this would mean that cell debris 
from the more populous luminal side could be forced through the wall of the trachea, 
if the decellularisation protocol was adequate, then full decellularisation should still 
be achievable. It was also likely that, as the luminal epithelium was very quickly 
removed  during  the  DEM  of  decellularisation,  that  it  could  be  equally  rapidly 
removed by the intra-luminal flow of decellularisation solutions in the PTD method.  
Due to the multiple failures of the ancillary parts of the bioreactor system, the initial 
major issue with the bioreactor system was its stability and reliability in allowing an 
experiment to be run without failure over the course of several days. The alteration 
of the system to incorporate a pump with top-loading pump-head, Bioprene tubing 
and one-way check valves had the most overall dramatic impact on the stability of 
the  bioreactor  system.  The  new  pump  in  collaboration  with  the  Bioprene  tubing 
produced an ancillary fluidic system that did not wear or fail. The new check valves 
enabled a stable pressure to be created and maintained within the internal chamber of 
the bioreactor system. The combination of these three changes radically improved 
the  stability  and  reliability  of  the  bioreactor  system  and  enabled  pressurised 
transmural flow to be achieved continuously over the duration of the experiment. 
This reliability allowed the focus to shift from optimizing the bioreactor system to 
developing a decellularisation methodology that could fully decellularise a trachea in 
a rapid time period in the pressurised transmural bioreactor system. Optimisation of  
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other aspects of the bioreactor system improved the ease of usability, controllability 
and reproducibility of the system. The incorporation of the luer connectors allowed 
for easy set up and commencement of the decellularisation process in the bioreactor 
system.  The  luer  connectors  furthermore  allowed  for  easy  adaptation  of  the 
bioreactor system set-up and integration of new components such as the check valves 
and the monitoring instrumentation. The online analogue pressure gauges and online 
digital  temperature  probes  initially  used  were  limited  to  solely  measuring  the 
pressure and temperature. Therefore only snapshots of the bioreactor system could 
be  recorded.  By  revising  this  part  of  the  system  to  integrate  online  digital 
temperature  probes  and  pressure  transducers  that  simultaneously  measured  and 
recorded the temperature and pressure every 15 seconds, it provided the ability to 
analyse the bioreactor’s robustness over multiple runs of the system, which would be 
a necessary step towards validating the decellularisation methodology if it were to be 
translated to GMP and/or commercialised. Future experimentation could take this 
further to incorporate feedback loops for both the temperature and pressure from the 
online  measurements  to  build  into  the  system’s  automated  controls  and  cascade 
systems. This was attempted with regard to the pressure control using the ORCA 
controller (Harvard Apparatus) but not realised due to time constraints and software 
issues; but would be possible with development. Similarly, with a more sophisticated 
software package and controller, a solution reservoir with a heat jacket and a heat 
jacket  for  the  decellularisation  bioreactor,  feedback  loops  could  also  be  used  to 
control  the  solution  temperature  accurately  at  37°C  in  the  decellularisation 
bioreactor. The use of the stent prevented the tracheae from over-deformation whilst 
under  pressure  which  could  have  resulted  in  superfluous  damage  to  the 
decellularised  scaffolds.  The  amendment  of  the  bioreactor  orientation  to  vertical 
prevented  any  build-up  of  air  pockets  which  would  have  impeded  the  ability  to 
deliver the decellularisation solutions to, and affected the decellularisation potential 
of, those regions of the trachea. 
The only aspect of the system that was not improved by the system amendments was 
the implementation of the water bath to allow the decellularisation to be performed 
on the laboratory bench. Although the temperature had not been monitored whilst the 
decellularisations  were  attempted  in  the  humidified  5%  CO2  incubator,  it  was 
assumed that the solution  reservoir and the decellularisation  bioreactor chambers  
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were reliably heated and maintained at 37°C as the surrounding air temperature was 
maintained at 37°C by the incubator. However the problems caused by installing the 
bioreactor system inside the incubator made doing so impractical resulting in the 
water-bath alternative being the only solution. Performing the decellularisation on 
the laboratory bench at room temperature with sole reliance of heating the entire 
bioreactor system using the heating of the solution reservoir in a water bath was 
always likely to be problematic. The desired internal chamber of 37°C was never 
achieved due to temperature loss from the tubing between the solution reservoir and 
the  bioreactor.  To  compensate,  the  temperature  of  the  decellularisation  solution 
reservoir in the water bath was raised above 37°C, however the temperature loss was 
too  substantial  to  overcome  without  potentially  impacting  the  stability  of  the 
decellularisation solutions. Although the average recorded temperature in the internal 
chamber  was  less  than  the  desired  temperature,  it  was  still  considered  an 
improvement  over  performing  the  decellularisation  at  room  temperature  and 
therefore an acceptable compromise. Future experimentation would be well advised 
to  investigate  the  use  of  a  heated  jacket  system  to  additionally  warm  the 
decellularisation bioreactor to 37°C to further lessen the impact of heat lost from the 
tubing. 
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4.5  Conclusion 
The dual chamber bioreactor designed for this project proved itself fit for purpose. It 
allowed  tracheae  to  be  attached  and  separate  luminal  and  abluminal  flow  to  be 
achieved. The ancillary parts of the bioreactor system proved to be the challenging 
aspect of the bioreactor system design and were the common point of failure in the 
attempt to achieve a pressurised system and transmural flow. The sites of failure 
were  most  frequently  associated  with  the  peristaltic  pump,  the  tubing  and  the 
clamping of the tubing downstream of the internal chamber to achieve the desired 
backpressure. Optimisation of these ancillary parts and the introduction of two one-
way check valves produced a reliable, stable and manually controllable bioreactor 
system  which  would  allow  tracheal  decellularisations  to  be  carried  out  over  the 
multiple days which,  from  historical  evidence,  was  presumed to be necessary  to 
produce  a  fully  decellularised  trachea.  Further  system  improvements  could  be 
incorporated in the future such as temperature and pressure control with feedback 
loops  to  automatically  control  the  desired  temperature  and  pressure  of  the 
decellularisation from predetermined set points and automatically control the filling 
and drainage of the decellularisation and wash solutions to and from the IC and EC 
chambers. 
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5  Pressurised transmural decellularisation 
5.1  Introduction 
Limitations  associated  with  the  scalability  and  automatability  of  the  DEM  of 
decellularisation process, which took approximately 28 working days to complete, 
and  the  quality  of  the  scaffold  product  derived  using  the  passive  DEM  of 
decellularisation for the trachea (Conconi, De Coppi et al. 2005)) drove the need to 
develop an alternative method for decellularisation. Specific quality issues related to 
the  loss  of  biomechanical  strength  of  the  resulting  scaffold  and  the  inadequate 
removal of DNA from the ECM of the scaffold (Partington, Mordan et al. 2013) 
meant that an innovative approach was necessary to develop an alternative method of 
decellularisation. Therefore, whilst building on prior experience and success in the 
field of tissue engineered tracheae, the composition of the applied decellularisation 
solutions, the temperature of the applied decellularisation solutions and the method 
of application of the decellularisation solutions were to be investigated. Ideally a 
quality by design (QbD) approach would be taken in the development of the new 
method and design of experiments (DoE) used to understand which are the important 
factors in the decellularisation process and are there any interactions between these 
factors. However, on the advice of DoE experts, due to the biological variability of 
the starting material in the porcine model and even more so with cadaveric human 
tracheae, it would be difficult to create the strict reproducibility required to obtain a 
design space or window of operation for optimal decellularisation parameters using 
DoE  and  QbD.  Therefore  the  more  traditional  approach  of  method  development 
where one factor at a time was changed was undertaken. 
The composition of the decellularisation solutions utilised in decellularisation can 
vary greatly from one decellularisation process to another depending on the type of 
tissue  to  be  decellularised.  Due  to  clinical  success  using  the  DEM  of 
decellularisation, detergent and enzymatic solutions were chosen as the basis of the 
decellularisation solutions for the method to be developed. With regard to detergent 
selection for tracheal decellularisation, it was preferable to choose a detergent that 
had shown to achieve good cell clearance whilst causing little disruption to the ECM 
and cartilage and minimal removal of GAGs from the ECM and cartilage. Sodium 
deoxycholate  had  been  well  documented  as  a  detergent  used  for  tracheal  
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decellularisation and was commonly prepared as a 4% solution in water ((Conconi, 
De  Coppi  et  al.  2005,  Macchiarini,  Jungebluth  et  al.  2008)).  Although  sodium 
deoxycholate was assumed to be more disruptive to the ECM than sodium dodecyl 
sulphate (SDS) ((Gilbert, Sellaro et al. 2006)), SDS has been reported to damage 
collagen and remove GAGs ((Gilbert, Sellaro et al. 2006)). Triton X-100 has also 
been used for tracheal decellularisations in conjunction with sodium deoxycholate 
prepared  in  Hank’s  Balanced  Salt  Solution  (HBSS)  in  tracheal  decellularisation 
(Lange,  Greco  et  al.  2015)  and  therefore  was  incorporated.  For  the  enzymatic 
selection, DNase is commonly used for DNA degradation and clearance and also 
RNase  is  often  included  to  aid  with  RNA  degradation  and  could  be  considered 
beneficial (Bolland, Korossis et al. 2007, Lange, Greco et al. 2015). However RNA 
is unstable and could degrade easily without the need for RNase, so the addition of 
RNase should be investigated to minimise the CoG. As previously discussed, the 
DNase is commonly dissolved in sodium chloride (NaCl), Phosphate Buffered Saline 
(PBS) or HBSS, however these buffers contain high levels of sodium chloride and 
potassium  chloride  which  can  inhibit  or  diminish  the  efficiency  of  the  DNase 
enzyme.  Therefore  a  DNase  buffer  which  is  specifically  designed  for  maximum 
DNase efficiency such as has been developed for DNA digestion in RNA samples 
prior to PCR, for example Tris buffer with set concentrations of MgCl2 and CaCl2, 
would be an alternative possible buffer. Tris buffer has been used as a buffer for 
decellularisation solutions and therefore could possibly be used as the buffer for the 
detergent, DNase and wash solutions (Bolland, Korossis et al. 2007).  
The temperature of applied decellularisation solutions varied greatly in the published 
literature.  In  the  DEM  method,  as  described  in  chapter  3,  the  detergent  and 
enzymatic steps are performed at room temperature and the main wash step was 
performed  overnight  at  4°C.  This  meant  that  the  enzymatic  step,  which  utilises 
DNase to non-specifically cleave DNA to reduce the length of the DNA strands, was 
performed at room temperature. DNase is often used to remove DNA from RNA for 
reverse transcriptase - polymerase chain reaction (RT-PCR). Although some DNase 
treatment protocols recommend that the DNase treatment can be performed at this 
temperature,  it  is  widely  acknowledged  that  DNase  treatment  will  often  be 
incomplete at this temperature and remnant DNA will still persist and that DNase is 
more effective and efficient when incubated at 37°C. It is also worth considering, for  
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steps performed at “room temperature” that the temperature is not a set temperature 
and  for  scientific  work  is  assumed  to  be  between  20°C  and  26°C  but  is  often 
described as 25°C. However, in the UK in the winter, room temperature could be as 
cool  as  16°C  -  18°C, which could  further reduce the efficiency  of DNase if the 
incubations are performed in a cool environment. Ideally, if processes such as DNase 
treatment were to be performed at room temperature, they would be controlled and 
ultimately  validated  by  performing  the  processes  in  a  temperature-controlled 
incubator  set  for  example  at  25°C  which  would  at  least  reduce  the  spatial  and 
temporal fluctuations of performing the lengthy processes on the bench.  
As  mentioned  in  section  4.1,  the  concept  of  transmural  flow  for  tracheal 
decellularisation  was  formed  from  the  comparative  technical  applicability  of 
tangential flow in tangential flow filtration (TFF). If a positively pressurised solution 
is passed through a separated internal chamber of a tubular structure and the tubular 
structure  is  permeable  to  the  solution,  then,  as  the  solution  is  recirculated,  a 
proportion of the solution will be forced through the wall of the tubular structure. In 
TFF this application can be used to concentrate solutions or harvest permeate. If it 
were to be applied to decellularisation, the application can be used to gently force 
decellularisation solutions transmurally through the trachea and in doing so penetrate 
the  entire  thickness  of  the  wall  of  the  trachea  rapidly  with  the  decellularisation 
solutions. 
Very few decellularisation methods have employed the use of transmural flow or 
convective flow as it has also been termed. In one example, bladder decellularisation 
using  distension  is  described  ((Bolland,  Korossis  et  al.  2007))  with  the  use  of 
detergent  and  nuclease  enzymatic  steps,  in  a  similar  manner  as  the  DEM.  A 
difference between the solutions used in the two methods is in the base buffer used 
in decellularisations. For the bladder decellularisation, a Tris buffer was used as the 
base and wash buffer instead of the water or sodium chloride based buffers that were 
used in the DEM. Another difference in the bladder decellularisation method was 
that the detergent used was sodium dodecyl sulphate (SDS) in a Tris buffer. The 
nuclease step also utilised ribonuclease A as well as deoxyribonuclease I in a Tris 
buffer (Bolland, Korossis et al. 2007).  
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In  another  example,  transmural  decellularisation  of  blood  vessels,  or  more 
specifically human umbilical vein (HUV), was achieved by generating a positive 
internal  pressure  gradient  using  a  peristaltic  pump  upstream  of  a  dual  chamber 
bioreactor  and  a  single  one-way  check  valve  downstream  of  the  bioreactor.  The 
decellularisation  involved  a  single  solvent-alcohol  based  solution  (acetone  and 
ethanol in water) to lyse the cells through dehydration and as well as solubilisation 
and  removal  of  the  lipids  (Montoya  and  McFetridge  2009,  Crapo,  Gilbert  et  al. 
2011). This  method of  solution  application demonstrated that internal  transmural 
pressure was able to decellularise these hollow organs more efficiently than simply 
immersing  the  organs  into  a  decellularisation  solution  (Montoya  and  McFetridge 
2009)  This  method  was  also  submitted  and  described  in  the  Patent  Grant  US 
7775965 B2 (McFetridge 2010). 
Examples detailing the application of transmural flow decellularisation to tracheal 
decellularisation were not found in the literature indicating that this could be the first 
example of transmural flow decellularisation in a tracheal model.  
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5.2  Aims and hypotheses 
Aims: 
  To develop  and optimise a pressurised transmural  decellularisation  (PTD) 
protocol that fully decellularises porcine trachea to produce a scaffold that 
retains important biochemical and biomechanical properties to a comparative 
level as native trachea. 
Hypotheses:  
  The  dual  chamber  transmural  flow  bioreactor  will  significantly  reduce 
processing time and make the decellularisation  process more amenable to 
scale-out/scale-up and automation. 
  Transmural  flow  produces  an  active  flow  of  decellularisation  solutions 
through the wall of the trachea which will breakdown and remove cell and 
cell  debris  in  a  continuous  flow.  Therefore  it  will  achieve  full 
decellularisation of porcine trachea more rapidly than methods such as DEM 
that rely solely on immersion in and passive diffusion of decellularisation 
solutions. 
  Decreasing the time taken to fully decellularise the trachea and therefore the 
scaffold exposure to decellularisation solutions will result in better retention 
of GAG, collagen and biomechanical strength. 
  Optimisation  of  nuclease  buffer  and  the  temperature  of  the  nuclease 
incubation steps will increased the removal and degradation of observable 
and detectable DNA and nucleic acids. 
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5.3  Materials and methods 
5.3.1  Preparation  of  the  pressurised  transmural  decellularisation  (PTD) 
decellularisation solution and waste reservoirs 
The decellularisation solution reservoirs were prepared as described below for the 
specific bioreactor versions. For bioreactor version 2.0 there were separate solution 
and waste reservoirs. The solution reservoir set-up was prepared (Figure 5.1) by 
inserting two spike to male luer connectors with a 10 cm length of tubing and a 
pinch clamp (S-M10, Origen Biomedical, Austin, USA) into the two ports on a 600 
mL transfer bag.  
 
Figure 5.1: Solution reservoir set-up for bioreactor version 2.0 which compromised a 
600 mL transfer bag with two male luer lock (MLL) port to spike lines. 
The waste reservoir set-up was prepared (Figure 5.2) by inserting 6.4 mm hose barb 
to female luer lock (FLL) connector into 6.4 mm ID silicone tubing and attaching 
this to the bottom port of a modified 500 mL Duran that had two 6.4 mm hose barbs 
added by a UCL glassmaker.   
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Figure 5.2: Waste reservoir set-up for bioreactor version 2.0 which compromised an 
adapted  500  mL  Duran  bottle  with  two  added  glass  6.4  mm  hose  barbs  ports. 
Silicone tubing with the other end connected to a hose barb to female luer lock 
(FLL) were added to the bottom served as the waste line. 
For  the  bioreactor  versions  2.1,  2.2  and  2.3  the  solution  reservoir  set-up  was 
amended  and  therefore  prepared  (Figure  5.3)  by  inserting  a  spike  to  two  port 
connector  (2P-S16,  Origen  Biomedical,  Austin,  USA)  into  a  port  of  a  600  mL 
transfer bag (Fenwal, Basingstoke, UK).  Into  the remaining port on the 600 mL 
transfer bag and the two ports of the 2 port to one spike, three spike to male luer lock 
(MLL) connectors with a 10 cm length of tubing and a pinch clamp (S-M10, Origen 
Biomedical, Austin, USA) were attached.   
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Figure  5.3:  Solution  reservoir set-up  for the bioreactor versions  2.1, 2.2 and 2.3 
which compromised a 600 mL transfer bag with a spike to two spike ports adapter 
and three MLL port to spike lines. 
To transfer the media into the solution reservoir, a spike to needle injection site was 
spiked into a haematology pump segment set at one end. At the other end, the spike 
of  the  haematology  pump  segment  was  sterilely  placed  into  a  500  mL  Duran 
containing the appropriately prepared and sterilised decellularisation solution. The 
needle injection site was then removed to reveal a FLL. This was connected to the 
MLL  connector  of  the  inlet  spike  to  solution  reservoir  and  the  decellularisation 
solution pumped (Watson-Marlow, Falmouth, UK) into the transfer bag making sure 
the appropriate pinch clamps were either open or shut. Once filled, any excess air in 
the bag was released and the pinch clamps closed.  
To drain the decellularisation/waste solution from the transfer bags, all of the ports 
were opened and the waste drained into a collection vessel where it was then treated 
with Virkon (VWR, Lutterworth, UK). 
5.3.2  Preparation  of  the  pressurised  transmural  decellularisation  (PTD) 
decellularisation solutions 
The  decellularisation  solutions  were  investigated  to  optimise:  the  type  of  the 
solutions used (primarily the buffer/wash used); the concentration of the detergent  
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solution; the order of application of the decellularisation solutions and the frequency 
and length of the application. 
The decellularisation solutions used are listed below. With regard to the preparation 
and for the application of the solutions in the PTD experiments refer to Table 5.1. 
  The detergent solution (I) consisted of either: a buffer of 1 x HBSS with 2% 
sodium  deoxycholate  and  0.3%  Triton  X-100  mixed  until  fully  dissolved 
containing 100 units/mL of penicillin, 100 µg/mL of streptomycin, and 250 
ng/mL of amphotericin B solution added immediately before use; or a buffer 
of 50 mM Trizma - HCl (pH 7.2 buffered with Trizma - base) into which 
between 0.3% to 2.25% sodium deoxycholate and between 0.125% to 0.3% 
Triton  X-100  were  mixed  until  fully  dissolved.  Details  for  the  exact 
concentration  used  are  listed  in  Table  5.1.  The  detergent  solutions  were 
autoclaved and 100 units/mL of penicillin, 100 µg/mL of streptomycin, and 
250 ng/mL of amphotericin B solution was added immediately before use. 
  The nuclease solutions (I/II) consisted of a buffer of 50 mM Trizma - HCl 
(pH  7.2  buffered  with  Trizma  -  base)  with  5.2  mM  MgCl2  and  130  µM 
CaCl2. The buffer was autoclaved and to this buffer 2 Kunitz units/mL of 
DNase (D4263, Sigma Aldrich, Poole, UK), 4U/mL RNase (AM2295, Life 
Technologies, Paisley, UK) and 100 units/mL of penicillin, 100 µg/mL of 
streptomycin,  and  250  ng/mL  of  amphotericin  B  solution  were  added 
immediately before use. 
  The wash buffers (I/II) consisted of either: a buffer of de-ionised water with 
100 units/mL of penicillin, 100 µg/mL of streptomycin, and 250 ng/mL of 
amphotericin B solution added immediately before use; or a buffer of 50 mM 
Trizma  -  HCl  (pH  7.2 buffered  with  Trizma  -  base),  details  of  the  exact 
buffers used are listed in Table 5.1. The wash buffers were autoclaved and 
100 units/mL of penicillin, 100 µg/mL of streptomycin, and 250 ng/mL of 
amphotericin B solution was added immediately before use.  
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5.3.3  Bioreactor versions for pressurised transmural decellularisation  
5.3.3.1  Bioreactor version 2.0 
The bioreactor system  was  set  up as detailed in  Figure  5.4  and  Figure  5.5. The 
predominant feature of this version being that the transmural flow was sent to waste 
and  not  re-circulated  through  the  system.  Briefly,  the  solution  reservoir  was 
positioned into the water bath. Connected to the solution reservoir was the spike to 
MLL line which connected to a three way stopcock. The stopcock was positioned to 
allow the inlet to change and air to be pumped through the bioreactor system to clear 
the lines of decellularisation solution. An optional connection of a 0.22 µm filter 
would allow the air to be filtered and sterile upon entry. The stopcock connected to a 
30 cm section of Bioprene tubing, with MLL to hose barb connectors at each end, 
with the pump positioned approximately 5 - 10 cm down the pump tubing line to 
pump  the  decellularisation  solutions  through  the  bioreactor  system  and  internal 
chamber of the bioreactor. Downstream of the pump tubing was the first FLL to FLL 
one-way check valve, set at 7.5 psi, to contain the pressurisation to within the next 
section of the bioreactor system by being capable of holding a back pressure of up to 
60 psi. Pressure gauges capable of measuring 0 - 25 psi (1.6 bar) were placed either 
side of the check valve using luer tee connectors, rotating MLL to FLL and MLL to 
G1/8 female connectors with a 0.22 µm filter between the pressure gauge and the 
bioreactor  system  as  the  pressure  gauges  were  not  sterile.  A  luer  tee  connector 
followed to allow the attachment of the first temperature probe via a MLL to tuohy 
borst adapter. Between the t-connectors and the bioreactor itself, rotating MLL to 
FLL connector attached to the lower FLL to male G1/8 port of the bioreactor to 
allow  easy  assembly  of  the  periphery  lines.  The  decellularisation  solution  then 
passed through the lumen of the trachea which was also described as the internal 
chamber of the bioreactor. Downstream of the upper FLL to male G1/8 port of the 
internal chamber another rotating MLL to FLL and a luer tee connector allowed for 
the attachment of the second temperature probe via a MLL to tuohy borst connector. 
A third pressure gauge attached via a tee connector, a rotating MLL to FLL, a 0.22 
µm filter and a MLL to G1/8 adaptor was positioned just upstream of the second 
FLL to FLL one-way check valve, set at 4.82 psi, which along with the first one-way 
check valve created the pressurisation of ~ 4.82 psi within the internal chamber of 
the bioreactor. After a 3-way stopcock, the solution then returned to the solution  
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reservoir via the MLL to spike line to allow continuous flow of decellularisation 
solution within the internal chamber of the bioreactor. Additionally to this, at the 
start  of  each  decellularisation  step,  after  ensuring  no  leakage  from  the  internal 
chamber when the trachea is under pressure, the lower male G1/8  to FLL port of the 
external chamber was connected to a rotating MLL to FLL, a 3-way stopcock and a 
MLL to hose barb, to connect to a section of sterile silicone tubing to a MLL to hose 
barb, a rotating MLL to FLL and a FLL to hose barb and finally a short section of 
sterile silicone tubing to attach the external chamber to the waste reservoir. The line 
on the 3-way stopcock was opened to allow drainage of the transmural waste. To the 
upper male G1/8 to FLL port of the external chamber a sterile silicone tubing line 
with MLL to hose barb connectors at each end was connected, and a sterile 0.22 µm 
filter  attached,  to  allow  sterile  venting  of  the  external  chamber  and  allow  the 
transmural waste to drain to the waste reservoir. 
 
Figure 5.4: Bioreactor system assembly components for bioreactor version 2.0 to 2.3.  
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Figure 5.5: Bioreactor version 2.0. With this version the decellularisation solution 
was  recirculated  through  the  internal  chamber/lumen  of  the  trachea  and  the 
transmural flow was collected in the waste reservoir.  
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5.3.3.2  Bioreactor version 2.1 
The bioreactor system was set up as detailed in Figure 5.4 and Figure 5.6. The main 
changes from the PTD version 2.0 bioreactor were:  
  The pressure gauges were removed from bioreactor v2.1 as evaluation of the 
pressures from PTD 1-3 experiments in bioreactor v2.0 had demonstrated the 
check valves reliably produced a pressure in the internal chamber of 4 - 5.5 
psi. 
  The transmural “waste” line from the outer chamber of the bioreactor was re-
positioned  so  the  decellularisation  solution  was  re-circulated  back  to  the 
solution reservoir as a return line. Therefore there was no transmural waste 
line. 
  The  transmural  return  line  from  the  outer  chamber  of  the  bioreactor  was 
relocated to the top port of the bioreactor so the outer chamber would be 
filled before the solution returned to the solution reservoir to allow the outer 
surface of the trachea to be immersed in the decellularisation solution. 
  For PTD 5 the bioreactor set-up was as described below and for PTD 6 and 7 
the bioreactor set-up had the below set-up with the following amendment; the 
external ports for the internal chamber were changed from a G⅛ -female luer 
to a G⅛ -male luer which omitted the need to have male to male adapters 
before and after the internal chamber.  
Briefly, the solution reservoir was positioned into the water bath. Connected to the 
solution reservoir was the inlet spike to MLL line which was connected to a three 
way  stopcock  sandwiched  between  two  rotating  MLL  to  FLL  connectors.  The 
stopcock was positioned to allow air to be pumped through the bioreactor system to 
clear the lines of decellularisation solution. An optional connection of a 0.22 µm 
filter  would  allow  the  air  to  be  filtered  and  sterile  upon  entry.  The  stopcock 
connected to a 30 cm section of Bioprene tubing, with MLL to hose barb connectors 
at each end, with the pump positioned approximately 5 - 10 cm down the pump 
tubing line to pump the decellularisation solutions through the bioreactor system and 
internal chamber of the bioreactor. Downstream of the pump tubing was a rotating 
MLL to FLL to aid connection, the first FLL to FLL one-way check valve, set at  
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4.82 psi, to contain the pressurisation to within the next section of the bioreactor 
system by being capable of holding a back pressure of up to 60 psi. Next, another 
rotating  MLL  to  FLL  connector  connected  to  a  luer  tee  connector  to  allow  the 
attachment of the first temperature probe, connected using a MLL to tuohy borst 
adapter, and a MLL to MLL adapter*. Downstream of the MLL to MLL adapter* 
there was another rotating MLL to FLL connector which attached to the lower male 
G1/8 to FLL or a male G1/8 to MLL port of the internal chamber of the bioreactor to 
allow  easy  assembly  of  the  periphery  lines.  The  decellularisation  solution  then 
passed through the lumen of the trachea which served as the internal chamber of the 
bioreactor. Downstream of the internal chamber from the upper male G1/8 to FLL 
port or a male G1/8 to MLL there was a rotating MLL to FLL, connected to MLL to 
MLL adapter*, another rotating FLL to MLL adapter*, then a luer tee connector 
which allowed attachment of the second temperature probe via a MLL to tuohy borst 
adapter. Downstream there was another rotating FLL to MLL connecter, the second 
one-way FLL to FLL check valve, set at 4.82 psi, which along with the first one-way 
check valve created the pressurisation within the internal chamber of the bioreactor, 
and  finally  a  3-way  stopcock.  The  solution  was  then  returned  to  the  solution 
reservoir via a MLL to spike return line to allow continuous flow of decellularisation 
solution within the internal chamber of the bioreactor. Connections on the external 
chamber ports were as follows: the lower male G1/8 to FLL port was closed using a 
MLL cap; downstream of the upper male G1/8 to FLL port was a rotating MLL to 
FLL then a 3-way stopcock before connecting to the MLL to spike return line to the 
decellularisation solution reservoir.  
*Due to the change of the internal chamber ports from G1/8 to FLL port to a male 
G1/8 to MLL, these connectors were not required for PTD 6 and 7.  
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Figure  5.6:  Bioreactor  version  2.1  with  the  two  differing  set-ups  from  the  size 
adjustable connectors (SACs) for PTD 5 or PTD 6 and 7. With these set-ups the 
decellularisation solution was recirculated through the internal chamber/lumen of the 
trachea and the transmural flow was collected in the same reservoir and recirculated.  
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5.3.3.3  Preparation  of  porcine  tracheal  scaffolds  by  transmural  decellularisation 
version 2.2 
The bioreactor system was set up as detailed in Figure 5.4 and Figure 5.7. The main 
changes from the PTD version 2.1 bioreactor were:  
  Three  pressure  transducers  were  incorporated  to  measure  digitally  the 
pressure before and after the internal chamber and outside of the external 
chamber by the upper port. 
  The temperature probes were changed from the flexible Biorep temperature 
probes  to  Physitemp  stainless  steel  shaft  probes  (Physitemp,  Clifton,  NJ, 
USA) which allowed for an improved seal to be created by the tuohy borst 
adapter.  
  The set-up incorporated the ORCA Controller with the Bio_1 software from 
Harvard Apparatus Regenerative Technology (Harvard Apparatus, Holliston, 
USA)  to  digitally  record  online  the  temperature  output  from  the  two 
temperature probes and the pressure output from the three pressure probes. In 
the  previous  bioreactor  systems  this  information  had  been  measured  via 
analogue systems and recorded manually.  
  Incorporation of a Dino-lite white light digital microscope (IDCP, Naarden, 
Netherlands)  to  automate  imaging  the  trachea  as  it  underwent 
decellularisation and enable remote viewing through live video capture. 
  Use  of  Harvard  Apparatus  pumps  for  some  of  the  PTD  experiments  was 
incorporated, however after use in a couple of PTD experiments they emitted 
a strange sound, as if they were on the verge of breaking, and therefore the 
Watson-Marlow pump was reinstalled. 
The bioreactor was as follows. Briefly, the solution reservoir was positioned into the 
water bath. Connected to the solution reservoir spike port was a spike to MLL line 
which was connected to a three way stopcock. The stopcock was positioned to allow 
air to be pumped through the bioreactor system to clear the lines of decellularisation 
solution. An optional connection of a 0.22 µm filter would allow the air to be filtered 
and  sterile  upon  entry.  The  stopcock  connected  to  a  30  cm  section  of  Bioprene  
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tubing, with MLL to hose barb connectors at each end, with the pump positioned 
approximately 5 - 10 cm down the pump tubing line to pump the decellularisation 
solutions  through  the  bioreactor  system  and  internal  chamber  of  the  bioreactor. 
Downstream of the pump tubing was a rotating FLL to MLL to aid connection, the 
first one-way FLL to FLL check valve, set at 4.82 psi, to contain the pressurisation 
to within the next section of the bioreactor system by being capable of holding a 
back pressure of up to 60 psi, a luer tee connector to allow the attachment of the first 
pressure transducer with a 3-way stopcock and 10 mL syringe and then a second luer 
tee connector to allow attachment of the first temperature probe, connected using a 
MLL  to  tuohy  borst  adapter.  Downstream  there  was  a  rotating  MLL  to  FLL 
connector  which  attached  to  the  lower  male  G1/8  to  MLL  port  of  the  internal 
chamber  of  the  bioreactor  to  allow  easy  assembly  of  the  periphery  lines.  The 
decellularisation solution then passed through the lumen of the trachea which served 
as the internal chamber of the bioreactor. Downstream of the upper male G1/8 to 
MLL port of the internal chamber, there was a rotating FLL to MLL then a tee 
connector which allowed attachment of the second temperature probe via a MLL to 
tuohy borst adapter. Downstream there was another luer tee connector to allow for 
attachment of the second pressure transducer with a 3-way stopcock and 10 mL 
syringe. Downstream of the tee connector there was the second FLL to FLL check 
valve, set at 4.82 psi, which along with the first one-way check valve created the 
pressurisation within the internal chamber of the bioreactor, a 3-way stopcock and 
finally a rotating MLL to FLL connector to allow easy connection of the periphery 
line. The solution was then returned to the solution reservoir via a MLL to spike 
return line to allow continuous flow of decellularisation solution within the internal 
chamber  of  the  bioreactor.  Connections  on  the  external  chamber  ports  were  as 
follows: downstream of the lower male G1/8 BSPP to FLL port was closed using a 
MLL cap or a 3-way stopcock; downstream of the upper male G1/8 BSPP to FLL 
port was a rotating MLL to FLL, then a luer t-connector connector to allow for 
attachment of the third pressure transducer with a 3-way stopcock and 10 mL syringe 
then a 3-way stopcock before connecting to the MLL to  spike return line to the 
decellularisation  solution  reservoir.  The  3-way  stopcocks  and  10  mL  syringes 
downstream  of  each  of  the  pressure  transducers  were  required  to  allow  the 
decellularisation solution to be drawn over the pressure transducers to enable the 
pressure to be accurately measured.  
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Figure 5.7: Bioreactor version 2.2. With this set-up the decellularisation solution was 
recirculated through the internal chamber/lumen of the trachea and the transmural 
flow  was  collected  in  the  same  reservoir  and  recirculated.  The  pressure  and 
temperature was measured and recorded online. 
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5.3.3.4  Preparation  of  porcine  tracheal  scaffolds  by  pressurised  transmural 
decellularisation version 2.3 
The bioreactor system  was  set  up as detailed in  Figure  5.4  and  Figure  5.8. The 
changes from the PTD version 2.2 bioreactor were:  
  Three additional 3-way stopcocks were added. The first was between the luer 
tee connector and the first pressure transducer, the second was between the 
luer tee connector and the second pressure transducer and the third was on 
the lower port of the external chamber after the rotating MLL to FLL. The 
addition of these three 3-way stopcocks allowed the inner and outer chambers 
to be emptied of the decellularisation solutions with minimal manipulation of 
the bioreactor chamber. Prior to the addition of these three stopcocks it was 
necessary to invert the bioreactor chamber to drain the solution from both 
chambers. Optional sterile 0.22 µm filters could be added to the upper 3-way 
stopcocks to ensure the air entering the internal and external chamber of the 
bioreactor was sterile when draining the internal and external chambers of the 
bioreactor. 
  The  removal  of  the  third  pressure  transducer  from  the  upper  port  of  the 
external chamber as it was deemed unnecessary.  
The bioreactor was as follows. Briefly, the solution reservoir was positioned into the 
water bath. Connected to the solution reservoir spike port was a spike to MLL line 
which was connected to a three way stopcock. The stopcock was positioned to allow 
air to be pumped through the bioreactor system to clear the lines of decellularisation 
solution. An optional connection of a 0.22 µm filter would allow the air to be filtered 
and  sterile  upon  entry.  The  stopcock  connected  to  a  30  cm  section  of  Bioprene 
tubing, with MLL to hose barb connectors at each end, with the pump positioned 
approximately 5 - 10 cm down the pump tubing line to pump the decellularisation 
solutions  through  the  bioreactor  system  and  internal  chamber  of  the  bioreactor. 
Downstream of the pump tubing was the first one-way FLL to FLL check valve, set 
at 4.82 psi, to contain the pressurisation to within the next section of the bioreactor 
system  by  being  capable  of  holding  a  back  pressure  of  up  to  60  psi,  a  luer  tee 
connector to allow the attachment of the first pressure transducer with an preceding 
3-way stopcock to  allow easy drainage of the internal  bioreactor chamber and  a  
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succeeding 3 way stopcock and a 10 mL syringe. Downstream there was a second 
luer  tee  connector  to  allow  attachment  of  the  first  temperature  probe,  connected 
using a MLL to tuohy borst adapter. Downstream there was a rotating MLL to FLL 
connector  which  attached  to  the  lower  male  G1/8  to  MLL  port  of  the  internal 
chamber  of  the  bioreactor  to  allow  easy  assembly  of  the  periphery  lines.  The 
decellularisation solution then passed through the lumen of the trachea which served 
as the internal chamber of the bioreactor. Downstream of the upper male G1/8 to 
MLL port of the internal chamber, there was a rotating FLL to MLL then a tee 
connector which allowed attachment of the second temperature probe via a MLL to 
tuohy borst adapter. Downstream there was another luer tee connector to allow for 
attachment of the second pressure transducer with a preceding 3-way stopcock to aid 
drainage  of  the  internal  chamber  and  a  succeeding  3-way  stopcock  and  10  mL 
syringe. Downstream of the tee connector there was the second FLL to FLL check 
valve, set at 4.82 psi, which along with the first one-way check valve created the 
pressurisation within the internal chamber of the bioreactor. The solution was then 
returned to the solution reservoir via a MLL to spike return line to allow continuous 
flow  of  decellularisation  solution  within  the  internal  chamber  of  the  bioreactor. 
Connections on the external chamber ports were as follows: downstream of the lower 
male G1/8 BSPP to FLL port was a rotating FLL to MLL and a 3-way stopcock to 
allow for easy drainage of the external bioreactor chamber; downstream of the upper 
male G1/8 BSPP to FLL port was a rotating MLL to FLL, then a 3-way stopcock, to 
allow for easy drainage of the external bioreactor chamber, before connecting to the 
MLL  to  spike  return  line  to  the  decellularisation  solution  reservoir.  The  3-way 
stopcocks and 10 mL syringes downstream of each of the pressure transducers were 
required  to  allow  the  decellularisation  solution  to  be  drawn  over  the  pressure 
transducers to enable the pressure to be accurately measured. 
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Figure 5.8: Bioreactor version 2.3. With this set-up the decellularisation solution was 
recirculated through the internal chamber/lumen of the trachea and the transmural 
flow was collected in the same reservoir and recirculated. The external chamber was 
pre-filled and minimal manipulation was required to drain the internal and external 
chambers. The pressure and temperature was measured and recorded online. 
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5.3.4  Preparation  of  porcine  tracheal  scaffolds  by  pressurised  transmural 
decellularisation  
5.3.4.1  Pressurised transmural decellularisation experiments 1, 2 and 3  
After  the  tracheae  had  been  prepared  following  procurement  from  Cheale  Meats 
(refer to section 2.1), they were stored frozen, to incorporate a freeze-thaw step, in 
Viaspan (Bristol-Myers Squibb, Uxbridge, UK) in a falcon tube at -80oC (PTD 1 and 
PTD 2) and dry at -20oC (PTD 3). The tracheae were used in the decellularisation 
process  within  1  month  of  freezing  or  discarded.  A  frozen  trachea  was  thawed 
overnight at 4oC. When defrosted the trachea was attached to the bioreactor using a 1 
PDS  (polydioxanone)  absorbable  suture  (Ethicon,  Livingston,  UK)  and  the 
bioreactor  assembled  according  to  bioreactor  version  2.0  (see  section  4.3  and 
5.3.3.1).  The  decellularisation  protocol  involved  the  application  of  the  following 
decellularisation solutions, 500 mL of each, for up to 24 hours each at 37oC in the 
following order; detergent I, wash I, nuclease I and wash II for PTD 1 and nuclease 
I, detergent  I, nuclease II and wash  I for PTD 2 and 3. For exact details of the 
solutions used refer to Table 5.1.  
At the start of each decellularisation step the internal chamber was checked to ensure 
no leakage from the trachea when pressurised. The decellularisation solution was 
pumped through the bioreactor system and the internal chamber at 20 rpm which 
equated to 60 mL/min. Decellularisation solution exchange was performed between 
the decellularisation solutions by clamping the solution reservoir and switching the 
3-way stopcock to pump air to clear the tubing of solution. The bioreactor chamber 
was inverted to ensure all the solution was removed from the internal chamber and 
the tubing. The spent solution reservoir was removed and the fresh solution reservoir 
was attached. The transmural decellularisation solution was pumped to waste from 
the lower port of the external chamber, therefore following brief manipulation of the 
bioreactor to ensure the external chamber and the waste tubing was clear. The spent 
waste bottle was exchanged for a fresh waste bottle. The spent solution and waste 
were treated with Virkon (VWR, Lutterworth, UK) prior to disposal. 
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Table 5.1: Summary of the experiments for the pressurised transmural decellularisation.    
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5.3.4.2  Pressurised transmural decellularisation experiments 5, 6, 7 and 8 
After the tracheae had been prepared following procurement from Cheale Meats (see 
section 2.1), the tracheae were frozen to -80°C in Viaspan. The tracheae were used in 
the decellularisation process within 1 month of freezing or discarded. For use in the 
decellularisation process a frozen trachea was defrosted overnight at 4oC before use. 
When  defrosted  the  trachea  was  attached  to  the  bioreactor  using  a  1  PDS 
(polydioxanone)  absorbable  suture  and  the  bioreactor  assembled  according  to 
bioreactor v2.1 (see section 4.3 and 5.3.3.2) for PTD 5, 6, and 7 and according to 
bioreactor version 2.2 (see section 4.3 and 5.3.3.3) for PTD 8. The decellularisation 
protocol involved the application of the following decellularisation solutions, 500 
mL of each, for 24 hours at 37oC in the following order; nuclease I, detergent I, 
nuclease II and wash II. For exact details of the solutions used refer to Table 5.1. At 
the start of each decellularisation step the internal chamber was checked to ensure no 
leakage  from  the  trachea  when  pressurised.  The  decellularisation  solution  was 
pumped through the bioreactor system and the internal chamber at 20 rpm which 
equated to 60 mL/min. Decellularisation solution exchange was performed between 
the decellularisation solutions by clamping the solution reservoir and switching the 
3-way stopcock to pump air to clear the tubing of solution. The bioreactor chamber 
was inverted to ensure all the solution was removed from the internal and external 
chambers and the internal and external chamber tubing. The spent solution reservoir 
was removed and the fresh solution reservoir was attached. The spent solution was 
treated with Virkon prior to disposal. 
5.3.4.3  Pressurised transmural decellularisation experiments 9 and 10  
After the tracheae had been prepared following procurement from Cheale Meats (see 
section 2.1), the tracheae were frozen to -80°C in Viaspan. The tracheae were used in 
the decellularisation process within 1 month of freezing or discarded. For use in the 
decellularisation process a frozen trachea was defrosted overnight at 4oC before use. 
When  defrosted  the  trachea  was  attached  to  the  bioreactor  using  a  1  PDS 
(polydioxanone)  absorbable  suture  and  the  bioreactor  assembled  according  to 
bioreactor version 2.2 (see section 4.3 and 5.3.3.3). The decellularisation protocol 
involved the application of the following decellularisation solutions, 500 mL of each, 
for 24 hours at 37oC in the following order; nuclease I, detergent I, wash I, nuclease  
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II and wash II. For exact details of the solutions used refer to Table 5.1. At the start 
of each decellularisation step the internal chamber was checked to ensure no leakage 
from  the  trachea  when  pressurised.  The  decellularisation  solution  was  pumped 
through the bioreactor system and the internal chamber at 20 rpm which equated to 
60  mL/min.  Decellularisation  solution  exchange  was  performed  between  the 
decellularisation solutions by clamping the solution reservoir and switching the 3-
way stopcock to pump air to clear the tubing of solution. The bioreactor chamber 
was inverted to ensure all the solution was removed from the internal and external 
chambers and the internal and external chamber tubing. The spent solution reservoir 
was removed and the fresh solution reservoir was attached. The waste was treated 
with Virkon prior to disposal. 
5.3.4.4  Pressurised transmural decellularisation experiments 13, 14 and 15 
After the tracheae had been prepared following procurement from Cheale Meats (see 
section 2.1), the tracheae were frozen to -80°C in Viaspan for PTD 13 and 15 and to  
-80°C in HBSS for PTD 14. The tracheae were used in the decellularisation process 
within 1 month of freezing or discarded. For use in the decellularisation process a 
frozen trachea was defrosted overnight at 4oC before use. When defrosted the trachea 
was attached to the bioreactor using a 1 PDS (polydioxanone) absorbable suture and 
the bioreactor assembled according to bioreactor version 2.2 (see section 4.3 and 
5.3.3.3)  for  PTD  13  or  according  to  bioreactor  version  2.3  (see  section  4.3  and 
5.3.3.4) for PTD 14 and 15. The decellularisation protocol involved the application 
of the following decellularisation solutions, 500 mL of each, for either 3, 21 or 24 
hours at 4°C, 37°C or room temperature in the following order; nuclease I, detergent 
I, wash I, nuclease II and wash II. For exact details of the solutions, timings and 
temperatures used refer to Table 5.1. At the start of each decellularisation step the 
internal  chamber  was  checked  to  ensure  no  leakage  from  the  trachea  when 
pressurised. Additionally for PTD 14 and 15, at the start of each decellularisation 
step,  after  ensuring  no  leakage  from  the  internal  chamber  when  the  trachea  was 
under pressure, the external chamber was filled with decellularisation solution by 
attaching  the  MLL  line  from  the  reservoir  to  the  3-way  stopcock  on  the  lower 
external port, opening the upper external port to air (an optional 0.22 µm filter can be 
attached) and filling the external chamber by gently applying pressure to the solution 
reservoir until the chamber was filled. The lower port was closed using the 3-way  
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stopcock and the MLL line from the reservoir was attached to the upper port and the 
line  opened.  The  decellularisation  solution  was  pumped  through  the  bioreactor 
system  and  the  internal  chamber  at  20  rpm  which  equated  to  60  mL/min. 
Decellularisation solution exchange for the bioreactor version 2.2 was  performed 
between  the  decellularisation  solutions  by  clamping  the  solution  reservoir  and 
switching  the  3-way  stopcock  to  pump  air  to  clear  the  tubing  of  solution.  The 
bioreactor chamber was inverted to ensure all the solution was removed from the 
internal and external chambers and the internal and external chamber tubing. The 
spent solution reservoir was removed and the fresh solution reservoir was attached. 
The  waste  was  treated  with  Virkon  prior  to  disposal.  Decellularisation  solution 
exchange for the bioreactor version 2.3 was performed between the decellularisation 
solutions by clamping the solution reservoir and switching the 3-way stopcock to 
pump  air to  clear the tubing of solution.  The  solution  reservoir tubing was  then 
attached to the lower drainage 3-way stopcock and the lines opened to allow the 
solution in the internal chamber to drain into the reservoir. The top 3-way drainage 
stopcock was opened after the lower stopcock was opened to allow the solution to 
fully drain. When the internal chamber was fully drained these lines were then closed 
and the reservoir attached to the 3-way stopcock on the lower port of the external 
chamber and the lines opened to allow the external chamber to drain. The 3-way 
stopcock on the upper port of the external chamber was opened and the bioreactor 
manipulated slightly to allow the solution to fully drain. The lines were then closed 
and the spent solution reservoir was removed and the fresh solution reservoir was 
attached. The waste was treated with Virkon prior to disposal. 
5.3.4.5  Pressurised transmural decellularisation experiments 11, 18 and 20 
After the tracheae had been prepared following procurement from Cheale Meats (see 
section  2.1),  the  tracheae  were  used  fresh  (no  freezing)  in  the  decellularisation 
process. The trachea was attached to the bioreactor using a 1 PDS (polydioxanone) 
absorbable suture and the bioreactor assembled according to bioreactor v2.2 (see 
section 4.3 and 5.3.3.3) for PTD 11 or according to bioreactor v2.3 (see section 4.3 
and 5.3.3.4) for PTD 18 and 20.  
The  decellularisation  protocol  involved  the  application  of  the  following 
decellularisation solutions, 500 mL of each, for 24 hours at 37oC in the following  
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order; nuclease I, detergent I, wash I, nuclease II and wash II. For exact details of the 
solutions,  timings  and temperatures  used refer to  Table 5.1. At  the start  of each 
decellularisation step the internal chamber was checked to ensure no leakage from 
the trachea when was pressurised. Additionally for PTD 18 and 20, at the start of 
each  decellularisation  step,  after  ensuring  no  leakage  from  the  internal  chamber 
when  the  trachea  was  under  pressure,  the  external  chamber  was  filled  with 
decellularisation solution by attaching the MLL line from the reservoir to the 3-way 
stopcock  on  the  lower  external  port,  opening  the  upper  external  port  to  air  (an 
optional 0.22 µm filter can be attached) and filling the external chamber by gently 
applying pressure to the solution reservoir until the chamber was filled. The lower 
port was closed using the 3-way stopcock and the MLL line from the reservoir was 
attached to the upper port and the line opened.  
The decellularisation solution was pumped through the bioreactor system and the 
internal chamber at 20 rpm which equated to 60 mL/min. Decellularisation solution 
exchange for the bioreactor version 2.2 was performed between the decellularisation 
solutions by clamping the solution reservoir and switching the 3-way stopcock to 
pump air to clear the tubing of solution. The bioreactor chamber was inverted to 
ensure all the solution was removed from the internal and external chambers and the 
internal and external chamber tubing. The spent solution reservoir was removed and 
the fresh solution reservoir was attached. The waste was treated with Virkon prior to 
disposal.  Decellularisation  solution  exchange  for  the  bioreactor  version  2.3  was 
performed between the decellularisation solutions by clamping the solution reservoir 
and switching the 3-way stopcock to pump air to clear the tubing of solution. The 
solution reservoir tubing was then attached to the lower drainage 3-way stopcock and 
the  lines  opened  to  allow  the  solution  in  the  internal  chamber  to  drain  into  the 
reservoir. The top 3-way drainage stopcock was opened after the lower stopcock was 
opened to allow the solution to fully drain. When the internal chamber was fully 
drained these lines were then closed and the reservoir attached to the 3-way stopcock 
on the lower port of the external chamber and the lines opened to allow the external 
chamber to drain. The 3-way stopcock on the upper port of the external chamber was 
opened and the bioreactor manipulated slightly to allow the solution to fully drain. 
The lines were then closed and the spent solution reservoir was removed and the  
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fresh solution reservoir was attached. The waste was treated with Virkon prior to 
disposal. 
5.3.5  Pressurised transmural decellularisation experiment failures   
5.3.5.1  Pressurised transmural decellularisation 4: 
This PTD was set up using a trachea that had been frozen for 32 days at -80oC in 
Viaspan. The experiment would have been performed as described for PTD 3 except 
the pressure gauge between the pump and the first check valve was omitted as it was 
deemed unnecessary and both pre and post IC check valves had a cracking pressure 
of 4.82 psi. A day after starting the experiment a leak was detected due to a small 
perforation in the trachealis muscle. This leak meant transmural flow would not be 
achieved and the experiment was abandoned and the tissue discarded. 
5.3.5.2  Pressurised transmural decellularisation 12: 
This PTD was set up using a trachea that had been frozen for 6 days at -80°C in 
Viaspan. The trachea was defrosted overnight at 4°C. The experiment would have 
been performed as described for PTD 9 with the same detergent concentrations and 
incubation  times.  Four  hours  into  the  second  wash  step,  the  final  step  of  the 
decellularisation  process,  a  leak  was  detected  due  to  a  small  perforation  in  the 
trachealis muscle. This leak meant transmural flow would not be achieved for the 
final wash step and the experiment was abandoned and the tissue discarded.  
5.3.5.3  Pressurised transmural decellularisation 16: 
This PTD was set up using a fresh trachea that had been harvested that morning. The 
experiment  would have been performed  as  described  for PTD 11 with the same 
detergent concentrations and incubation times. As with PTD 15 the outer chamber 
was also pre-filled to ensure the outer surface of the trachea was submerged and 
immersed in the decellularisation solution from the start of each of the experiment 
steps. Shortly after commencing the first DNase/RNase step, the first step of  the 
decellularisation process, a leak was detected at the point where the trachea was 
attached to the upper port of the bioreactor. This leak meant transmural flow would 
not be achieved and the experiment was abandoned and the tissue discarded.  
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5.3.5.4  Pressurised transmural decellularisation 17: 
This PTD was set up using a fresh trachea that had been stored at 4°C for 2 days in 
Viaspan. The experiment would have been performed as described for PTD 11 with 
the same detergent concentrations and incubation times. As with PTD 15 the outer 
chamber was also pre-filled to ensure the outer surface of the trachea was submerged 
and  immersed  in  the  decellularisation  solution  from  the  start  of  each  of  the 
experiment steps. Shortly after commencing the first DNase/RNase step, the first 
step of the decellularisation process, a leak was detected from the bioreactor and in 
trying to fix that leak, one of the male G⅛ to MLL connectors broke and started to 
leak. This was not easily fixable so the bioreactor was disassembled, the experiment 
abandoned and the tissue discarded. 
5.3.5.5  Pressurised transmural decellularisation 19: 
This PTD was set up using a fresh trachea that had been harvested that morning. The 
experiment would have been performed as described for PTD 11 and 18 with the 
same  detergent  concentrations  and  incubation  times.  As  with  PTD  15  the  outer 
chamber was also pre-filled to ensure the outer surface of the trachea was submerged 
and  immersed  in  the  decellularisation  solution  from  the  start  of  each  of  the 
experiment steps. Whilst changing the decellularisation solution for the first wash 
step, the third step of the decellularisation process, a three way stopcock valve on the 
IC  return  line  to  the  solution  reservoir  was  accidently  not  opened  causing  the 
pressure to rise in the internal chamber of the bioreactor (the inside of the trachea). 
This caused a perforation in the trachealis muscle. This leak meant transmural flow 
would not be achieved and the experiment was abandoned and the tissue discarded. 
5.3.6  Cost comparison of the DEM and PTD methods 
The cost of the reagents only were calculated for the DEM and PTD methods to 
create a basic cost of goods (CoG) analysis by calculating the cost of each reagent 
multiplied by the percentage of reagent used per step and by the number of steps in 
which it was used in the total process. This was summed to give an overall CoG.    
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5.4  Results 
5.4.1  Pressurised transmural decellularisation 1 to 3 (PTD 1 - 3) 
Following the setting up of the bioreactor system v2.0 (Figure 5.5 and Figure 5.9), it 
was noted that the bioreactor system worked well in that: no bubbles were trapped in 
the system; the desired pressure was maintained; and transmural flow was achieved. 
The first three pressurised transmural decellularisations (PTD 1 – 3) were defined 
primarily by the transmural flow going directly to a waste reservoir from the bottom 
port  of  the  external  chamber.  There  were  however  issues  due  to  the  fact  the 
transmural waste was sent to a directly to a waste reservoir which meant the external 
chamber  never  filled  and  therefore  the  abluminal  side  of  the  trachea  was  never 
submerged in decellularisation solution. This resulted in what appeared to be patches 
of tissue which were decellularised and patches of tissue where the decellularisation 
solution had not come through transmurally and therefore not decellularised as well. 
This was more evident in the PTD 3 which had been frozen dry and therefore not 
washed or immersed in solution previously. This was confirmed when DNA analysis 
of the less or “non decellularised” (NDC) regions (334.49 ± 10.01 ng/mg) had five 
times more DNA remaining in samples than the “decellularised” (DC) regions (66.94 
± 12.77 ng/mg) (Figure 5.10). 
Another issue with the transmural solution being sent to a waste reservoir was that if 
the transmural flow was high then all of the decellularisation solution would flow 
through the trachea in less than the desired 24 h. At the highest flow rate of 156 
mL/h,  the  500  mL  of  decellularisation  solution  flowed  transmurally  through  the 
trachea  in  3  hours  10  min  (Table  5.2).  At  this  rate  a  minimum  of  3.79  L  of 
decellularisation  solution  would  be  required  to  decellularise  the  trachea  with 
transmural flow for the full 24 h which would greatly increase the cost of the process 
in terms of raw materials. It was therefore decided that it would be cost effective to 
investigate the effect of recycling the transmural solution to the solution reservoir to 
allow  a  full  24  hours  of  PTD  by  returning  the  transmural  flow  to  the  solution 
reservoir via the upper port of the external chamber to allow the abluminal side of 
the trachea to also be immersed in the decellularisation solution. 
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Figure 5.9: Bioreactor version 2.0 in use with the PTD 3.  
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Figure 5.10: Differences in remaining DNA in the “decellularised” (DC) regions of 
the trachea compared to the “non-decellularised” (NDC) regions of the trachea due 
to uneven transmural flow. 
Several  other  parameters  of  the  decellularisation  were  investigated.  The  tracheae 
were either freeze-thawed at -80°C in Viaspan (PTD 1 and 2) or at -20°C dry (PTD 3) 
to identify whether this had an effect on the decellularisation. Freezing at -20°C dry 
appeared to greatly increase the rate of transmural flow (Table 5.2) which could 
indicate  greater  ECM  disruption  during  the  freeze-thaw  process,  which  was  not 
desirable so freezing was subsequently performed in Viaspan to -80°C.  
 
Table 5.2: Transmural flow rates of the decellularisation solutions for PTD 1-3. 
Different decellularisation regimes were also tested; a detergent, wash, nuclease and 
wash regime, which is similar to the DEM regime, was initially tested for PTD 1. It 
was noted that debris and viscous material had collected in the external chamber 
during the detergent and wash steps which was removed by the nuclease step. Given 
that the freeze-thawing of the trachea would cause cell lysis and release of nuclear 
material  it  was  theorised  that  the  viscous  material  could  be  nuclear  material  
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(Meezan, Hjelle et al. 1975). Therefore it was decided to perform a nuclease step at 
the start of the process for the next PTD experiments with a nuclease, detergent, 
nuclease and wash regime. The latter regime achieved an increased transmural flow 
rate earlier in the process, but in the final wash a similar flow rate was achieved for 
both  regimes  in  these  instances.  However  there  was  a  no  build-up  of  viscous 
material, which implied it was released nuclear material, and therefore the nuclease, 
detergent, nuclease and wash regime was adopted for the future PTD experiments.  
A noted issue was, in order to heat the decellularisation solution to the temperature 
of 37°C upon entry to the internal chamber, it was necessary to set the water bath to 
44°C. However, according to a thermometer the water bath was actually at 41°C. 
The first temperature probe measured the decellularisation solution just before the 
internal chamber as being 36.9°C indicating a loss of 4.1°C in the tubing between the 
water bath and the entry to the bioreactor. The second temperature probe measured 
the decellularisation solution just after the internal chamber as being 34°C indicating 
a loss of 2.9°C in the internal chamber of the bioreactor. 
Observations  were  also  made  to  assess  the  effectiveness  of  the  check  valves  at 
maintaining the pressure within the internal chamber (Figure 5.11) The measured 
pressure  was  consistently  lower  after  the  internal  chamber  (pressure  gauge  3), 
average 4.17 psi  ±  0.3 psi,  than before the internal  chamber (pressure  gauge 2), 
average 5.21 psi ± 0.43 psi, and had an average between the two pressure gauges of 
4.67 psi ± 0.31 psi. The pressure measured by the first pressure gauge between the 
first  check  valve  and  the  peristaltic  pump  varied  greatly  and  fluctuated  between  
approximately 4 and 13 psi for each turn of the pump due to the peristaltic pumping 
mechanism.  
Histological analysis of the trachea indicated that regions remained undecellularised 
and nuclei were visible after PTD 1 -3 (black arrows, Figure 5.12 A and B) in not 
only the cartilage rings, as had also been observed in the DEM of decellularisation, 
but  also  in  the  mucous  glands  indicating  the  protocol  for  the  PTD  1  -  3  was 
inadequate and required amendment.  
Page - 170 - of 223 
 
 
Figure 5.11: Readings from the pressure gauges before (PG2) the and after (PG3) the 
internal chamber. 
 
Figure 5.12: Histological analysis of the mucous glands (A) and cartilage rings (B) 
of the trachea (PTD 2 results shown) stained with H&E revealed the presence of 
nuclei in both regions indicating these regions were not adequately decellularised. 
5.4.2  Pressurised transmural decellularisation 5 to 8 (PTD 5 - 8) 
The  decellularisation  experiments  PTD  5  to  8  were  characterised  by  all  having 
undergone a freeze-thaw step at the start, then a DNase step, a detergent step (at 
three different detergent concentrations), followed by the second DNase step and 
finally a wash  step. The bioreactor set-up was amended so  that, after filling the 
external chamber of the bioreactor, the transmural flow would be recirculated to the 
solution reservoir and  be available for recirculation through the lumen and available 
for further transmural flow (Figure 5.6 and Figure 5.13). The result was that the 
solution reservoir was not depleted by the transmural flow being sent to waste and  
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the solution recirculated continuously and with transmural flow for the full 24 hours 
for each step. Again the bioreactor worked well with the transmural flow, pressure 
and the temperature being maintained throughout the entire decellularisation process. 
 
Figure 5.13: Bioreactor version 2.1 in use with the PTD 5. 
Histological analysis using H&E staining indicated total decellularisation had not 
been achieved in the trachealis muscle and mucous gland regions of the trachea for 
the PTD 5 and 6 experiments where lower concentrations of detergent had been used 
(Figure 5.14). The PTD 7 and 8 experiments incorporated an increased concentration 
of detergent and the resulting effect was complete cell clearance within the different 
regions of the tracheal scaffold with the occasional nuclei remaining in the cartilage 
ring region (Figure 5.14), as observed with the DEM of decellularisation.    
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Figure 5.14: Histological analysis of the mucous glands (A) and trachealis muscle 
(B) of experiment PTD 6 stained with H&E revealed the presence of nuclei in these 
regions indicating an inadequate level of cell clearance compared to the analysis of 
the  mucous  glands  (C)  and  trachealis  muscle  (D)  of  experiment  PTD  8  which 
indicated a good level of cell clearance.  
The method of compression testing of the trachea and the decellularised scaffolds 
was  introduced  from  experiment  PTD  5  and  was  considered  to  be  a  more 
representative test for tracheal cartilage ring resistance to mimic compression and 
collapse in vivo. Results from this compression testing indicated that for PTD 5 and 
6 the tracheal resistance to collapse under load was approximately 50% (2.04 ± 0.19 
N) of that of native tissue (4.23 ± 0.89 N) and approximately equivalent to that 
observed in tracheae that had undergone a freeze thaw process, either -80°C in UW 
(1.99 ± 0.75 N) or             -80°C in HBSS (2.40 ± 1.02 N) or -20°C dry (2.29 ± 0.56 
N)  (Figure  5.15).  This  indicated  that  the  decellularisation  process  at  this 
concentration of detergent  was  not  detrimental  to  the mechanical  strength  of the 
scaffold. However, as shown, it also did not achieve complete decellularisation by 
cell clearance. The PTD 7 & 8 experiments at increased concentration of detergent  
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achieved cell clearance in the non-cartilaginous regions of the scaffolds. However, 
the compression testing indicated in increased weakening of the PTD 7 and the PTD 
8 scaffolds to approximately 13% of the native tissue (0.56 ± 0.09 N) (Figure 5.15). 
 
Figure 5.15: Compression testing in the PTD 5 - 8 experiments indicated weakened 
scaffolds comparable to tracheae that had undergone a freeze-thaw step for PTD 5 
and 6 when a lower detergent concentration was used and increased weakening in 
the scaffold beyond that observed in freeze-thawed tracheae for PTD 7 and 8 when a 
higher detergent concentration was used. 
The inclusion of the Dinocapture microscope to monitor the decellularisation during 
experiment  PTD  8  also  highlighted  another  potential  issue  of  increasing  the 
detergent concentration. From two hours after the start of the second DNase step 
there was the formation of salt crystals on the abluminal side of the tracheal scaffold 
(Figure  5.16)  that  dissolved  back  into  solution  during  the  wash  step.  It  was 
hypothesised that this could be due to the sodium from the detergent reacting with 
the chloride ions from either the Trizma-HCl, MgCl2 or CaCl2 in the DNase buffer. 
For future PTD experiments, a wash step was incorporated between the detergent 
step  and  the  second  DNase  in  order  to  remove  the  remnant  detergent  from  the 
scaffold before the DNase step commenced.   
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Figure 5.16: Formation of salt crystals on the ablumen of the tracheae during the 
second DNase step of PTD8. 
5.4.3  Pressurised transmural decellularisation 9 and 10 (PTD 9 & 10) 
The decellularisation experiments PTD 9 and 10 were characterised by all having 
undergone a freeze-thaw step at the start, then a DNase step, a detergent step (at two 
differing detergent concentrations), then a wash step followed by the second DNase 
step and finally a second wash step in the bioreactor v2.2 set up(Figure 5.17).  
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Figure 5.17: Bioreactor v2.2 whilst performing experiment PTD 10. 
The additional 24 hour wash step between the detergent step and the second DNase 
step was added to ensure the detergent had been cleared from the bioreactor system 
before proceeding with the DNase step. Images confirmed that the introduction of 
this wash step achieved its purpose as no salt crystals were observed. Two different 
detergent concentrations were also investigated under these conditions PTD9 at a 
total of 1.25% detergent and PTD 10 at 0.75% detergent. Histological observation 
demonstrated  that  good  cell  clearance  was  observed  for  PTD  9  at  the  higher 
detergent concentration with all of the non-cartilaginous regions of the trachea being 
successfully  cleared  of  cells  (Figure  5.18).  However  at  the  lower  detergent 
concentration the cell clearance was not adequate with cells being observed in the 
mucous  glands  and  the  trachealis  muscle  regions  as  well  as  the  cartilage  rings 
(Figure 5.18).  
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Figure  5.18:  Histological  analysis  of  the  cell  clearance  in  PTD  9  revealed  good 
removal of cells from the trachea by the decellularisation process in all regions of the 
trachea, for example the mucous glands (A) and the trachealis muscle (B) with a few 
nuclei remaining in the cartilage rings. However for PTD 10 cells were observed to 
be present after decellularisation in the mucous glands (C) and the trachealis muscle 
(D) as well as the cartilage rings. 
With regard to the effect of the additional wash step on the biomechanical strength, 
the compression testing indicated that the PTD 9 and 10 scaffolds (0.75 ± 0.34 N) 
were  comparable  in  compressive  resistance  to  the  PTD  7  and  8  scaffolds  at 
approximately 17% of the strength  of the native tracheal tissue (4.23  ±  0.89 N) 
(Figure 5.19). This indicated that, even at the lower concentration of detergent, the 
additional 24 hours of processing was deleterious to the scaffolds beyond the freeze-
thaw step.  
It  was  therefore  decided  to  investigate  shortening  the  wash  step  between  the 
detergent step and the second DNase step and to perform the wash step at 4°C as this 
also may help maintain the biomechanical strength in the scaffolds.   
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Figure  5.19:  Compression  testing  in  the  PTD  9  &  10  experiments  indicated 
weakened scaffolds beyond the tracheae that had undergone a freeze-thaw step. 
Pressurised transmural decellularisation 13 to 15 (PTD 13 - 15) 
The decellularisation experiments PTD 13 to 15 were characterised by all having 
undergone a freeze-thaw step at the start, then a DNase step, a detergent step (all at a 
total of 1.25% detergent), then a 3 hour wash step at 4°C followed by a second 21 
hour DNase step and finally a 24 hour wash step at 4°C. Bioreactor v2.2 was used 
for PTD 13 and bioreactor v2.3 was used for PTD 14 and 15 (Figure 5.20). 
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Figure 5.20: Bioreactor v2.3 which had extra ports included to allow for easy fill and 
drain of the decellularisation solutions. 
Histological analysis of the tracheal scaffolds indicated good cell clearance from 
most regions of the trachea including the mucous glands and the trachealis muscle as 
shown for PTD 14 (Figure 5.21). However there were some apoptotic cells visible in 
the cartilage rings and nuclei visible in the lamina propria as shown for PTD 14 
(Figure 5.21).  
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Figure 5.21: Histological analysis of PTD 14 indicated removal of cells from the 
mucous gland (A) and the trachealis muscle (D) however there were some remaining 
nuclei in the lamina propria (B) and some apoptotic cells visible in the cartilage rings 
(C).  
The compression testing indicated that compressive resistance  for PTD 13 to  15 
(1.98 ± 1.20 N) were similar to tracheae that had been freeze-thawed (2.00 ± 0.75 N) 
and therefore just under 50% the strength of native tracheal tissue (4.23 ± 089 N) 
(Figure 5.22). This indicated that there was a benefit to shortening the first wash step 
and perhaps by performing the wash steps at 4°C. However the scaffolds still only 
retained 50% compressive strength of the native tissue which appeared to be caused 
by  the  initial  freeze  thaw  step  performed  at  the  commencement  of  the 
decellularisation  process.  It  was  therefore  decided  to  perform  the  pressurised 
transmural decellularisation on trachea that had not been freeze-thawed to ascertain 
if decellularisation  could be achieved whilst  the biomechanical  strength retained. 
Due to the anticipated increased retention in compressive strength due to the starting 
decellularisation  material  being  fresh,  longer  washes  and  the  higher  levels  of  
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detergent were used to increase the probability of good cell clearance also being 
achieved. 
 
Figure 5.22: Compression testing of PTD 13 – 15 indicated a comparable loss in 
strength in the decellularised scaffolds as tracheae that had undergone a freeze-thaw 
step and approximately 50% of the compressive strength of native tracheae. 
5.4.4  Pressurised transmural decellularisation (PTD 11, 18 and 20) 
The decellularisation experiments PTD 11, 18 and 20 were characterised by being 
performed on fresh trachea with a nuclease step, a detergent step (all at a total of 
2.5% detergent), then a wash step followed by a second nuclease step and then a 
final wash step. All steps were 24 hours in length and performed at 37°C. Bioreactor 
v2.2 was used for PTD 11 and bioreactor v2.3 was used for PTD 18 and 20 (Figure 
5.20). The inclusion of the ORCA bioreactor allowed certain process parameters, 
temperature and pressure, to be monitored and recorded online. The average pre-
internal chamber (pre-IC) temperature was 33.59 ± 0.66°C and the average post-
internal  chamber  (post-IC)  temperature  was  33.10  ±  1.31°C  (Figure  5.23).  The 
average pre-internal chamber (pre-IC) pressure was 4.79 ± 0.17 psi and the average 
post-internal chamber (post-IC) pressure was 4.00 ± 0.16 psi (Figure 5.24).  
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Figure 5.23: The ORCA controller was able to record the online temperature of the 
decellularisation solutions from the readings off the temperature probes positioned 
before and after (pre and post) the internal chamber (IC) or tracheal lumen. Both 
temperatures were stably maintained over the course of the decellularisation with an 
average difference of 0.84°C detected across the lumen with the solution cooling as 
it travelled down the fluidic path from the solution reservoir.  
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Figure 5.24: The ORCA controller was able to record the online pressure of the 
decellularisation  solutions  from  the  readings  from  the  pressure  transducers 
positioned  before  and  after  (pre  and  post)  the  internal  chamber  (IC)  or  tracheal 
lumen.  Both  pressures  were  stably  maintained  over  the  course  of  the 
decellularisation with an average difference of 0.79 psi detected across the lumen 
with the pressure of the solution diminishing as it travelled further down the fluidic 
path from the peristaltic pump.  
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5.4.4.1  Macroscopic overview of the native trachea and PTD scaffolds 
The  porcine  tracheal  scaffolds  produced  using  PTD  (PTD  20  shown)  appeared 
denuded, compared to the native porcine trachea, as was expected of a decellularised 
organ. The overall morphological structure was retained, notably with the cartilage 
rings maintaining the open structure of the hollow organ (Figure 5.25). The rings 
also resisted collapse under light pressure. The epithelial lining of the lumen was 
also intact and denuded, as would be expected. 
 
Figure 5.25. Comparing the native trachea (A) with the PTD 20 tracheal scaffold (B), 
the gross morphological appearance of the scaffold is retained appearing denuded 
with the cartilage rings maintaining an open structure and a visible epithelial layer 
lining the lumen. 
5.4.4.2  Histological analysis of PTD scaffolds by H&E staining  
H&E staining of native tracheae and decellularised scaffolds (PTD 11, 18 and 20) 
demonstrated that under microscopic observation the structure of the trachea and the 
structure  of  the  tracheal  sub-regions  were  retained  after  pressurised  transmural 
decellularisation  (Figure  5.26).  Histological  analysis  by  H&E  staining  also 
demonstrated  excellent  cell  and  nuclei  removal  from  the  majority  of  the 
decellularised scaffolds. Histological analysis was categorised into the major sub-
regions of the trachea to cover the mucosa region of the lamina propria, the sub-
mucosal gland region of the lamina propria, the cartilage rings and the adventitia. It 
was extended to also include the trachealis muscle region, having observed some 
inadequate  removal  of  cells  from  this  region  in  previous  versions  of  the  PTD 
method. Analysis of these sub-regions demonstrated that in the mucosa (epithelial 
and sub-epithelial) region (Figure 5.27), the sub-mucosal region (Figure 5.27), the  
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adventitia (Figure 5.28) and the trachealis muscle (Figure 5.29) complete clearance 
of  the  cells  and  the  nuclei  was  achieved  in  the  decellularised  scaffolds.  In  the 
cartilage  ring,  as  with  the  DEM,  chondrocytes  were  observed  after  the 
decellularisation  process  in  the  scaffolds  (Figure  5.28).  For  the  PTD  18  and  20, 
histological  analysis  also  revealed  potential  damage  could  have  occurred  to  the 
trachealis muscle as the amount of visible smooth muscle appears to have decreased 
(Figure 5.29).    
 
Figure 5.26: Low power (x4) microscopic evaluation of native trachea (A) and PTD 
demonstrated overall retention of the microscopic structure of the tracheae in the 
decellularised scaffold and overall clearance of cells.  
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Figure 5.27: High power (x60) microscopic evaluation comparing native trachea and 
PTD 11, PTD 18 and PTD 20 demonstrated retention of the microscopic structure of 
the tracheae in the decellularised scaffold and total clearance of cells in the mucosa 
and mucosal glands regions of the decellularised scaffold.  
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Figure 5.28: High power (x60) microscopic evaluation comparing native trachea and 
PTD 11, PTD 18 and PTD 20 demonstrated retention of the microscopic structure of 
the  tracheae  in  the  decellularised  scaffold  and  total  clearance  of  cells  in  the 
adventitia  region  of  the  decellularised  scaffold.  However  chondrocytes  were 
observed in the cartilage rings of the decellularised scaffold.  
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Figure 5.29: Low power (x10) microscopic evaluation comparing native trachea and 
PTD 11, PTD 18 and PTD 20 demonstrated retention of the microscopic structure of 
the tracheae in the decellularised scaffold and total clearance of cells in the trachealis 
muscle region of the decellularised scaffold.  
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Image analysis was performed to quantify the cell clearance from the various regions 
of the tracheae. In native trachea the number of cells observed were 8910 ± 1280 
cells/mm2 in the mucosa, 7639 ± 2418 cells/mm2 in the sub-mucosa, 1298 ± 346 
cells/mm2 in the adventitia, 6917 ± 372 cells/mm2 in the trachealis muscle and 1257 
± 412 cells/mm2 in the cartilage. In the PTD treated scaffolds no cells were observed 
in the mucosa, sub-mucosa, adventitia and trachealis muscle regions (Figure 5.30). 
In the cartilage regions 1302 ± 412 cells/mm2 were observed in the PTD treated 
scaffolds which indicated no cell clearance from the cartilage rings, however of these 
759 ± 599 cells/mm2 were observed to have undergone apoptosis (Figure 5.31). 
 
Figure  5.30:  Quantification  of  the  cell  clearance  observed  in  the  mucosa,  sub-
mucosa, adventitia and trachealis muscle regions of the trachea demonstrated total 
cell clearance was achieved in these non-cartilaginous regions.  
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Figure  5.31:  Quantification  of  the  cell  clearance  observed  in  the  cartilage  rings 
regions of the trachea demonstrated no cell clearance was achieved however over 
50% of the cells appeared to have undergone apoptosis. 
5.4.4.3  Analysis of DNA removal in PTD scaffolds 
Quantitative  analysis  of  residual  DNA  to  determine  the  effectiveness  of  DNA 
removal by the PTD method demonstrated statistically significant improved removal 
of  DNA  compared  with  the  DEM  of  decellularisation.  After  PTD,  38.53  ±  9.84 
ng/mg of DNA remained compared to 264.7 ± 69.92 ng/mg (P<0.05) in the DEM 
(Figure 5.32). This represented a 6.7 fold increase in DNA removal using the new 
PTD method compared to the DEM. However both of the methods demonstrated 
significant removal (P<0.005) of DNA when compared to the levels of DNA (695.87 
± 159.02 ng/mg) observed in native tissue (Figure 5.32).  
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Figure 5.32: Quantitative DNA analysis demonstrated a significant decrease in the 
DNA concentration in the PTD scaffold (38.53 ± 9.84 ng/mg) compared to native 
trachea  (695.87  ±  159.02  ng/mg)  and  scaffolds  produced  with  the  DEM  of 
decellularisation (264.7 ± 69.92 ng/mg).  
5.4.4.4  Analysis of collagen in PTD scaffolds 
Quantitative analysis of total collagen following PTD revealed comparable levels of 
retained collagen in the PTD scaffolds (379.29 ± 14.36 µg/mg) as in the native tissue 
(387.16 ± 22.44 µg/mg) (Figure 5.33). When collagen levels from the PTD method 
were  compared  to  the  DEM  (298.07  ±  39.66  µg/mg),  statistically  significant 
increased levels of collagen (P<0.005) were retained by the PTD method (Figure 
5.33).    
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Figure 5.33: Quantitative analysis of the total collagen content of the native tissue 
versus DEM and PTD scaffolds indicated native levels of collagen were retained in 
the PTD scaffolds (97.97% retained) whereas loss of collagen content was identified 
in the DEM scaffolds (76.99% retained) (P<0.005).  
5.4.4.5  Analysis of glycosaminoglycans in PTD scaffolds 
Quantitative  analysis  of  GAGs  following  PTD  revealed  slightly  decreased  but 
comparable  levels  of  retained  GAG  in  the  PTD  scaffolds  (34.55  ±  2.98  µg/mg) 
compared to native tissue (39.67 ± 5.82 µg/mg) (Figure 5.34). When GAG levels 
from the PTD method were compared to the DEM (22.12 ± 7.32 µg/mg), statistically 
significant increased levels of GAG (P<0.001) were retained by the PTD method 
(Figure 5.34).    
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Figure 5.34: Quantitative analysis of the GAG content of the native tissue versus 
DEM and PTD scaffolds indicated comparable levels of GAGs were retained in the 
PTD scaffolds (87.09% retained) whereas loss of GAGs were identified in the DEM 
scaffolds (55.76% retained) (P<0.005). 
5.4.4.6  Tensile testing of PTD scaffolds 
Tensile  testing  was  performed  on  the  decellularised  scaffolds  to  determine  the 
biomechanical strength of the PTD scaffolds compared to native tracheal tissue and 
DEM  decellularised  scaffolds.  When  analysing  the  tensile  modulus  of  the  PTD 
scaffolds, there was no statistical change in modulus of the PTD scaffolds (49.41 ± 
11.39 MPa) when compared to the native trachea (54.07 ± 9.42 MPa) (Figure 5.35). 
This was in contrast to scaffolds produced by the DEM of decellularisation (39.86 ± 
6.54 MPa) where there was statistically significant decrease (P<0.05) observed in the 
tensile modulus (Figure 5.35).  
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Figure  5.35:  Measurement  of  the  tensile  modulus  indicated  comparable  tensile 
modulus was retained between the native tracheae and the PTD scaffolds (91.39%) 
however tensile modulus decreased in the DEM scaffolds  (73.71%) compared to 
native tracheae (P<0.05). 
From the tensile testing, the ultimate tensile strength could also be determined. These 
data  showed  that  a  statistically  significant  loss  of  ultimate  tensile  strength  was 
observed in both the scaffolds produced by DEM (9.12 ± 1.73 MPa) (P<0.05) and 
the PTD (7.79 ± 2.8) (P<0.01) compared to the native tracheal tissue (12.13 ± 2.71) 
(Figure 5.36).   
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Figure  5.36:  Measurement  of  the  ultimate  tensile  stress  indicated  a  loss  of  the 
ultimate  tensile  stress  capacity  of  the  PTD  scaffolds  (64.25%)  (P<0.05)  and  the 
DEM scaffolds (75.19%) (P<0.01) compared to native tracheae. 
 
From the tensile testing the ultimate tensile strain could also be determined. The 
PTD scaffolds (20.21 ± 5.4%) demonstrated a statistically significant decrease in 
ultimate tensile strain from both the native tissue (35.56 ± 7.57 %) (P<0.005) and the 
DEM produced scaffolds (32.22 ± 4.03 %) (P<0.005) (Figure 5.37). 
 
Figure  5.37:  Measurement  of  the  ultimate  tensile  strain  indicated  a  loss  of  the 
ultimate  tensile  strain  capacity  of  in  the  PTD  scaffolds  (56.85%)  (P<0.005)  
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compared to native tracheae whilst comparative strain was observed in the DEM 
scaffolds (90.61%). 
5.4.4.7  Compression testing of PTD scaffolds 
Compression testing of complete sections of trachea was performed to assess the 
collapse resistance of the trachea and decellularised scaffolds to 50% occlusion. It 
was anticipated that this test should better represent biomechanical resistance to in 
vivo  collapse  post-transplantation.  The  greater  the  force  required  to  occlude  the 
trachea/scaffolds to 50% occlusion the stronger the trachea/scaffold. Tests on the 
PTD decellularised scaffolds (3.61 ± 1.67 N) demonstrated a noticeable but non-
statistically  significant  decrease  (14.54%)  in  the  force  required  to  occlude  the 
scaffold to 50% compared to the native tissue (4.23 ± 0.89 N), demonstrating that the 
scaffolds produced by PTD were comparable to native trachea in this test (Figure 
5.38). 
 
Figure 5.38: Measurement of the compression testing indicated the force required to 
occlude the lumen to 50% was statistically comparable between the native tracheae 
and the PTD scaffolds (85.45%). 
5.4.5  Pressurised transmural decellularisation experiment failures   
5.4.5.1  Pressurised transmural decellularisation 4: 
The  experiment  was  abandoned  after  only  24  hours  of  decellularisation  so  no 
meaningful results were obtained from this experiment.   
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5.4.5.2  Pressurised transmural decellularisation 12: 
The  experiment  was  abandoned  only  20  hours  prior  to  the  completion  of  the 
decellularisation due to a perforation in the trachealis muscle. Therefore the trachea 
was not submitted to the range of analytical tests due to the failure of the experiment. 
However, it was observed that the trachea felt weakened, indicating degradation to 
the cartilage rings due to the decellularisation process.  
5.4.5.3  Pressurised transmural decellularisation 16: 
The experiment was abandoned shortly after commencing the initial decellularisation 
step so no meaningful results were obtained from this experiment.  
5.4.5.4  Pressurised transmural decellularisation 17: 
The experiment was abandoned shortly after commencing the decellularisation due 
to a failure in the bioreactor integrity so no meaningful results were obtained from 
this experiment.  
5.4.5.5  Pressurised transmural decellularisation 19: 
The experiment was abandoned during commencement of the third process step of 
the decellularisation so no meaningful results were obtained from this experiment.  
5.4.6  Cost comparison of the DEM and PTD methods 
The cost of the reagents only were calculated for the DEM and PTD methods to 
create a basic cost of goods (CoG) analysis. The reagent CoG for the DEM totalled 
£733.18  and  the  reagent  CoG  for  the  PTD  totalled  £71.37  (Figure  5.39).  This 
indicated a  greater than 10 fold reduction in  the CoG could  be achieved on the 
reagent costs alone by using the PTD methodology.  
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Figure 5.39: Reagent CoG for the DEM and PTD methods  indicated a >10 fold 
reduction in the CoG for the PTD compared to the DEM.  
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5.5  Discussion  
The  bioreactor  version  2.0  demonstrated  successful  containment  of  the  pressure 
within  the  internal  chamber  using  a  two  check  valve  system  and  achieved 
recirculation of the decellularisation solution along with transmural flow. The use of 
two check valves were instrumental to the set-up and with the bioreactor system in 
use demonstrated that the first check valve, along with containing the pressurisation 
in the internal chamber, also served to protect the lumen of the trachea from the 
fluctuating effect of pressure caused by the peristaltic pump. The reliability of the 
bioreactor  system,  based  on  the  improvements  described  in  chapter  4,  enabled 
decellularisations utilising pressurised transmural flow to be performed on tracheae 
in a reproducible manner. The first three experiments did however highlight issues 
with the bioreactor set-up with regard to the transmural flow being sent to a separate 
waste reservoir. This design element appeared to cause insufficient decellularisation 
of the tracheae, with cells and nuclei being observed in the apparently decellularised 
tissue  and  higher  levels  of  DNA  remaining  in  regions  judged  to  be  less 
decellularised.  Another  issue  was  the  level  of  transmural  flow  was  higher  than 
originally  anticipated  and  as  a  result  an  increased  volume  of  decellularisation 
solution would be required to run the steps of the decellularisation, particularly the 
latter steps, as the porosity of the scaffold increased with decellularisation. However 
for these experiments the volume was restricted to a set limit of 500 mL for cost 
reasons and therefore some of the latter process steps were completed in a matter of 
hours.  This  would  also  have  decreased  the  time  exposure  of  the  tissue  to  the 
decellularisation solutions which have reduced the decellularisation potential.  
These early experiments did answer some questions though. The lower flow rates 
observed in the tracheae that had undergone the freeze-thaw step to -80°C in Viaspan 
(or UW solution) had final flow rates of approximately half that of the final flow 
rates  of  the  trachea  that  had  undergone  the  freeze-thaw  step  to  -20°C  dry.  This 
evidence suggests an increased final porosity in the tracheae that had been frozen to -
20°C dry and therefore a more open final ECM. This could also be interpreted as an 
increase in the level of damage and therefore it was decided to not use the -20°C dry 
frozen  method  as  a  way  of  storing  the  tracheae  post-harvest  until  use  in  the 
decellularisation method. It also resolved the process step order in that the first step 
should be a DNase step. When detergent  was  introduced as  the first  step in  the  
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decellularisation process, as employed by the DEM of decellularisation, a build-up 
of viscous material was observed, which was only cleared by the subsequent DNase 
step. By considering what that buildup of viscous material was, it was realised that 
mucous produced by the mucous glands and ducts coat the trachea and through the 
ducts it permeates the lamina propria and sub-mucosal regions at the start of the 
decellularisation process. It is also well documented that mucous contains DNA and 
DNase-based medicine (Pulmozyme) and is used by Cystic Fibrosis patients to help 
breakdown the DNA in the mucous to loosen the mucous and aid expectoration. 
With the addition of the freeze thaw step that will have caused cell lysis and release 
of nuclear material, it was no surprise that the buildup of a viscous material, likely to 
have been nuclear material, occurred. By amending the order of the process steps 
and starting the decellularisation steps with a nuclease step it was surmised that the 
first nuclease step would break down the residual mucous allowing increased access 
to the lamina propria and the sub-mucosal regions and additionally breakdown the 
nuclear material that had been released through cell lysis. The change in the order of 
the process steps was affirmed when the buildup of viscous/nuclear material was 
avoided for the entire process and therefore taken forward into future experiments as 
the optimal order for the process steps. 
With the changes to the bioreactor amended to incorporate the recirculation of the 
transmural flow and the order of the process steps resolved, it was possible to focus 
the next set of experiments on the investigation of different detergent concentrations. 
It was hypothesised that the detergent concentration would be key to obtaining the 
required level of cell clearance and maintaining the desired level of biomechanical 
strength.  Therefore the lower and higher extremes of the detergent concentration 
were  investigated.  The  results  demonstrated  clearly  that  if  the  detergent 
concentration was too low then cell clearance would not be adequately achieved 
although  biomechanical  strength  would  be  retained  to  a  comparable  level  of  a 
trachea undergoing a freeze-thaw step. Conversely, if the detergent concentration 
was too high then cell clearance would be obtained but with the compromise of 
biomechanical strength being lost. It was realised that a fine balance of detergent 
concentration would be required to obtain adequate cell clearance whilst retaining 
biomechanical strength. Another discovery from this set of experiments was that at 
higher concentrations of detergent salt crystals precipitated out of solution in the  
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second nuclease step. Given that salt crystals were likely sodium chloride, this could 
reduce  the  efficacy  of  the  DNase  as  sodium  chloride  inhibits  DNase  activity. 
Therefore to prevent salt precipitation in the second nuclease step, a wash step was 
introduced to remove the residual detergent from the bioreactor and the scaffold, 
which was shown to resolve the issue.      
The next two experiments investigated the effect of the additional wash step at two 
new detergent concentrations that were in-between the previously employed higher 
and lower detergent concentrations. Adequate cell clearance was only achieved in 
the experiment that employed the higher detergent concentration of the two but both 
scaffolds suffered from a reduction in biomechanical strength which indicated that 
increased exposure of the tracheal scaffold to the bioreactor to five days and the 
additional wash was not optimal for the scaffold strength.  
The next set of three experiments focused on the successful detergent concentration 
from  the  previous  two  experiments  which  had  obtained  good  cell  clearance,  but 
shortened the five days of processing back to four days by greatly reducing the wash 
step between the detergent step and the second nuclease step from 24 hours to 3 
hours and slightly reducing the second nuclease step from 24 hours to approximately 
21 hours. Both wash steps were also performed at 4°C. Adequate cell clearance was 
mostly achieved at this detergent concentration, however donor to donor variability 
of  the  tracheae  demonstrated  that  at  this  concentration,  the  efficacy  of  the  cell 
clearance was at its limit, as in one of the scaffolds, nuclei were still visible in the 
lamina propria. The reduction in processing time and perhaps the reduction in the 
wash  step  temperature  did  have  the  desired  effect  though  as  the  biomechanical 
strength was not reduced beyond that observed from freeze-thawing the scaffold. 
The inability to store decellularised tracheal scaffolds without deterioration of the 
scaffold is a known issue (Baiguera, Del Gaudio et al. 2012). Therefore the use of a 
freeze-thaw step prior to decellularisation to aid both the decellularisation of the 
trachea and add flexibility to the commencement of the decellularisation process, by 
allowing storage of the trachea for up to one month was considered favourably. The 
step  had  been  introduced  to  the  concept  of  PTD  decellularisation  after 
recommendation of the use of the freeze-thaw step from the decellularisation team at 
the  Department  of  Surgical  Research  at  Northwick  Park  Institute  for  Medical  
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Research  (NPIMR). Although the freeze-thaw step was  clearly beneficial  from  a 
flexibility point of view and could be aiding the decellularisation, it was clear from 
the compression testing results that the freeze-thaw step was detrimental and caused 
a  50%  reduction  to  the  biomechanical  strength  of  the  scaffold.  It  was  therefore 
decided to investigate if the PTD decellularisation could be successfully performed 
on fresh trachea that had not undergone any freeze-thaw steps.  
The initial impressions of the tracheal scaffolds post PTD 11, 18 and 20 were of 
scaffolds  that  appeared  fully  denuded  by  the  decellularisation  process  but  still 
retained the overall structure and biomechanical strength. Histological staining gave 
the first insight into how successful the PTD decellularisation had been on fresh 
trachea.  Microscopic  observation  using  the  4x  objective  demonstrated  that  the 
microscopic  structure  of  the  tracheae  had  been  preserved  with  the  various  sub-
regions of the trachea remaining distinct and intact. Under increased magnification, 
microscopic observation demonstrated total cell clearance from all non-cartilaginous 
regions of the tracheae. In the cartilage rings, as with the DEM of decellularisation, 
chondrocytes and nuclei were still observed in the cartilage matrix. Clearly, cartilage 
restricts the movement of solution through the tissue due to retaining its own turgid 
state.  The  impermeability  of  cartilage  might  in  itself  explain  why  retained 
chondrocytes does not cause an immunologic reaction in patients who have already 
received engineered airways.  
Further  analysis  of  the  effect  of  PTD  on  the  biochemical  state  of  the  tracheal 
scaffolds revealed the PTD achieved a significant improvement in the removal of 
residual  DNA  from  the  scaffold  compared  to  the  DEM  of  decellularisation. 
Approximately 6.7 times more DNA was removed by the PTD method compared 
with the DEM. This is achieved even though only two nuclease steps (48 hours in 
total) are performed using the PTD method compared to the twenty-five DNase steps 
(75  hours  in  total)  that  are  performed  by  the  DEM.  It  is  probable  that  this 
improvement in DNA removal is due to the optimisation of the nuclease buffer and 
the performance of the nuclease steps at near 37°C as well as possibly the inclusion 
of RNase to the nuclease step. It has been suggested that the quantitative criteria for 
DNA removal in tissues to be used for transplantation purposes is to reduce the DNA 
concentration to less than 50 ng/mg (dry weight) of dsDNA ((Badylak, Weiss et al.  
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2012)) which the PTD method is likely to achieve based on current results. Other 
biochemical  tests  looked  at  the  total  collagen  concentration  and  the  GAG 
concentration in  the PTD scaffolds  compared to native tracheal  tissue and DEM 
scaffold  tissue.  Again  the  results  suggested  a  significant  improvement  in  the 
retention of collagen and GAG in the PTD scaffolds compared to the DEM scaffolds, 
with  the  PTD  scaffolds  retaining  a  similar  level  of  collagen  and  GAG  to  that 
observed in the native tissue whilst significant amounts of collagen and GAG are lost 
when  the  tracheae  is  decellularised  using  the  DEM.  This  could  be  due  to  the 
reduction in the process time for decellularisation of the scaffolds. The DEM takes 
28 days to complete whilst the PTD is 7 fold faster, taking 5 days to complete. This 
suggests  that  even  though  the  PTD  scaffolds  are  subject  to  a  more  intense 
decellularisation regime where the decellularisation solution is forced through the 
scaffold, the overall reduction in the length of exposure is beneficial to the retention 
of these key ECM proteins.   
As discussed in section 3.5, the ability for the tracheal scaffolds to maintain an open 
airway would be a CQA in a tracheal scaffold. Therefore biomechanical testing was 
performed using two different methods, tensile testing which had been reported on 
previously with the DEM scaffolds and a new method of compression testing, which 
was anticipated to be more representative. The tensile testing informed on the tensile 
modulus, the ultimate tensile stress and the ultimate tensile strain of the scaffolds. 
The tensile modulus of the PTD scaffolds were comparable to the native scaffold 
whereas  for  the  DEM  scaffolds  there  was  a  significant  reduction  in  the  tensile 
modulus. This corresponded well with the PTD scaffold biochemical results where 
the levels of collagen and GAGs were retained and were comparable to the native 
trachea. This would suggest, as hypothesised, that retaining key ECM components 
known to contribute to the biomechanical properties of the cartilage would enable 
the scaffolds to retain their biomechanical strength and therefore tensile modulus. 
Whereas, in the DEM scaffolds, the reduction observed in the collagen and GAG 
levels resulted in a reduced tensile modulus. The ultimate tensile stress and ultimate 
tensile strain results for the PTD scaffolds, which were the raw outputs from the 
tensile  testing,  were  confusing  at  first.  Statistically  significant  decreases  were 
observed for both ultimate tensile stress and ultimate tensile strain which suggested, 
in contrast to the tensile modulus, that the PTD scaffolds had lost biomechanical  
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strength compared the native tissue and the DEM scaffolds. Young’s modulus is a 
measure of the stiffness of the material being tested and the stiffness of the cartilage 
rings  was  considered  an  important  factor  in  the  ability  of  the  cartilage  rings  to 
maintain an open airway. When interrogating the ultimate tensile stress and ultimate 
tensile strain results, the cartilage rings from the DEM scaffolds stretched the same 
amount as those from the native trachea with an equivalent ultimate tensile strain, 
however they ruptured under significantly less ultimate tensile stress than those from 
the native trachea which resulted in the cartilage rings from the DEM scaffolds being 
significantly weaker and more flaccid than those from the native trachea. With the 
ultimate tensile stress and ultimate tensile strain results from the cartilage rings of 
the PTD scaffolds, whilst the cartilage rings stretched significantly less they also 
rupture under significantly less stress than those from the native trachea. Because 
both  the  ultimate  tensile  stress  and  ultimate  tensile  strain  were  reduced 
proportionally by a comparable amount then ultimately the stiffness of the cartilage 
rings in the PTD scaffolds had been maintained and shown to be comparable to the 
cartilage rings from the native tracheal tissue. If the stiffness of the PTD scaffolds 
was truly maintained to that of the native trachea then it would be expected that 
comparable level of external force would be required to compress sections of those 
scaffolds.  Therefore  these  data  from  the  tensile  testing  experiments  were 
corroborated by the compression testing results where the force required to occlude 
the lumen of the PTD scaffolds was shown to be equivalent to the force required to 
occlude the lumen of the native trachea.  
Although, if time allowed, more experimental parameters would have been explored 
and a wider range of characterising assays employed to investigate PTD produced 
scaffolds using fresh trachea, the data obtained so far was encouraging and appeared 
to have built upon upon prior experimental knowledge and hypotheses to develop a 
potentially  improved  scaffold  for  tracheal  tissue  engineering.  Although  the 
development of the decellularisation scaffold is only a single piece of the work that 
must be achieved to manufacture a tissue engineered trachea, by manufacturing a 
scaffold that retains biomechanical strength whilst being immunologically inert, it is 
providing  the  recellularisation  part  of  the  process  with  what  would  currently  be 
considered the best starting point. The ability of these PTD scaffolds to engraft with 
the host tissue, recellularise and enable the re-establishment of cartilage homeostasis  
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would need to be investigated in representative models before they are employed for 
tissue engineering purposes. 
The bioreactor overall proved successful however there was a 25% failure rate which 
was unacceptably high. Three of the failures were due to a rupture in the trachealis 
muscle of the trachea, due to that region not being able to withstand the pressure 
administered.  Two  of  these  failures  were  due  to  the  tissue  itself  being  naturally 
weaker due to donor to donor variability. In order to prevent trachealis muscle failure 
it would be pragmatic to investigate if using lower pressures in the internal chamber 
could  achieve  comparable  decellularisation  whilst  lowering  the  risk  of  failure. 
However,  the  donor  to  donor  variability  of  the  starting  material  is  noted  to  be 
problematic when attempting to scale-up and automate reproducible manufacturing 
strategies for regenerative medicine (Brindley, Wall et al. 2013). The other scaffold 
failure was due to a user error causing a pressure build-up. In any highly-manual 
non-automated process, potential user errors are a high risk (Brindley, Wall et al. 
2013). The rupture due to user error could be avoided by employment of thorough 
SOPs, quality manufacturing principles, operator training as well as simplification 
and automation of the bioreactor (Williams, Thomas et al. 2012). Of the other two 
failures, one was due to the attachment of the trachea to the bioreactor not being 
sufficiently  sealed  and  one  was  due  to  the  bioreactor  leaking  due  to  repetitive 
autoclave fatigue. These could both be avoided by an improved bioreactor design. 
Machining the entire bioreactor body out of a single piece of autoclavable material 
would  be  necessary  to  prevent  this  issue  reoccurring.  Implementing  these 
improvements would hopefully reduce the failure rate and improve the reliability of 
the bioreactor system.  
By  reducing  the  number  of  process  steps  and  reagent  quantities,  there  was  a 
significant ten-fold reduction in the reagent CoG. The CoG will be critical to reduce 
when scaling-up the process to achieve affordable commercialisation of the process. 
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5.6  Conclusion 
A prototype bioreactor system was successfully built and improved upon enabling 
process  development  of  the  PTD  method  and  in-process  monitoring  of  the 
decellularisation process. Over the course of 15 successful decellularisation process 
runs, a series of product-informed improvements were implemented. Histological 
analysis along with biochemical and biomechanical assays indicated that the PTD 
method described for PTD 11, 18 and 20 using fresh tracheae as the starting material 
produced porcine scaffolds that have the potential to fulfill the CQA required for 
tissue  engineering.  The  method  improvements  included  the  introduction  of  a 
pressurised transmural flow as a way to decellularise tissue, the optimisation of the 
decellularisation  buffers  used,  a  change  in  the  order  of  application  of  the 
decellularisation solutions and an increase in the temperature the decellularisation 
was performed at. These improvements enabled a reduction in the processing time 
from 28 days to 5 days and a ten-fold reduction in the reagent CoG. The resulting 
scaffold  from  this  PTD  method  had  absolute  cell  clearance  from  the  non-
cartilaginous  regions  of  the  trachea,  remnant  DNA  levels  that  were  below  the 
recommended  DNA  levels  for  decellularised  products  to  be  used  in  advanced 
therapy medicinal products (ATMPs), retained the key ECM components of collagen 
and  GAG  to  a  level  comparable  to  native  trachea  and  retained  biomechanical 
strength and stiffness to a level comparable to native trachea. This suggests that, the 
final PTD method is a rapid and fit-for purpose method that has the potential to 
manufacture  tracheal  scaffolds  for  tissue  engineering  purposes  in  a  reproducible 
process and advance this area of clinical study.  
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6  Discussion 
6.1  Current process 
6.1.1  Unmet clinical need 
The driving force behind the need to translate tissue engineered trachea from the 
research lab to clinic is the current unmet clinical need to treat patients suffering 
from congenital tracheal atresia or stenosis and tracheal injury or disease in both 
children and adults. Currently, methodology has relied upon on producing bespoke 
tissue  engineered  trachea  or  tracheal  scaffolds  for  named  patients  on  a 
compassionate  basis  under  the  UK  “Specials”  scheme  which  allows  for  the 
manufacture  and  release  of  Advanced  Therapeutic  Medicinal  Products  (ATMPs) 
without clinical trials or marketing authorisation (MA) (Macchiarini, Jungebluth et 
al. 2008, Elliott, De Coppi et al. 2012, Gonfiotti, Jaus et al. 2014). If current medical 
need is to be met then this production of bespoke tissue-engineered tracheae needs to 
be translated into an ability to manufacture the quantities required, estimated to be 
two hundred per year (Boseley 2008), to meet current UK demand. The guiding 
principles that should be employed to achieve this aim are those currently employed 
for precision manufacturing where process knowledge and validation of the process 
leads to the principle of the “process is the product” (Williams, Thomas et al. 2012, 
Brindley,  Wall  et  al.  2013).  This  means  knowing  your  process  is  knowing  your 
product, but the complexity of regenerative medicine and tissue engineering products 
can make achieving these principles particularly challenging (Brindley, Wall et al. 
2013). 
This thesis addressed this challenge by firstly investigating the current gold standard 
methodology, the detergent-enzymatic method (DEM) for decellularisation of the 
tracheae (Conconi, De Coppi et al. 2005, Macchiarini, Jungebluth et al. 2008), which 
had been used in the first in man studies on a named compassionate basis. Despite 
the reported clinical successes, in some of the cases partial collapse and/or stenosis 
were  observed  and  it  was  acknowledged  that  further  development  of  the 
decellularisation process was required (Badylak, Weiss et al. 2012, Gonfiotti, Jaus et 
al. 2014). In-house studies indicated the DEM had many limitations including: the 
loss  of  observed  biochemical  and  biomechanical  properties  of  the  decellularised 
scaffold (Partington, Mordan et al. 2013); the process taking 28 days to complete;  
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the  process  requiring  multiple  operator  managed  wash/decellularisation  solution 
exchanges per day or cycle; and the process requiring 25 detergent-enzymatic cycles. 
Additional to this, the need to repeat the detergent-enzymatic cycle 25 times drove 
up  the  cost  of  goods  (CoG)  and  some  aspects  of  the  methodology  appeared 
counterintuitive to achieving an optimal product. One of the principle investigators 
of  this  research  co-authored  a  paper  which  suggested  changes  which  could  be 
implemented  to  overcome  potential  issues  with  the  product  including:  additional 
DEM  cycles  or  a  freeze-thaw  step  if  adequate  decellularisation  had  not  been 
achieved; or reducing the number of DEM cycles if a loss of structural integrity was 
observed  in  the  tissue  (Bader  and  Macchiarini  2010).  Although  these  could  be 
solutions to the challenges observed, a radical rethink of the decellularisation process 
as a whole could present a more elegant solution. 
6.1.2  Process developments 
Whilst changes to the length of the incubations, the temperature the incubations are 
performed at and the decellularised solutions used could improve the decellularised 
scaffold, these are minor changes. This thesis focused on a major rethink of how the 
decellularisation solutions were applied to the tissue with the use of pressure and 
transmural  flow  to  force  the  decellularisation  solutions  through  the  tissue  being 
considered a radical change from the passive diffusion into the tissue via immersion 
of the tissue in the decellularisation solutions as currently employed by the DEM. 
The first challenge in creating a decellularisation system with pressurised transmural 
flow was to design, make and validate a bioreactor system capable of creating and 
maintaining  a  stable  transmural  flow.  The  second  challenge  was  to  optimise  the 
ancillary parts of the bioreactor system, such as the pump, the pump tubing and the 
clamps/check valves required to create the appropriate level of back pressure for 
stable transmural flow to be achieved. The latter challenge proved to be the most 
problematic  aspect  of  the  bioreactor  system  design.  These  issues  were  however 
overcome  and  a  stable  bioreactor  system  was  achieved  which  allowed  for  the 
methodology of pressurised transmural decellularisation (PTD) process, using the 
bioreactor system, to be optimised.  
The development and implementation of an automatable and controllable bioreactor 
system will ultimately be critical in the need to reduce the failure rate, standardise  
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the  manufacturing  process  and  the  commercialisation  of  decellularised  tracheal 
scaffolds  and  therefore  tissue-engineering  tracheae  to  ensure  consistency  in  final 
product  and  enable  cross-site  comparability  in  the  manufacturing  process.  The 
improvement  to  the  manufacturing  process  should  impact  on  and  result  in  both 
process and product improvements such as reduced processing time, a reduction in 
the CoG, a lower risk of contamination and ultimately a final product of reproducible 
high quality (Williams, Thomas et al. 2012, Brindley, Wall et al. 2013). 
The basis of the PTD method was drawn from both the DEM (Conconi, De Coppi et 
al. 2005, Macchiarini, Jungebluth et al. 2008) and vacuum assisted decellularisation 
(VAD) (Ansari 2011, Lange, Greco et al. 2014) methodologies due to the clinical 
application of these methods, with commonality in the detergent and enzymatic steps 
being applied. Additionally, a freeze-thaw step was added at the start of the process, 
with a presumed beneficial effect due its inclusion in the VAD method as well as 
other decellularisation methods and the possible necessity of the freeze-thaw step to 
achieve complete decellularisation due to the anticipated reduction in the number of 
process steps required in the PTD method. The methodology development of the 
PTD method focused primarily on varying the detergent concentration whilst the 
nuclease  step  stayed  constant.  It  was  apparent  from  the  initial  PTD  experiments 
performed, which incorporated the freeze-thaw step, that higher concentrations of 
detergent resulted in an acellular but weakened scaffold and lower concentrations of 
detergent  resulted  in  a  stronger  scaffold  but  regions  of  scaffold  remained 
undecellularised.  Further  biomechanical  tests  on  scaffolds  part  way  through  the 
decellularisation process revealed that the freeze-thaw step alone, whether performed 
to  -80°C  in  Viaspan  solution  or  to  -20°C  with  the  trachea  kept  dry,  resulted  in 
approximately  a  50%  reduction  in  scaffold  strength.  It  was  therefore  decided  to 
attempt  a  5  day  PTD  process  without  the  initial  freeze-thaw  step,  which  was 
considered then to be detrimental to the biomechanical strength of the scaffold. The 
resulting scaffolds retained biomechanical strength, along with native levels of GAG 
and  collagen  whilst  being  acellular  in  the  non-cartilaginous  regions  with 
approximately 95% of the DNA removed. This success supported the hypothesis that 
PTD could be a rapid decellularisation method that produced tracheal scaffolds that 
met the required critical quality attributes. The reduction in the number of process 
steps and days required to achieve the appropriate decellularisation also resulted in a  
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ten-fold reduction in the basic CoG, which would benefit commercialisation of the 
process.  
6.1.3  Limitations of the current process 
There were however limitations and restrictions on what was or could be achieved 
within the time limit. Overcoming these limitations could be a body of work which 
would  progress  the  PTD  system  towards  clinical  use.  One  of  the  most  limiting 
factors was the source and variation of the starting material, a tracheae from a human 
cadaver (Brindley, Wall et al. 2013). In the porcine model this variation was not as 
discernible due to pigs of a set age, sex and weight from a single abattoir being the 
sole tissue source. However with a human source from the National Health Service 
Blood  and Transplant  (NHSBT), the availability  of organ donors  was  in  general 
limited. This was amplified when trying to source tracheae as they are an uncommon 
organ to donate. However, as the physique of the donors varies greatly, so did the 
dimensions of the donated tracheae. This meant that, when sourcing a trachea for a 
patient, the choice of trachea would be extremely limited and therefore a degree of 
compromise was required to obtain a trachea that would be suitable for the patient. 
Potentially the optimal method of mitigating this variation would be to investigate a 
storage method either pre or post decellularisation to enable a stock of tracheae to be 
available for matching the most suitable trachea available to the patient (Baiguera, 
Del Gaudio et al. 2012) An example of large scale tissue storage is the Euro Tissue 
Bank which utilises glycerol to store donated skin for up to two years for use in 
allografts or tissue engineering (Euro_Tissue_Bank 2015). 
Other limiting factors of the PTD bioreactor system were the manual tasks required 
to  attach  the  trachea  to  the  bioreactor  and  assemble  the  bioreactor,  which  was 
composed  of  many  pieces  and  required  diligence  during  assembly.  These  highly 
manual tasks posed as risks for the introduction of contamination or errors (Brindley, 
Wall et al. 2013). Future work could simplify the bioreactor set up by amending the 
bioreactor design with new ports to enable direct attachment of pressure transducer 
and  temperature  probes.  Daily  interaction  was  also  required  to  drain  the  spent 
decellularisation  solution  and  refill  the  bioreactor  with  the  next  decellularisation 
solution.  With  the  use  of  manifolds,  automated  pinch  valves  and  programmable 
pump  systems  the  solutions  could  be  automatically  drained  from  the  bioreactor  
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chambers  to  a  large  waste  bag  and  filled  from  sterile  bags  that  are  prepared  in 
advance. However, due to the limited stability of the DNase and RNase, the addition 
of these components and solutions would need to be prepared fresh on the day of the 
use. The use of sterile weldable tubing to attach and seal bags or manifold sets to and 
from the system as required would also fully close the bioreactor system and allow 
processing to be achieved to a GMP compliant standard in a grade D background 
laboratory. 
In addition to the work to simplify the bioreactor system set up, the main body of the 
bioreactor would also require redesigning. The ports on the external chambers were 
machined and then glued onto the main cylindrical body of the bioreactor. When the 
bioreactor was autoclaved tiny air pockets in the glue expanded in between the joints 
and with multiple autoclaving resulted in the joints leaking. This was temporarily 
solved  with  a  sealant  around  the  exterior  of  the  joint  but  meant  that latter  PTD 
experiments could not be performed in a sterile manner as the bioreactor could not 
be  autoclaved.  Therefore  before  embarking  on  any  further  work,  the  bioreactor 
would need to be redesigned to ensure that it was either machinable from a single 
piece of plastic or built from multiple parts clamped together and sealed with O-
rings.  Additionally,  the  use  of  a  biocompatible  and  autoclavable  thermoplastic 
polymer, such the polyetheretherketone (PEEK) polymer Ketron® Peek-Classix™ 
LSG would be recommended as it is approved for contact or implantation in human 
tissue for up to 30 days. Another manufacturing option could be injection moulding. 
The bioreactor could be reusable and autoclavable if using a thermoplastic such as 
Ultem™  resin  (polyetherimide)  as  used  by  Biorep  for  their  reusable  Ricordi 
Chambers. Alternatively, if CoG allow, the bioreactor could be disposable if using a 
DuraStar™ polymer as used by Biorep for their disposable Ricordi Chambers. By 
manufacturing from a single piece of plastic, it should remove the need for glue to be 
used between joints which could potentially fail. It also means the entire bioreactor 
could be manufactured using a single validated material which would reduce the 
need for additional validation of extractables and leachables when translating into 
GMP.   
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6.1.4  Future work 
In addition to development of the bioreactor system, further development of the PTD 
methodology would be recommended prior to GMP translation and implementation 
into a manufacturing process. The final PTD decellularisation process described in 
this thesis using fresh (non-freeze-thaw treated) tracheae had only been performed 
using one condition after it was realised that using fresh trachea was a critical criteria 
for  obtaining  a  product  that  could  potentially  attain  the  assumed  critical  quality 
attributes of the decellularised scaffold product. Further process development of the 
decellularisation process could involve titrating the detergent and DNase solutions to 
determine the lowest possible concentrations that could be used whilst ensuring the 
critical quality attributes of the scaffold are still achieved. Also, several experimental 
failures  were  caused  due  to  the  pressurisation  of  the  internal  chamber  causing 
perforation of the trachealis muscle. Therefore it would be prudent to investigate 
alternative  pressure  levels  below  4.82  psi  to  investigate  if  transmural  flow  and 
decellularisation  can  be  achieved  with  equivalent  efficiency  at  a  lower  internal 
pressure level whilst reducing the number of scaffold failures. It would be preferable 
if these experiments could be performed using a DoE approach to gain insight into 
the  importance  of  and  the  interactions  between  the  different  decellularisation 
solutions and pressure level but due to the variability of the starting material, this 
may not be achievable. 
An interesting output from the PTD experiments 11, 18 and 20 (section 5.4.4.6) was 
the result from tensile testing which suggested the scaffold appeared to lose tensile 
strength and strain, which suggests the scaffold was weaker and stiffer, whilst also 
appearing to retain proportionally equivalent elasticity from the Young's modulus 
result, when compared to the native tissue. As biomechanical strength is assumed to 
be  critical  to  the  decellularisation  scaffold,  it  would  be  necessary  to  further 
investigate this result and to fully understand the impact of the decellularisation on 
the  biomechanical  properties  as  well  as  investigating  and  understanding  the 
methodology  of  biomechanical  testing  to  ensure  the  biomechanical  testing  being 
performed is relevant and informative. 
Additional to this, once sterile decellularisation is again possible and implemented, 
further work investigating contaminants in the decellularised scaffold product would  
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need to be investigated. This would likely be a three pronged approach looking at 
chemical contaminants such as leachables from the bioreactor system components 
and  residual  contaminants  from  the  decellularisation  solutions  which  would,  for 
example,  inform  if  further  wash  steps  were  required.  It  would  also  investigate 
microbial, mycobial and viral contamination that where either still present from the 
starting material or had been introduced during the process and would inform on the 
level  of  decontamination,  using  irradiation  or  other  methods,  required  prior  to 
storage or recellularisation. Once these contaminant issues, if necessary, had been 
resolved then the immunogenicity of the scaffold would need to be established in an 
animal model, e.g. sub-cutaneous implantation in a rat, to ensure the scaffold was 
suitable for implantation and not induce graft vs. host disease, tissue rejection or 
failure. 
6.2  Future projects 
Future project work that would need to be investigated to ultimately progress this  
project  to  regular  clinical  use  would  include;  the  length  of  the  shelf  life  of  the 
decellularised scaffold, the optimal storage conditions, the impact of storage on the 
scaffold and the incorporation of irradiation/sterilisation protocols prior to storage to 
increase preservation of the scaffold (Baiguera, Del Gaudio et al. 2012). Prior to 
clinical trials, non-clinical trials would be required with the scaffolds implanted sub-
cutaneously  to  determine  the  host  immune  response  and  graft  remodelling.  The 
recellularisation of the scaffold would be necessary (Go, Jungebluth et al. 2010) both 
for  the  replacement  of  mesenchymal  stem  cells  directly  into  the  decellularised 
tracheal scaffold and the luminal epithelial layer which could be delivered onto the 
decellularised  tracheal  scaffold  or  produced  as  a  cell  sheet  on  a  decellularised 
skin/membrane scaffold (Bhargava, Chapple et al. 2004, Richters, Pirayesh et al. 
2008) and added to the tracheal scaffold after the trachea has been revascularised in 
vivo  as  well  as  validated  assays  to  determine  adequate  cell  seeding  had  been 
achieved (Jungebluth, Haag et al. 2013). If such a surgical strategy were used, pre-
clinical studies would then be required to ensure that hetero-transplantation in vivo 
resulted in vascularisation of the tracheal scaffold and survival of the mesenchymal 
stem  cells,  and  subsequent  ortho-transplantation  and  incorporation  of  the 
recellularised  epithelial  cell  sheet  allowed  for  continued  survival  without  a 
debilitating immune response. For clinical delivery of the final recellularised tracheal  
Page - 213 - of 223 
 
product, a comprehensive recellularisation strategy with process development will be 
required as well as incorporating the logistics of product delivery to the clinical site 
and clinician training for hetero- and ortho- transplantation into the patient, post-
operative care and patient follow-up following release from clinical care. The project 
presented  in  the  thesis  has  helped  inform  subsequent  ongoing  projects  that  are 
currently involved in pre-clinical studies with pig models to address epithelialisation 
and vascular integration as well as ensuring immunological inertness of the scaffold. 
From the use of the Harvard Apparatus ORCA controller and Bio_1 software it was 
realised that online pressure transducers could be used to create a feedback loop to 
control and maintain a stable internal chamber pressure using two peristaltic pumps 
by controlling the fluid flow into the internal chamber (pump 1) with the fluid flow 
out of the internal chamber (pump 2). Using two peristaltic pumps in this manner 
would mitigate the need for one-way check valves and easily allow different pressure 
levels to be tested or changed throughout the decellularisation process. It is likely 
that  the  OCRA  controller  and  the  Bio_1  software  is  currently  not  sophisticated 
enough to achieve this set up but using a more sophisticated controller and software 
system e.g. the Finesse G3Lab Bioreactor Controller with TruBio software, would 
allow the set points to be achieved by controlling cascade mechanisms on the two 
pumps.  
The  methodology  of  the  mechanical  testing  requires  further  improvement  to 
representatively mimic in situ stresses. The introduction of the compression testing, 
as described in chapter 2 and 5, to measure the force required to occlude the lumen 
of  tracheae  and  compare  to  decellularised  scaffolds,  resulted  in  a  perceived 
improvement to method of biomechanical testing of the tracheae compared to the 
methods originally reported in the literature ((Baiguera, Jungebluth et al. 2010, Go, 
Jungebluth et al. 2010)) and the tensile testing described in chapter 2 and 3. Further 
improvements  could  however be made to  build a more representative  assay. For 
example, a luminal occlusion assay which, utilising Bose or Instron instrumentation, 
oscillated between set representative pressures over a period of time, for example 24 
hours, whilst  the trachea or scaffold was  maintained in  a sterile PBS  bath.  This 
would be a representative mimic of an observed in vivo condition in a patient where 
the trachea was compressed between the oesophagus and the aortic loop. Due to the 
pulsatile  effect  of  the  blood  pumping  through  the  aorta,  the  compression  of  the  
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trachea was pulsatile and the external pressure on the trachea oscillated. This in vitro 
assay set up would hopefully inform the scaffold’s ability to withstand over time any 
oscillating external pressure without weakening.  
Once  a  suitable  manufacturing  process  for  both  the  bioreactor  system  and  the 
scaffold  have  been  established,  proven  to  demonstrate  reproducibility  and  been 
validated to achieve the required critical quality attributes through the manufacture 
of a representative number of decellularised tracheal scaffolds to account for any 
variability in the starting material, then it can be assumed that the process is the 
product. Therefore the final product manufactured for patients should not need to be 
tested  to  the  same  degree  and  release  criteria  assays,  which  are  selected  critical 
quality attributes that can measured within the product shelf-life pre-implantation, 
can be determined and implemented. This process and product knowledge, based on 
the  principles  of  quality  manufacturing,  should  aid  GMP  translation  of  the 
decellularised scaffold product and market authorisation of a recellularised scaffold 
as an ATMP for clinical use. 
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7  Conclusions 
This  thesis  investigated  the  decellularisation  of  tracheae  for  tissue-engineering 
purposes and sought to investigate if an improved method of decellularisation that 
would aid scale-up and commercialisation of the process could be developed. The 
current  clinically-used  decellularisation  method,  the  detergent-enzymatic  method 
(DEM), was assessed and deemed unsuitable as a scalable method due to the length 
of  the  process,  the  difficulty  in  automating  the  numerous  process  steps  and  the 
potentially detrimental effect of the process on the resulting scaffold. A new method 
of decellularisation was proposed that would investigate if pressurised transmural 
flow  could  be  used  to  decellularise  trachea.  A  novel  bioreactor  system,  which 
incorporated  a  solution  reservoir,  a  pump  and  a  dual  chamber  bioreactor,  was 
developed which could permit flow through either the internal chamber, the external 
chamber or both chambers. Added online probes enabled measurement of certain 
process  parameters,  temperature  and  pressure,  to  validate  the  decellularisation 
process. The development of the bioreactor system enabled pressurised transmural 
decellularisation (PTD) to be explored. Various PTD conditions were tested and a 
successful  method  developed  which  achieved  in  the  decellularised  scaffold:  the 
requisite removal of donor cells; an acceptable reduction of donor nuclear material; 
the retention of key ECM components, GAGs and collagen, comparable to native 
tracheae; and retained overall biomechanical strength comparable to native tracheae. 
This  scaffold  improvement  was  achieved  alongside  a  process  improvement  of:  a 
reduction in  the number of process  steps from  76 to  5 steps;  a reduction in  the 
process time from 28 to 5 days; and a ten-fold reduction in the basic cost of goods. 
With  further  process  development  the  bioreactor  system  could  be  simplified, 
controlled by the online feedback from the process parameters and automated using 
software  programming  to  enable  minimal  operator  interaction.  By  accomplishing 
this, the PTD could achieve the principles of quality manufacturing and progress the 
process of biological scaffold manufacture and ultimately tracheal tissue engineering 
towards routine clinical use. 
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